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Cancer is one of the major causes of mortality in the world, and the worldwide 
incidence of cancer continues to increase. It is estimated that there will be 15 million 
new cases every year by 2020. Drug delivery systems have captivated scientists and 
engineers over the past many years because Drug delivery systems provide new 
strategies for the delivery of biologically active compounds at the right dose, at the 
right time and at the right place. Nanoparticles of biodegradable polymers are 
composed of natural or synthesized macromolecules, which are compatible with the 
human body (biocompatible) and are degradable under physiological condition into 
harmless byproducts. While delivering the imaging/therapeutic agents to the diseased 
cells, the polymeric matrix degrades and eventually disappears. The aims of this thesis 
were to synthesize a novel copolymer, poly(lactide)– poly(lactide acid) - 
d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) with desired 
degradation rate and hydrophobic/hydrophilic balance and develop the copolymer 
nanoparticles for cancer chemotherapy and imaging, as well as to prepare targeted 
nanoparticles for cancer therapy and imaging using a new strategy that is the contents 
of targeting ligands on the surface of nanoparticles can be controlled through 
adjusting the component ratio of two polymers. 
First of all, a novel system of poly(lactide acid) - d-α-tocopheryl polyethylene glycol 
1000 succinate (PLA-TPGS) nanoparticles (NPs) for quantum dots (QDs) formulation 
was developed to improve imaging effects and reduce side effects as well as to 
promote a sustainable imaging. PLA-TPGS copolymers were successfully synthesized 
by the ring-opening bulk polymerization of lactide monomer with TPGS in the 
presence of stannous octoate as a catalyst. The QDs loaded copolymers nanoparticles 
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were prepared by a modified solvent extraction/evaporation method. It was found that 
the QDs formulated in the PLA-TPGS NPs can result in higher fluorescence intensity 
and higher photostability than the bare QDs as well as lower cytotoxicity than the 
MAA-coated QDs. 
Nanoparticles (NPs) of the blend of two component polymers was also prepared by 
the solvent extraction/evaporation single emulsion method and then decorated by 
folate for targeted chemotherapy with paclitaxel used as model drug. One component 
is poly(lactide) – d-α-tocopheryl polyethylene glycol succinate (PLA-TPGS), which is 
of desired hydrophobic-lipophilic balance, and another is carboxyl-terminated 
(TPGS-COOH), which facilitates conjugation with folate for targeting. The 
PLA-TPGS is used to increase the half-life of the NPs in the blood system, and the 
TPGS-COOH is used to facilitate the folate conjugation on the NP surface. It was 
showed in this thesis that the nanoparticle formulation has great advantages vs the 
pristine drug and the folate-decoration can significantly promote targeted delivery of 
the drug to the corresponding cancer cells and thus enhance its therapeutic effects and 
reduced its side effects. 
Next, a new strategy was developed to prepare folate-decorated nanoparticles of 
biodegradable polymers for QDs formulation for targeted and sustained imaging. In 
order to reduce the cytotoxicity of QDs, two methods were used. One method is by 
surface modification and polymeric nanoparticle formulation. Another method is by 
targeted delivery of QDs, which can deliver QDs selectively to the cancer cells with 
greater efficiency. These folate-decorated (FD) NPs encapsulating QDs can increase 
biocompatibility and stability of QDs, prolong circulation time of QDs, and improve 
the selective uptake and imaging specificity, sensitivity of cancer cells with minimal 
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cytotoxicity to normal cells through selective delivery to appropriate tumor cell lines. 
This technology can be helpful in molecular imaging and medical diagnostics, 
especially the cancer detection in its early stage. 
Finally, multifunctional NPs of biodegradable polymers loaded with QDs and 
docetaxel for targeting, therapy and imaging were prepared and characterized. In this 
study, docetaxel and quantum dots were employed as the model anticancer drug and 
imaging agent, respectively. Nanoparticles of polymer blend containing PLGA and 
TPGS-COOH were prepared using the nanoprecipitation approach and subsequently 
decorated with folate for targeted drug delivery and imaging. These multifunctional 
NPs were able to provide targeting effects on the sites of cancerous cells, reducing 
side effects of docetaxel, enhancing docetaxel therapeutic effects and improving QDs 
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MCF-7 breast cancer cells treated with QDs-loaded 11.1% 
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FD NPs and (C) NIH-3T3 cells treated with QDs-loaded 
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Chapter 1 Introduction 
1.1 General background  
According to reports from the World Health Organization, cancer is one of the leading 
causes of human mortality in the world, which leads about 13% of all deaths in 2007. 
It was reported from American Cancer Society that 7.6 million people died from 
cancer in the world during 2007. Cancer is a class of diseases in which a group of 
cells display uncontrolled growth (division beyond the normal limits), invasion 
(intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to 
other locations in the body via lymph or blood) (http://en.wikipedia.org/wiki/Cancer). 
Different from cancer, benign tumors are self-limited, do not invade or metastasize. 
Cancer may affect people at all ages, even fetuses. Cancer is the first-leading cause of 
death in Singapore, and the proportion of cancer deaths in all causes of death was 
27.7% in 2007 (http://www.moh.gov.sg).  
Nanoparticles of biodegradable polymers are prepared from natural or synthesized 
macromolecules, which are biocompatible and biodegradable under physiological 
condition into harmless byproducts. After the imaging/therapeutic agents are 
delivered to the diseased cells, the polymeric matrix gradually degrades and 
eventually disappears. It is believed that biodegradable polymeric NPs can be 
formulated to encapsulate poorly soluble drugs like paclitaxel and docetaxel, which 
can enhance the solubility of the water insoluble drugs by tens to thousands of times. 
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Additionally, the advantages of polymeric nanoparticles include maintenance of 
therapeutically effective drug level for prolonged time, protection of active agents 
from in vivo degradation, facilitated passive targeting and active targeting upon 
appropriate surface coating, reversion of multidrug resistance and so on. However, 
once introduced into the blood, conventional nanoparticles (without surface 
modification) will interact with blood proteins (opsonization) and are recognized as 
foreign objects by the body defense system. Consequently, these nanoparticles are 
captured by the macrophages in the reticuloendothelial system (RES) and then cleared 
out from the circulation. In order to prolong systemic circulating half-life, the surface 
of conventional nanoparticles are usually modified by grafting, conjugating, or 
adsorbing sterically amphiphilic polymers such as poly(ethylene glycol) (PEG). The 
formed hydrophilic and flexible PEG layer on the particles surface can be used to 
prevent or minimize the recognition and clearance of the administered particles. 
Compared to other drug delivery methods, these biodegradable polymer systems can 
provide drug levels at an optimum range over a longer period of time, thus increasing 
the efficacy of the drug and maximizing patient compliance, while enhancing the 
ability to use highly toxic, poorly soluble, or relatively unstable drugs. Novel 
biodegradable polymers/copolymers with desired prolonged residence time in the 
circulation system and enhanced therapeutic efficacy of the loaded drug are thus 
needed. 
Currently, surgical intervention, radiation and chemotherapeutic drugs are widely 
used methods for cancer treatments. But these approaches often also kill healthy cells 
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and lead to toxicity for the patients. Therefore, the development of chemotherapeutics 
that can either passively or actively target cancerous cells will be expected. By 
conjugating nanocarriers containing chemotherapeutics with molecules that bind to 
overexpressed antigens or receptors on the target cells, active targeting can be 
achieved. Targeting therapeutic approaches would significantly benefit from the 
combination of targeted delivery with controlled release technology. This will 
improve cancer therapy through delivering a large amount of drug to cancer cells per 
targeting biorecognition event, and reaching a steady state cytotoxic drug 
concentration at the tumor site over an extended period of time. In addition, the 
harmful nonspecific side effects of chemotherapeutics can be reduced by this 
approach since the drug is encapsulated and biologically unavailable during transit in 
systemic circulation. Furthermore, formulation of these nanoparticles with imaging 
contrast agents provides a very efficient system for cancer diagnostics and therapy. 
Given the exhaustive possibilities available to polymeric nanoparticle chemistry, 
research has quickly been directed at multi-functional nanoparticles, combining 
tumour targeting, tumour therapy and tumour imaging in an all-in-one system, 
providing a useful multi-modal approach in the battle against cancer. 
1.2 Objective and thesis organization 
The overall purpose in this thesis is to develop nanoparticles of biodegradable 
polymers for molecular imaging and targeted therapy. In particular, the objectives of 
this thesis include: 
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1) to prepare a novel system of poly(lactide acid) - d-α-tocopheryl polyethylene 
glycol 1000 succinate (PLA-TPGS) nanoparticles (NPs) loading quantum dots 
(QDs) formulation to improve imaging effects, reduce side effects, and promote a 
sustainable imaging. 
2) to synthesize nanoparticles (NPs) of the blend of two component polymers for 
targeted chemotherapy with paclitaxel used as model drug. 
3) to develop a new strategy to prepare folate-decorated nanoparticles of 
biodegradable polymers loading QDs for targeted and sustained imaging for 
cancer diagnosis at its early stage. 
4) to prepare biodegradable polymeric multifunctional nanoparticles for targeted 
chemotherapy and imaging with docetaxel as model drug and quantum dots as 
imaging agent. 
The Chapter 2 presents an overview of the related literatures. In Chapter 3, 
poly(lactide acid) - d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS) 
copolymers were synthesized by the ring-opening bulk polymerization of lactide 
monomer with TPGS in the presence of stannous octoate as a catalyst. The 
QDs-loaded PLA-TPGS NPs were prepared by a modified solvent 
extraction/evaporation technique (single oil-in-water emulsion technique). The 
QDs-loaded PLA-TPGS NPs are found of ~200 nm in diameter. FESEM, AFM and 
TEM demonstrated that the QDs were encapsulated in the polymeric matrix of the 
 5 
PLA-TPGS NPs, which are of spherical shape and relatively uniform in size. The 
QDs encapsulation efficiency in the PLA-TPGS nanoparticles was measured by 
ICP-OES, which was found to be 46%, which is quite high for nanoparticle of such 
small size. Surface chemistry of the QDs-loaded PLA-TPGS NPs were analyzed by 
XPS and FT-IR, which showed that there were no QDs on the nanoparticle surface 
and the QDs were encapsulated in the interior of the polymeric matrix. The in vitro 
cellular uptake of the QDs-loaded PLA-TPGS NPs was visualized by CLSM. In vitro 
MCF-7 cell cytotoxicity of the QDs-loaded PLA-TPGS NPs was at various QDs 
concentration in 1, 2 and 3 days, which showed that the cytotoxicity of the QDs 
increases with the QDs concentration and incubation time. Our research showed that 
the QDs-loaded PLA-TPGS NPs can have great advantages versus the bare QDs in 
improving the imaging quality and extending the half-life of the QDs. Compared with 
the MAA-coated QDs, our PLA-TPGS NP formulation can have less side effects at 
proper NPs concentration. With molecular probes conjugated onto the nanoparticle 
surface, the QDs-loaded PLA-TPGS NPs can be used for molecular imaging for 
detection of diseases at their earliest stage, which is a key to determine the prognosis 
of the treatment. 
In Chapter 4, two types of polymers, PLA-TPGS copolymer and TPGS-COOH 
polymer, were firstly synthesized and characterized. The PLA-TPGS copolymer is 
employed to achieve desired hydrophobic-lipophilic balance of the polymeric matrix 
material and the TPGS-COOH polymer is used to facilitate folate decoration for 
targeting the cancer cells rich of the folate receptors on their surface. Nanoparticles of 
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the two-polymer blend at various component ratios were prepared by the solvent 
extraction/evaporation single emulsion method and then decorated by folate for 
controlled and targeted chemotherapy of paclitaxel employed as a model anticancer 
drug, which were then decorated with folate molecule. The targeting effect was 
qualitatively and quantitatively investigated by cancer cell uptake of the coumarin 
6-loaded NPs and further confirmed by the cytotoxicity of the cancer cells treated 
with the drug formulated in the folate-decorated nanoparticles of various polymer 
blend ratio. We showed that the nanoparticle formulation has great advantages vs the 
pristine drug and the folate-decoration can significantly promote targeted delivery of 
the drug to the corresponding cancer cells and thus enhance its therapeutic effects and 
reduced its side effects. 
In Chapter 5, a new strategy was developed to prepare folate-decorated nanoparticles 
of biodegradable polymers for QDs formulation for targeted and sustained imaging 
for cancer diagnosis at its early stage. Two polymers of poly(lactide)-vitamin E TPGS 
(PLA-TPGS) and vitamin E TPGS-carboxyl (TPGS-COOH) were synthesized, which 
were blended at various weight ratio to make QDs-loaded nanoparticles which were 
decorated with folate for targeted and sustained imaging. Here the TPGS-COOH was 
utilized to conjugate with folate-NH2. The merit is that the amount of folate ligand 
conjugated onto the NPs surface can be made as desired by adjusting the component 
ratio between PLA-TPGS and TPGS-COOH polymers. The size of such NPs was 
found in the range of 280-300 nm. In vitro cellular uptakes of such NPs were 
investigated with CLSM, which demonstrated much higher internalization of the 
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folate-decorated QDs-loaded PLA-TPGS/TPGS-COOH NPs by MCF-7 breast cancer 
cells which are of over-expression of folate receptors than the cellular uptake by NIH 
3T3 fibroblast cells which are of low expression of folate receptors. Compared with 
the free QDs, the QDs formulated in the PLA-TPGS/TPGS-COOH NPs showed lower 
in vitro cytotoxicity for both of MCF-7 cells and NIH 3T3 cells. Additionally, our 
findings indicated that under same conditions, cytotoxicity of QDs formulated in the 
PLA-TPGS/TPGS-COOH NPs is lower for normal cells such as NIH 3T3 cells than 
that for beast cancer such as MCF-7 breast cancer cells due to folate targeting 
effect. Our
In Chapter 6, folate-decorated nanoparticles of biodegradable polymers loaded with 
QDs and docetaxel for targeting, therapy and imaging were prepared and 
characterized. In this study, docetaxel and quantum dots were employed as the model 
anticancer drug and imaging agent respectively. Nanoparticles of two polymer blend 
(PLGA and TPGS-COOH) were prepared using the nanoprecipitation approach and 
subsequently decorated with folate for targeted drug delivery and imaging. The 
prepared nanoparticles were found to be about 260nm size in diameter, spherical in 
shape and relatively uniform. TEM and XPS have also demonstrated the successful 
encapsulation of quantum dots and docetaxel within the NPs matrix. The targeting 
performance of the prepared nanoparticles was investigated both quantitatively and 
 study showed that QDs formulated in folate-decorated nanoparticles of 
PLA-TPGS/TPGS-COOH polymer blender is feasible for targeted imaging to 
improve imaging specificity and sensitivity as well as to reduce side effects of QDs to 
normal cells. 
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qualitatively by performing MCF-7 cancer cellular uptake. The targeting effect of the 
QDs/docetaxel-loaded nanoparticles with folate decoration was further confirmed by 
the cytotoxicity results of the cancer cells. Experimental results have conclusively 
shown that FD NPs developed here have much superior advantage over Taxotere®
Finally, conclusions and recommendations of the whole work are presented in 
Chapter 7.  
 
whereby targeting, imaging and therapy can be achieved simultaneously. These 
multifunctional NPs realize targeting nanoparticles to the sites of cancerous cells, 
reducing side effects of docetaxel, enhancing docetaxel therapeutic effects and 
improving QDs imaging specificity, sensitivity to cancer cells with minimal 
cytotoxicity to normal cells. 
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Chapter 2 Literature Review 
2.1 Nanocarriers for Cancer Therapy 
2.1.1 Passive and active targeting 
Current cancer treatments include surgical intervention, radiation and 
chemotherapeutic drugs, which often also kill healthy cells and cause toxicity to the 
patient. It would therefore be desirable to develop chemotherapeutics that can either 
passively or actively target cancerous cells.  
The passive targeting approach uses the unique features of tumor microenvironment, 
include: (i) leaky tumor vasculature, which is highly permeable to macromolecules 
relative to normal tissue; and (ii) a dysfunctional lymphatic drainage system, which 
retains the accumulated nanocarriers and allows them to release drugs into the vicinity 
of the tumour cells (Matsumura and Maeda 1986; Maeda and Matsumura 1989). As a 
result of these characteristics, the concentration of polymeric NPs and 
macromolecular assemblies found in tumor tissues can be up to 100 times higher than 
those in normal tissue (Matsumura and Maeda 1986; Maeda and Matsumura 1989). 
The tumor-specific deposition, also known as the enhanced permeability and retention 
(EPR) effect, occurs as NPs extravasate out of tumor microvasculature, leading to an 
accumulation of drugs in the tumor. 
Although passive targeting approaches form the basis of clinical therapy, they suffer 
from the biggest limitation, which is the inability to achieve a sufficiently high level 
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of drug concentration at the tumor site resulting in low therapeutic efficacy and 
eliciting undesirable systemic adverse effects (Brigger, Dubernet et al. 2002; Ferrari 
2005). One way to overcome this limitation is to develop active targeting nanocarriers 
by attaching targeting agents such as ligands to the surface of the nanocarriers by 
various conjugation chemistries. These targeted nanocarriers can recognize and bind 
to specific ligands that are unique to cancer cells. The cytotoxic drug encapsulated in 
the NPs can be transferred directly to cancer cells while minimizing harmful toxicity 
to non-cancerous cells adjacent to the targeted tissue. For primary tumors, which have 
not yet metastasized, this approach is particularly useful. For example, it was 
demonstrated that suicide targeted gene delivery can kill effectively prostate cancer 
but not damage healthy muscle cells in xenograft mouse models of prostate cancer 
(Brigger, Dubernet et al. 2002; Anderson, Peng et al. 2004). For metastatic cancers, 
local delivery approaches is impractical, because the location, abundance and size of 
tumor metastasis within the body limits its visualization or accessibility. In this case, 
the drug delivery vehicle would be administered systemically. 
2.1.2 NP carriers for targeted therapy 
Nanocarriers can carry multiple drugs and/or imaging agents. It is possible to achieve 
high ligand density on the surface for targeting purposes due to nanocarriers’ high 
surface-area-to-volume ratio. And nanocarriers can also be used to increase local drug 
concentration by carrying the drug within and control-releasing it when bound to the 
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targets. Currently, several classes of nanocarriers include biodegradable polymers, 
liposomes, dendrimers, nucleic-acid-based NPs, and nanoshells. 
2.1.2.1 Biodegradable polymer NPs  
Biodegradable polymer NPs have been widely studied for cancer therapy (Gref, 
Minamitake et al. 1994; Moghimi, Hunter et al. 2001). By grafting, conjugating, or 
adsorbing sterically amphiphilic polymers such as polyethylene glycol (PEG) to the 
particle surface, polymeric NPs can prolong systemic circulating half-life (Gref, Lück 
et al. 2000; Owens Iii and Peppas 2006). Polymeric NPs can be used to encapsulate 
hydrophilic or hydrophobic small drug molecules, and macromolecules such as 
proteins and nucleic acids (Tobio, Gref et al. 1998; Perez, Sanchez et al. 2001). The 
encapsulated drugs in these NPs can be released at a controlled rate via surface or 
bulk erosion, diffusion, or swelling followed by diffusion, in a time- or 
condition-dependent manner. The strategies of modification of the polymer sidechain, 
development of novel polymers, or synthesis of copolymers can be utilized to control 
the rate of drug release (Langer and Folkman 1976; Langer 1990; Edelman, 
Mathiowitz et al. 1991; Langer 1995; Langer 1998). Generally, in comparison with 
other drug delivery methods, these biodegradable polymer systems can keep drug 
levels at an optimum range over a longer period of time, which increase the efficacy 
of the drug and maximize patient compliance. And biodegradable polymer NPs can 
enhance the ability to use highly toxic, poorly soluble, or relatively unstable drugs. 
Combination of targeted delivery with controlled release technology would 
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significantly benefit to targeted therapeutic approaches, thus allowing for a large 
amount of drug to be delivered to cancer cells (Ferrari 2005), and keeping a steady 
state cytotoxic drug concentration at the tumor site over an extended period of time. 
Additionally, the likelihood of significant systemic toxicity could be decreased by the 
combination of targeted delivery and controlled release since the drug is encapsulated 
and biologically unavailable during transit in systemic circulation. The most 
commonly used biocompatible polymers for controlled release of drugs include 
Poly(D,L-lactide) and poly(glycolide) and their copolymer 
poly(D,L-lactide-co-glycolide) (PLGA), which have been extensively reviewed in the 
past (Shive and Anderson 1997; Avgoustakis 2004; Astete and Sabliov 2006). 
2.1.2.2 Liposomes 
The amphiphilic unilamellar/multilamellar membranes of natural or synthetic lipids 
can be used to prepare liposomes (Torchilin 2005). Lipids are characterized by a 
hydrophilic head group and a hydrophobic tail. The first liposome approved by US 
Food and Drug Administration (FDA) was Doxorubicin-encapsulated liposome 
(Doxil), which has potent antineoplastic activity against a wide range of human 
cancers including Kaposi's sarcoma and ovarian cancer (James, Coker et al. 1994; 
Gibbs, Pyle et al. 2002; Mrozek, Rhoades et al. 2005). Furthermore, the Doxil surface 
was modified by conjugating with methoxypolyethylene glycol, which provides a 
hydrophilic ‘stealth’ coating, in order to increase the circulation half-life (Gabizon, 
Tzemach et al. 2002; Gabizon, Shmeeda et al. 2003). Liposomes are limited by 
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suboptimal stability and drug release profiles in vivo, despite the clinical success of 
these nanocarriers (Slepushkin, Simoes et al. 1997; Reddy and Low 2000; Turk, 
Reddy et al. 2002; Slepushkin, Simoes et al. 2004). 
2.1.2.3 Dendrimers 
Dendrimers become an important class of drug-encapsulating NPs due to their unique 
architecture and macromolecular characteristics. A typical dendrimer molecule 
consists of an initiator core, highly branched layers composed of repeating units, and 
multiple active terminal groups. Typically, dendrimers are synthetic, highly branched, 
spherical, monodispersed macromolecules with an average diameter of 1.5-14.5 nm 
(Patri, Majoros et al. 2002; Andresen, Jensen et al. 2005). For example, the 
intracellular release doxorubicin after hydrolysis of the hydrazone linkage could be 
achieved by developing biodegradable polyester dendrimers based on 
2,2-bis(hydroxymethyl)-propanoic acid monomers (Padilla De Jesús , Ihre et al. 2002). 
Tumor accumulation can be optimized by further studies based on tunable 
architectures and molecular weights of polyester dendrimers as a drug delivery system 
(Gillies and Fréchet 2002; Gillies, Dy et al. 2005; Lee, Gillies et al. 2006). 
2.1.2.4 Nucleic-acid-based NPs 
Nucleic-acid-based NPs use DNA and RNA macromolecules as substrates for 
developing therapeutic and imaging nanocarriers. It was reported in 2004 that a 
multivalent DNA delivery vehicle, with an average size of 100 nm, was developed for 
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simultaneous targeted drug delivery, imaging, and gene therapy (Yougen, Tseng et al. 
2004). And Khaled et al. developed targeted multifunctional RNA NPs (25-40 nm) 
with a trivalent RNA core, RNA aptamers for targeting, and siRNAs for therapeutic 
effect (Khaled, Guo et al. 2005). 
2.1.2.5 Nanoshells 
Diblock copolymers can be assembled into a core/shell structure to form polymeric 
nanoshells. Generally, nanoshells are made by self-assembly of oppositely charged 
polymers covering the surface of the drug NPs. Therefore, the chemistry of the 
polymers and the diffusion coefficient through the polymeric layer can control the 
drug release rate. For example, amphiphilic 
tercopolymerpoly(N-iso-propylacrylamide-co-N,N-dimethylacrylamide-co-10-undece
noic acid) was used to synthesize nanoshells encapsulating doxorubicin, which can 
trigger intracellular doxorubicin release at pH 6.6. Metallic nanoshells are prepared by 
a dielectric core coated with a thin metallic shell to improve their biocompatibility 
and optical absorption (Hirsch, Gobin et al. 2006). These particles shows a highly 
tunable plasmon resonance mediated by the size of the core and the thickness of the 
shell, which in turn determines their absorbing and scattering properties over a broad 
range of the spectrum from the near-ultraviolet to the mid-infrared (Hirsch, Gobin et 
al. 2006). For the purpose of in vivo photothermal therapy using near-infrared light, 
Au nanoshells have been developed (Hirsch, Stafford et al. 2003). Furthermore, 
thermally sensitive polymeric hydrogels and optically active nanoshells have been 
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developed for photothermally modulated drug delivery. Nanoshell particles consisting 
a magnetic core (carbonyl iron) and a biodegradable poly(butylcyanoacrylate) (PBCA) 
shell have also been prepared for controlled release of 5-fluorouracil (Arias, Gallardo 
et al. 2006). Particle targeting to specific sites of the body in response to an externally 
applied magnetic field have also been developed by the combination of magnetic 
nanoshells with a drug-encapsulated biodegradable polymer. 
2.1.3 Targeting molecules for the development of targeted NPs 
2.1.3.1 Folate-based targeting molecules 
Folic acid (folate) is one of the most extensively studied small molecule targeting 
moieties for drug delivery, because many tumor cells possess over-expressing folate 
receptors (FRs) on their surfaces (Antony 1992). A variety of folate derivatives and 
conjugates can selectively deliver molecular complexes to cancer cells with 
minimizing damage to normal cells through folate specifically binding to FRs with a 
high affinity. Current reports have pointed out that drug delivery vehicles including 
liposomes, protein toxins, polymeric NPs, linear polymers, and dendrimers were 
combined with folate to deliver drugs selectively into cancer cells using FR-mediated 
endocytosis (Benns, Mahato et al. 2002; Quintana, Raczka et al. 2002). It was 
reported that folate-decorated dendrimer-based targeted anticancer therapeutics have 
demonstrated promising in vivo efficacy in terms of targeting and specific killing of 
cancer cells via multivalent interaction (Kukowska-Latallo, Candido et al. 2005; Hong, 
Leroueil et al. 2007). 
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2.1.3.2 Monoclonal antibodies 
One of the preferred classes of targeting molecules is monoclonal antibody (mAb). To 
decrease their immunogenicity, the antibodies with chimeric, humanized, and fully 
humanized derivatives have been developed in recent years. Some of these 
antibody-based drugs have been successfully applied in the clinical environment such 
as rituximab (Rituxan®), trastuzumab (Herceptin®), cetuximab (Erbitux®), and 
bevacizumab (Avastin®). The FDA approved rituximab for treating B-cell lymphoma 
in 1997. And trastuzumab is another successful therapeutic mAb approved by the 
FDA for treating breast cancer in 1998 by binding to HER2 receptors. The FDA 
approved cetuximab for treating colorectal cancer in 2004 and head/neck cancer in 
2006 through binding to epidermal growth factor receptors (EGFR). Bevacizumab, 
which is a tumor angiogenesis inhibitor that binds to vascular endothelial growth 
factor (VEGF), was approved for treating colorectal cancer in 2004. Due to the 
success of these mAbs as a monotherapy, mAbs are now being tested as adjuvant 
therapies combinated with chemotherapeutic agents (Byrd, Murphy et al. 2001; 
O'Brien, Kantarjian et al. 2001; Eisenbeis, Grainger et al. 2004; Haioun 2004; Kay, 
Geyer et al. 2004; Haioun, Mounier et al. 2005; Piccart-Gebhart, Procter et al. 2005; 
Romond, Perez et al. 2005; Wadehra 2005; Haioun 2006; Khan, Emmanouilides et al. 
2006; Kay, Geyer et al. 2007; Smith, Procter et al. 2007). Current studies have 
focused on the encapsulation chemotherapeutic drugs into NPs and then 
functionalization the particle surface with mAbs for targeting efficacy, which provide 
some protection to these drugs from metabolism or early excretion. Thus 
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chemotherapeutic drug loading capacity could also be increased. For example, 
trastuzumab and rituximab conjugated to poly(lactic acid) (PLA) NPs achieved higher 
rate of particle uptake than similar particles without mAb (Nobs, Buchegger et al. 
2004; Nobs, Buchegger et al. 2006). Some studies also reported antibody derivatives 
were used as the targeting ligand for targeted NPs. Long-circulating 
doxorubicin-encapsulated immunoliposomes were conjugated to human HER2 
antibodies, which exhibited mediate internalization of targeted liposomes and 
intracellular drug release (Nellis, Ekstrom et al. 2005). Although some success studies 
on mAbs-conjugated NPs were made, the limitations from these NPs still exist due to 
big size and complex of mAbs molecular (Brennan, Shaw et al. 2004; Weinberg, 
Frazier-Jessen et al. 2005). Other limitations of antibodies include expensive to 
manufacture relative to small-molecule drugs, increase the size of the NPs due to big 
hydrodynamic size of antibodies (Brennan, Shaw et al. 2004; Weinberg, 
Frazier-Jessen et al. 2005). 
2.1.3.3 Aptamer targeting molecules 
In the last decade, aptamers have emerged as a promising class of molecules with 
potential applications in therapeutic and diagnostic fields (Gold 1995; Jayasena 1999). 
Aptamers are DNA or RNA oligonucleotides or modified DNA or RNA 
oligonucleotides that fold by intramolecular interaction into unique conformations 
with ligand-binding characteristics (Wilson and Szostak 1999). Similar to antibodies, 
aptamers can bind target antigens with high specificity and affinity.  
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In comparison with antibodies, aptamers have some potential advantages in using as 
targeting molecules. In vitro selection, which is a process called systemic evolution of 
ligands by exponential enrichment (SELEX), can be performed to prepare aptamers 
with high affinity for a target (Ellington and Szostak 1990). Obtained aptamers are 
small (～15 kD relative to ～150 kD for antibodies), lack immunogenicity, and good 
tumor/plasma distribution and tumor-penetration properties compared with antibodies 
(Green, Ellington et al. 1990; Ellington and Szostak 1992). Furthermore, because the 
SELEX process is a chemical one that does not involve animals, nucleic acid ligands 
can be prepared to bind to any target regardless of the toxicity or immunogenicity of 
the target (Green, Ellington et al. 1990; Irvine, Tuerk et al. 1991; Ellington and 
Szostak 1992; Schneider, Tuerk et al. 1992). Moreover, in contrast to antibodies, 
nucleic acid ligands identified through the SELEX process can be synthesized using 
chemical oligonucleotides synthesis, which exhibit little or no variation batch-to-batch 
variation in quality during scale-up production (Irvine, Tuerk et al. 1991; Schneider, 
Tuerk et al. 1992). 
Aptamers have been isolated for a wide variety of targets, including intracellular 
proteins, transmembrane proteins, soluble proteins, carbohydrates, and 
small-molecule drugs. Today, more than 200 aptamers have been isolated (Lee, 
Hesselberth et al. 2004; Lee, Stovall et al. 2006). For example, NeXstar 
Pharmaceutical (acquired by Gilead Science in 1999) isolated RNA aptamers to the 
vascular endothelial growth factor (VEGF165) isoform with 2’-O-methylpurine and 
2’-F pyrimidines, in 1995 and 1998, respectively. VEGF aptamers with remarkable 
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stability in plasma in monkeys can lead to regression of tumor vessels. Macugen 
(Pegaptanib sodium), targeted against the (VEGF) 165, was approved by the FDA in 
2004 for the treating neovascular macular degeneration (Vinores 2003; Gragoudas, 
Adamis et al. 2004). 
Relative to NPs without aptamers, NPs conjugated with aptamers shown high efficient 
therapeutics or diagnostics. NP-aptamer (NP-Apt) conjugates were developed to 
regress tumor size effectively following a single intratumor injection over a 109-day 
study (Farokhzad, Cheng et al. 2006). This study also demonstrated that docetaxel 
delivered using the NP-Apt is more efficacious than non-targeted docetaxel therapy in 
murine xenograft models of prostate cancer (Farokhzad, Cheng et al. 2006). A novel 
strategy was also created by Bagalkot et al. through the formation of an 
aptamer-doxorubicin physical conjugate for the targeted delivery of anthracyclic 
agents (Bagalkot, Farokhzad et al. 2006). Liposomes conjugated with aptamers have 
also been prepared for prolonging their circulation lifetime and enhancing effect in 
vivo (Willis, Collins et al. 1998). 
2.1.3.4 Oligopeptide-based targeting molecules 
Peptide is a potent targeting ligand in recent years. Peptides are becoming an 
attractive alternative to antibodies because of their small size, lower immunogenicity, 
higher stability, and ease of manufacture. For example, Cilengitide® is a cyclic 
arginine-glycine-aspartic acid (RGD) peptide that binds to integrins and is currently in 
phase II clinical trials for the treatment of non-small cell lung cancer and pancreatic 
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cancer (Burke, DeNardo et al. 2002). Despite the success listed above, RGD-targeted 
therapy still encounters many challenges. First and foremost is the limitation 
associated with the nonspecific adhesive nature of the RGD-integrin targeting system. 
Integrins are extracellular receptors that are not only expressed on cancer cells but 
also on virtually all epithelial cells and are therefore not cancer specific (Bibby, 
Talmadge et al. 2005; Montet, Montet-Abou et al. 2006). Recent development of 
phage display screening methods has successfully isolated peptide ligands with high 
specificity and affinity to cell-surface hormone receptors (LHRH receptors (Wells, 
Souto et al. 2002; Randolph, Waid et al. 2004), somatostatin receptors (Hofland, Van 
Der Hoek et al. 2004; Lang 2004; Saveanu, Gunz et al. 2006) and tumor vasculature 
antigens (Zhu, Arendsen et al. 2001; Cortijo, Sanz et al. 2006). Arap et al. have 
disclosed peptides that bind specifically to tumor vasculature in patients and show 
potential as a platform for an in vivo phage library selection (Arap, Kolonin et al. 
2002). The development of protocols to select potent peptide sequences as targeting 
ligands and nanotechnologies will lead to the clinical translation of new technologies 
for cancer therapy and diagnosis. 
2.2 Molecular Imaging  
2.2.1 Introduction  
With the advances in molecular and cell biology techniques, much research attention 
about diagnostics of disease has been rightfully directed toward underlying molecular 
and genomic aberrations rather than toward clinical signs and symptoms alone. 
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Molecular imaging is a growing research discipline aimed at visually characterizing 
normal and pathologic processes in living organisms at the cellular and molecular 
levels (Massoud TF 2003; Jaffer and Weissleder 2005). Scientists from diverse 
disciplines, such as molecular and cell biology, imaging sciences, chemistry, 
nanotechnology, pharmacology, have been attracted in the field of molecular imaging 
(Tempany and McNeil 2001; Wickline and Lanza 2003; Hengerer, Wunder et al. 
2005). 
Current assessment of disease is based on anatomic and/or physiologic variations. 
Such changes are often nonspecific and late phenotypic manifestations of underlying 
molecular derangements (Weissleder and Mahmood 2001). By contrast, directed 
imaging probes were exploited to sense molecular changes that truly underlie disease 
in molecular imaging. Direct imaging of these molecular changes will directly affect 
patient care by allowing much earlier and more precise detection of disease. 
Consequently, the disease progression can be monitored efficiently. Moreover, the 
effects of therapy can be obtained by directly imaging about underlying alterations of 
disease (Jain 2002). Thus, the effectiveness of treatment after therapy can be directly 
determined. In contradistinction, the determination whether pharmacologic or biologic 
intervention will spend many months with current diagnostic methods. Presently, 
several human trials of molecular imaging are carried on (Harisinghani, Barentsz et al. 
2003; Jacobs, Voges et al. 2003; Voges, Reszka et al. 2003). 
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In studying disease, molecular imaging monitors noninvasively molecular phenomena 
in living individuals, and analyses can be performed in real time with minimal 
disturbance to whole biologic systems (Kitano 2002). Therefore, molecular imaging 
assays are more predictive and relevant. In vivo research can also be benefited from 
this technology. For example, in traditional in vivo research the animals need to be 
killed at fixed time points to get tissue for in vitro analyses; however the imaging of a 
single animal can be obtained repetitively to monitor the molecular phenomena 
through molecular imaging. 
The application of molecular imaging tools in the preclinical arena has been 
accelerated by these advantages. The basis science research of dynamic biologic 
processes has adopted imaging of experimental small animal models, usually mice. 
Some examples were given such as hypoxia (Serganova, Doubrovin et al. 2004), 
inflammation (Lindner 2001), apoptosis (Zhao, Beauregard et al. 2001), angiogenesis 
(Schirner, Menrad et al. 2004), tumorigenesis (Weissleder 2002), and gene expression 
(Gambhir, Herschman et al. 2000; Blasberg 2002). Other applications include 
monitoring of the distribution and efficacy of novel therapeutic moieties (Rudin and 
Weissleder 2003) and stem cell trafficking (Cao, Lin et al. 2006). Possibly, the most 
promising applications of molecular imaging come from drug discovery and 
development (Contag 2002; Wang and Maurer 2005). 
2.2.2 Imaging modalities 
 23 
Modalities used in molecular imaging encompass positron emission tomography 
(PET), magnetic resonance (MR) imaging, single photon emission computed 
tomography (SPECT), optical imaging, and ultrasound (US). These modalities differ 
in terms of spatial resolution, temporal resolution, sensitivity in probe detection, depth 
of signal penetration, availability of biocompatible molecular imaging agents, and 
cost. Each has its unique advantages and disadvantages, and the choice of imaging 
system ultimately depends on the specific conditions. In Table 2-1 summarizes the 
characteristics of each modality (Weissleder and Mahmood 2001). 
Table 2-1 Attributes of molecular imaging modalities 






SPECT Medium Low Low High 
PET High Low Low High 
MR imaging Low High High High 
US Medium Medium High Medium 
Optical 
imaging 
High Low High Low 
2.2.2.1 Nuclear imaging 
Nuclear imaging (PET, single photon emission computed tomographic [SPECT], 
planar imaging) techniques are widely used clinically and are the most prevalent 
molecular imaging modalities currently because of their high intrinsic sensitivity, 
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their unlimited depth penetration, and the relative ease of radiolabeling molecular 
probes (Gambhir 2002). Hundreds of nuclear imaging probes have been developed 
such as radiolabeled enzyme substrates, receptor ligands, antibodies, drugs, and 
oligonucleotides (Phelps 2000). Nuclear imaging is based on the radioactive 
emissions from targeted radionuclides. PET specifically detects pairs of coincident 
-rays generated from positron/electron collisions after positron emission. Common 
positron-emitting isotopes include 18F, 11C, 13N, 15O, and 124I (Phelps 2000). 
SPECT, by contrast, detects -rays directly from -emitting isotopes such as 99mTc, 
111In, 123I, and 131I (Massoud TF 2003).  
In fact, PET is 10–100 times more sensitive for imaging molecular processes than 
SPECT, and therefore radiolabeled probes are needed in only tracer quantities 
(Massoud TF 2003). This offers the visualization of targets of low concentration and 
minimization perturbation of the system under investigation. In addition, 
positron-emitting isotopes in PET can be readily substituted for naturally occurring 
atoms (eg, substituting 18F for hydrogen or 11C for elemental carbon) (Hengerer, 
Wunder et al. 2005). Similarly, the availability of positron-emitting radionuclides of 
common elements allows for radiolabeling by direct isotopic substitution, which 
minimizes alterations in the biologic properties of the parent molecule (Park and 
Gambhir 2005). This is particularly advantageous in the use of imaging to evaluate 
novel drugs (Wang and Maurer 2005). Last, PET enables the additional benefit of 
providing quantitative measures of tracer uptake. The limited spatial resolution of 
current clinical PET scanners ranges from 3 mm to 6 mm but is approaching 1 mm for 
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small-animal PET (microPET) scanners (Gambhir 2002). To overcome this limitation, 
the combined PET/CT systems are exploited and are expected to simultaneously 
achieve high probe detection sensitivity and spatial resolution, allowing for direct 
anatomic correlation and more precise target localization (Townsend and Beyer 
2002). 
Other disadvantages include patient exposure to radiation, the high cost of associated 
equipment and the need for an on-site cyclotron to synthesize a broad range of 
radioactive tracers, because the half-lives of positron-emitting radionuclides are short 
and the decay process cannot be controlled. 
2.2.2.2 MR Imaging 
MR imaging monitored molecular events by detecting a signal generated from proton 
spin relaxation after the application of a radiofrequency pulse. The signaling 
components of MR molecular probes include paramagnetic agents (eg, gadolinium) 
and superparamagnetic agents (eg, iron oxide). Paramagnetic agents shorten T1 
relaxation times to produce signal enhancement on T1-weighted images, whereas 
superparamagnetic agents shorten T2 relaxation times to produce negative contrast on 
T2-weighted images (Allen and Meade 2004; Basilion, Yeon et al. 2005). 
In comparing nuclear imaging, MR imaging has the significant advantages of 
exceptional spatial resolution (10–100 µm) and the ability to concurrently provide 
anatomic and molecular information. Other advantages are the absence of ionizing 
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radiation and good depth penetration. The main limitation of MR imaging is relatively 
low sensitivity in the detection of imaging probes. Therefore, this technology needs 
highly efficient signal amplification techniques and necessitating high probe 
concentrations from millimolar to micromolar (Weissleder and Mahmood 2001), 
which may cause complex amplification steps or potential toxicities. However, the 
recent development of super-fast pulse sequences and higher field strengths may 
expand the application of MR images.  
2.2.2.3 Ultrasound 
Image from US is based on the detection of differential reflection of sound waves. 
Encapsulated microbubbles, liposomes, and perfluorocarbons emulsions are used as 
US contrast agents (Lindner 2004; Christiansen and Lindner 2005). These agents 
oscillate strongly in response to acoustic pulses to produce signal enhancement, which 
make these agents more reflective than normal tissue (Liang and Blomley 2003). 
However, molecular imaging applications of US have been limited to vascular 
processes such as angiogenesis (Ellegala, Poi et al. 2003; Leong-Poi, Christiansen et 
al. 2003; D 2004), inflammation (Lindner 2001), and thrombosis (Lanza, Wallace et 
al. 1997) because of the big size of these agents (0.1–8 µm in diameter). 
In direct contrast to nuclear imaging and MR imaging, US lack high sensitive and 
high spatial resolution, respectively. But US provides a good balance between 
detection sensitivity and spatial resolution (50–500 µm). Higher frequencies can 
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achieve higher spatial resolution at the expense of depth penetration(Liang and 
Blomley 2003). 
The advantages of US include that extracting anatomic and molecular information 
simultaneously, higher temporal resolution, and allowing for greater operator control 
and the ability to capture dynamic processes. Further benefits include portability, low 
cost, absence of ionizing radiation, and the potential for hybrid imaging/drug delivery 
probes. 
2.2.2.4 Optical Imaging 
An emerging molecular imaging mode is optical imaging, that is, the detection of 
photons after their interaction with tissue, and in particular, near-infrared fluorescence 
(NIRF) imaging, which makes use of photos emitted in the near-infrared far-red range. 
The generation of optical imaging is rendered by detection light photons with 
sensitive CCD cameras that use an absorptive process to convert light photons to an 
electric signal (Spibey, Jackson et al. 2001). For in vivo optical imaging, light photons 
emitted from imaging probes must travel through intervening tissue to reach the 
detector. As a result, signal can be attenuated because of scattering and absorption, 
mainly by hemoglobin (for visible light) and water (for near-infrared [NIR] light) 
(Weissleder R 2003). Consequently, the primary barrier in the translation of optical 
imaging from in vitro to in vivo application is from the depth at which light photons 
can travel through opaque tissue. 
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Fluorescence and bioluminescence imaging are two principal optical approaches to 
molecular imaging (Contag, Olomu et al. 1998; Weissleder R 2003). In fluorescence 
imaging, a fluorophore or fluorescent protein is first excited by an external light 
source of one wavelength and then emits visible light at a lower wavelength. Some 
fluorescent protein lacks optimization of signal-to-noise ration as a result of an 
emission wavelength (510 nm) overlapping with the autofluorescence of many 
tissues(Tsien 2005). This disadvantage can be solved by exploiting fluorochromes, 
which emit light in the NIR range (650–900 nm), in which there is minimal tissue 
absorption and autofluorescence and therefore improved signal penetration (Chance 
1998; Weissleder R 2003). 
Bioluminescence imaging is obtained by converting chemical energy to light with 
naturally occurring enzymes generically called luciferase. In such process, enzyme 
oxidizes its substrate, generically called luciferin, to produce an electronically excited 
molecule that emits light (Contag, Olomu et al. 1998). The emission colors from these 
enzyme are blue to yellow-green in color (490–620 nm) (Hastings 1996).In these 
reactions, oxygen, adenosine triphosphate, and other cofactors are often involved. To 
date, the genes for these enzymes have been cloned from many light-emitting 
organisms including firefly (Photinus pyralis), coral (Renilla reniformis), and jellyfish 
(A. aequorea) (Hastings 1996). In practice, the tissue being studied must first be 
genetically modified to express the luciferase enzyme with use of established 
gene-transfer techniques (Voss and Kruskal 1998). The subject then receives systemic 
administration of the luciferin substrate before data acquisition. 
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Bioluminescence is superior to fluorescence for imaging molecular processes because 
it has the significant advantage of not requiring external illumination to fluoresce; 
therefore, background noise is minimal and detection sensitivity is increased. The 
need for genetic manipulation is the main disadvantage for applications of 
bioluminescence.  
However, as a result of limitation of depth (< 2 cm) at which probes can be visualized, 
clinical applications of optical imaging are restricted to the in vivo imaging of small 
animals and superficial structures (Massoud TF 2003), such as dermatologic (Fischer, 
Dickson et al. 2001), intraoperative (Funovics, Weissleder et al. 2004; Raabe, Beck et 
al. 2005), endoscopic (Funovics, Weissleder et al. 2004), and intravascular imaging 
(Weissleder R 2003). Efforts to overcome this limitation have led to the development 
of fluorescence-mediated tomography, in which there is high spatial resolution and 
depth penetrations as great as 10 cm (Ntziachristos, Ripoll et al. 2002). 
High sensitivity and spatial resolution at the limited depths required for small-animal 
imagines are achieved with optical imaging. Additional advantages include fast, easy 
to perform, relatively inexpensive and plenty of optical reporters and dyes available 
for imaging multiple processes simultaneously (Weissleder 1999).  
2.2.3 Molecular imaging of cancer 
2.2.3.1 Cancer diagnosis and staging 
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Early diagnosis and accurate staging play an important role in successful cancer 
therapy (Welch, Schwartz et al. 2000). Molecular imaging offers as following 
advantages in sensing molecular alterations in tumor expression patterns, such as 
better distinguishing malignant from benign lesions, sensitively detection small 
cancers, and reduction the delay between initial malignant transformation and 
diagnosis. Tumors smaller than 0.3 mm in diameter in animal models were detected 
by Weissleder et al. with imaging tumor-associated proteases (Weissleder, Tung et al. 
1999).The essence of these strategies is the identification and validation of reliable 
and specific molecular markers of cancer (Sidransky 2002).  
FDG PET provides more accurate than CT alone in the detection and staging of 
several cancers, such as non–small-cell lung cancer, breast cancer, lymphoma, and 
melanoma (Bar-Shalom, Valdivia et al. 2000). Therefore, FDG PET has been a 
widely used oncologic imaging tool. However, due to its spatial resolution limitations, 
PET alone is being replaced by combined PET/CT for its improved anatomic detail 
and more precise lesion localization (Gambhir 2002). In contrast to PET or CT, 
PET/CT provided additional information in 41% of patients and demonstrated a 
significantly improved staging accuracy of 88% versus 40%–58% for PET or CT 
alone (Lardinois, Weder et al. 2003). 
At present, scientists are investigated on MR imaging of in vivo macrophage 
monocrystalline uptake for diagnosis of lymph node metastases. Because nodal 
tissues invaded by cancer cells are unable to physically accommodate macrophages, 
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the absence of T2 hypointensity of lymph nodes on MR imaging would provide an 
imaging marker for nodal invasion. In a human study of prostate cancer (Harisinghani, 
Barentsz et al. 2003), MR imaging after infusion of lymphotrophic monocrystalline 
particles was able to detect nodal metastases smaller than 2 mm in diameter and 
yielded sensitivity and specificity rates greater than 95%.  
2.2.3.2 Tumor characterization 
Invasive tissue acquisition for analysis was required to characterize tumors in current 
methods. But Receptor- and enzyme-based molecular imaging methods may offer 
noninvasive means of gaining real-time insights into tumor biology. In a mouse study 
comparing aggressive and well-differentiated breast cancer tissue (Bremer, Tung et al. 
2002), NIR fluorescence imaging of a cathepsin B–sensitive activatable probe can 
depicted differential levels of cathepsin activity .In contrast to the well-differentiated 
cancer tissue, NIR fluorescence signal was 1.5 times greater in the aggressive breast 
cancer tissue. This correlated well with increased cathepsin B expression and rapid 
tumor growth. Receptor imaging may be useful for tailoring the use of targeted 
molecular therapeutics. Methods have been invented to image HER-2/neu expression 
by MR imaging (Artemov, Mori et al. 2003), estrogen and progesterone receptor 
status by nuclear imaging (Jonson and Welch 1998) and epidermal growth factor 
receptor expression by optical imaging (Ke, Wen et al. 2003).  
2.2.3.3 Therapy assessment 
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In traditional criterion, assessment oncologic therapeutic response mainly depends on 
decreased tumor size (Prasad, Jhaveri et al. 2002). Many novel oncologic therapies 
aim to inhibit cell proliferation and angiogenesis and may therefore arrest tumor 
growth but not necessarily reduce tumor size. Additionally, morphologic changes 
after therapy are late and nonspecific, precluding timely adjustments in therapeutic 
regimen (Herschman 2003). However, molecular imaging provides noninvasive and 
repetitive monitor cellular and molecular processes, treatment response can be 
detected by performing serial imaging and noting changes in the surrogate endpoint.  
2.2.4 Conclusions 
The development of molecular imaging has brought out improvement of patient care. 
In the laboratory setting, molecular imaging holds promise application for dissection 
of the cellular and molecular features of various biologic processes within the milieu 
of living organisms. In clinical practice, molecular imaging provides innovative tools 
for disease characterization, earlier and more precise disease diagnosis, and 
assessment of therapeutic response.  
The practice of molecular medicine will include prevention, diagnosis, and treatment 
methods that directly target the molecular, cellular, or physiologic defects responsible 
for disease. Molecular imaging sits at the interface of this transition and offers a clear 
opportunity for interventional radiology to have a strong presence in this age of 
molecular medicine (Partain, Chan et al. 2005).  
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Further growth of molecular imaging agent and hardware technologies may 
complement existing diagnostic modes and may expand the capability to diagnose 
microscopic and subclinical disease, to provide a molecular basis for tailored disease 
therapy, and to assess the efficacy of molecular therapeutics.  
2.3 QDs as Cellular Probes 
The use of quantum dots (QDs) in biology is one of the fastest moving and most 
exciting interfaces of nanotechnology. Because traditional fluorescent labels based on 
organic molecules fall short of offering long-term stability and simultaneous detection 
of multiple signals, the unique optical properties of QDs enable them appealing as in 
vivo and in vitro fluorophores in a variety of biological investigations.  
2.3.1 Properties of QDs 
Fluorescent semiconductor nanocrystals, also called Quantum dots, are widely used 
and researched in the field of analytical chemistry and bioengineering, especially in 
fluorescent labeling for both in vivo cellular imaging and in vitro assay detection 
during the last decades. Generally, QDs are inorganic semiconductor nanocrystals in 
the size range of 1-10 nm (Alivisatos 1996; Sutherland 2002). In some cases, QDs can 
also be synthesized as rod and tetrapods in shapes (Peng 2003).  
Compared to organic fluorophores, QDs have several dramatically different properties 
especially in their unique optical spectra (Alivisatos, Gu et al. 2005). Organic dyes 
typically have narrow absorption spectra, which enable them be excited within a 
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narrow window of wavelengths. And their emission spectra are asymmetric emission 
spectra broadened by a red-tail. In contrast, QDs have broad absorption spectra, which 
mean they can be excited by a wide range of wavelengths. Furthermore, the QDs have 
symmetric and narrow emission spectra. Consequently, multicolor nanocrystals of 
different sizes can be excited with minimum signal overlap by a single wavelength 
shorter than their emission wavelengths. QDs are less susceptible to photobleaching 
than organic dye molecules owing to their inorganic composition (Bruchez, Moronne 
et al. 1998; Pinaud, King et al. 2004). This high photostability makes QDs very 
promising probes for imaging thick cells and tissues over long time periods without 
damaging the specimen. Additionally, other interesting optical properties include 
tunable emission from visible to infrared wavelengths by changing their size and 
composition, high quantum yield of fluorescence (Alivisatos, Gu et al. 2005). 
In some cases, QDs also have some drawbacks. One of them is blinking, which means 
QDs randomly alternate between an emitting state and a nonemitting state. 
Consequently, intermittence of emission from QDs can be observed from single dots, 
which limit its application under single-molecule detection. Other disadvantage is 
photobrightening, which is a QD fluorescence intensity increase upon excitation 
(Gerion 2001; Kloepfer 2003). This property may lead to some troubles in 
fluorescence quantization studies. 
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Other disadvantages includes that QDs are toxic, not water soluble, not biocompatible, 
and do not have functional groups for conjugation with biomolecules (Alivisatos, Gu 
et al. 2005). 
In fact, it is impossible that QDs can replace completely organic dyes in all biological 
application. The limitations are as following. First, in contrast to organic dyes, QDs 
are still expensive. Second, before QDs can be applied in molecular labeling, probe 
size and steric hindrance must be examined. Since different size of particles perturb 
the biological process in different extent. When several biomolecules with QDs in 
different sizes were labeled, the degree of perturbation can vary due to the large 
differences in the QDs size. In contrast, most organic dyes have almost similar size in 
spite of their different in optical properties (Hines and Guyot-Sionnest 1996; Peng, 
Schlamp et al. 1997). 
2.3.2 Synthesis of quantum dots and QDs solubilization 
As recent literature described, high quality QDs have been synthesized successfully 
(Peng and Peng 2001; Talapin, Rogach et al. 2001; Reiss, Bleuse et al. 2002). They 
are generally from groups II and VI elements (e.g. CdSe and CdTe) or groups III and 
V elements (e.g. InP and InAs) of the periodic table. 
At present, the main challenge in biomedical application comes from the availability 
of stable water-soluble QDs. In most cases, QDs are synthesized in hydrophobic 
organic solvents. There is a layer of hydrophobic organic ligands on their surface, 
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which make the QDs insoluble and thus confine their applications in the biological 
condition. There are two strategies to make QDs soluble in aqueous buffers (Michalet 
2005). One involves ligand exchange with thiol-containing molecules which contains 
a hydrophilic end. Gao et al prepared highly luminescent and biocompatible CdSe 
QDs and synthesized QD-encoded micro- and nano-beads. They showed that 
chemically modified proteins can be used to coat the surface of water-soluble QDs, to 
restore their fluorescence, and to provide functional groups for bioconjugation. In 
their work, mercaptoacetic acid (MAA) was linked to QDs, in which mercapto group 
binds to a Zn atom, and the carboxylic group allowed the QDs water-soluble and 
covalent coupling to different bimolecular (Gao, Chan et al. 2002). Pinaud et al 
reported that synthetic phytochelatin-related peptides can be used as an organic coat 
on the surface of colloidal CdSe/ZnS QDs synthesized from hydrophobic coordinating 
trioctyl phosphine oxide (TOPO) solvents (Pinaud, King et al. 2004). The peptides 
were designed to bind to the QDs via a C-terminal adhesive domain, which was 
composed of multiple repeats of cysteines pairs flanked by hydrophobic 
3-cyclohexylalanines. This surface coating chemistry results in small, buffer soluble, 
monodisperse peptide-coated nanoparticles with high colloidal stability and ensemble 
photophysical properties similar to those of TOPO-coated nanocrystals (Pinaud, King 
et al. 2004). Kim and Bawendi in 2003, QDs were connected with oligomeric ligands 
to solve the problem of their tunable compatibility in diverse environments (Kim and 
Bawendi 2003). Also, QDs were encapsulated with the dendron box to make QDs 
biocompatible and stable under different environments (Guo, Li et al. 2003). The 
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other is to coat the QDs by a layer of amphiphilic molecules, which contain 
hydrophilic and hydrophobic moieties. Gao et al developed a system of 
multifunctional nanoparticle probes based on semiconductor quantum dots (QDs) for 
cancer targeting and imaging in living animals, which involves encapsulating 
luminescent QDs with an ABC triblock copolymer and linking this amphiphilic 
polymer to tumor-targeting ligands and drug-delivery functionalities. They achieved 
sensitive and multicolor fluorescence imaging of cancer cells under in vivo conditions 
(Gao, Cui et al. 2004). Polymerized shells were also used to encapsulate QDs, which 
made them soluble in biological conditions (Gerion 2001). QDs can also be coated by 
multiple layers of different molecules. The approach of formulating a double-layered 
solubilizing shell on the surface of QDs was reported by Sukhanova et al (Sukhanova, 
Devy et al. 2004). This method made QDs biocompatible with high bright (PL 
quantum yield > 60%). It was also reported that QDs could be encapsulated in an 
amphiphilic polymer shell by nonspecific hydrophobic interaction between the alkyl 
chains of poly (maleic anhydride alt-1-tetradecene) and the QDs surfactant molecules 
(Pellegrino, Manna et al. 2004). Meanwhile, QDs can be formulated in phospholipid 
micelles, which can be a mixture of n-poly(ethylene glycol) 
phosphatidylethanolamine (PEG-PE) and phosphatidylcholine (PC) (Dubertret 2002). 
2.3.3 Conjugating QDs with biomolecules  
QDs- biological hybrids combine the spectroscopic characteristics of the QDs and the 
biomolecular function of the surface-attached entities. Several proteins can be 
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attached simultaneously to a single QD due to relative larger size compared to that of 
many proteins. Therefore, a multifunctional QDs–biological hybrid can be created by 
attachment of several proteins, or other biomolecules on the surface of QDs. 
Medintz et al. in 2003 demonstrated that 6-nm-diameter QD can be conjugated to 
about 15–20 maltose binding proteins (Medintz 2003). In these assemblies, several 
key parameters, such as surface cap used and number and size of the biomolecules 
attached to the surface, determined the conjugate dimensions. 
Different strategies for attaching proteins to QDs have been devised over the past few 
years, including (1) condensation to react carboxy groups on the QD surface to 
amines by using EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide;(2) thiolated 
peptides or polyhistidine can be directly conjugated on the surface of QDs (HIS) 
residues.; and (3) adsorption or non-covalent self-assembly using engineered proteins 
(Medintz, Uyeda et al. 2005).  
In the first strategy, intermediated aggregation may often be produced when QDs 
were capped with thiol-alkyl-COOH ligands owning to poor QD stability in 
neutral/acidic buffers. Moreover, this chemistry for QDs encapsulated with polymeric 
shells bearing COOH groups creates large conjugates with poor control over the 
number of biomolecules attached to a single QD. In spite of these disadvantages in 
this method, commercial QD-streptavidin conjugates having 20 proteins in each 
conjugate has been produced with relatively high quantum yield according to this 
method. 
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The second strategy is based on two types of QD surface–protein interaction such as 
dative thiol-bonding between QD surface sulphur atoms and cysteine residues 
(Akerman ME 2002), and metal-affinity coordination of HIS residues to the QD 
surface Zn atoms (Hainfeld, Liu et al. 1999; Slocik, Moore et al. 2002). The Weiss et 
al. pointed out that the former by using phytochelatin-related peptides to cap 
CdSe/ZnS core/shell QDs, providing not only surface passivation and water solubility, 
but also a point of biochemical modification (Pinaud, King et al. 2004). Using 
peptides for both dispersion and biofunctionalization may represent a new class of 
designed multifunctional biological cap (Mattoussi, Kuno et al. 2002).  
Engineering proteins with positive charge can self-assembled onto the surface of 
negatively charged QDs through electrostatic assembly (Mattoussi, Mauro et al. 2000). 
Some engineering proteins such as MBP and protein G have been attached 
successfully to QDs using this method (Goldman 2002). 
Despite some developments of conjugating QDs with biomolecules have been 
achieved, there are two limitations (Medintz, Uyeda et al. 2005): (1) the lack of 
homogeneous attachment when attaching proteins to QDs; (2) the inability to finely 
control ratios of proteins/QD. The former caused heterogeneous protein orientation on 
the QD surface, which may produce conjugates with surface-attached proteins that are 
not optimally functional. For example, antibodies may not be correctly oriented to 
bind their intended target and this will result in low avidity. The successful 
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applications of QDs in biology will ultimately depend on the development of 
bioconjugation. 
2.3.4 Cellular imaging and tracking 
Over the past severer years, major advances in the use of QDs for sensitive and 
multicolor cellular imaging have been achieved as a result of the developments in QD 
synthesis, surface chemistry and conjugation. 
Wu et al. (Wu, Liu et al. 2003) reported that linked polymer-protected QDs to 
streptavidin and demonstrated cell skeleton structures with confocal microscopy in 
detail. Furthermore, Dahan, Jovin and their coworkers illustrated real-time 
visualization of single-molecule movement in single living cells (Dahan, Levi et al. 
2003; Lidke 2004), which almost impossibly realize with organic dyes. The current 
advance in sensitivity of single-molecule will benefit studying receptor diffusion 
dynamics, ligand–receptor interactions, biomolecular transport, enzyme activity and 
molecular motors.  
In long-term cell imaging and tracking, Dubertret et al. reported that QDs were 
encapsulated with PEG-derivatized phospholipid micelles and injected them into frog 
embryos (Dubertret 2002). The results proved that PEG-coated QDs remain highly 
stable and biocompatible in normal embryo up to 4 days (Dubertret 2002).  
For in vivo imaging of pre-labeled cells, it was reported that large amounts of QDs 
can be delivered into live mammalian cells via three different mechanisms: 
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non-specific pinocytosis, microinjection, and peptide-induced transport (Gao, Cui et 
al. 2004). Some groups proved that the presence of two billion QDs almost did not 
effect on the viability, proliferation or migration in a single cell when QDs were 
delivered into its nucleus (Lewin M 2000; Dubertret 2002; Voura EB 2004). The 
developments in imaging single-cell migration and differentiation in real time are 
crucial in many fields such as cancer metastasis, stem-cell therapeutics, 
embryogenesis, and lymphocyte immunology. 
2.3.5 Tumor targeting and imaging 
In 2004, Gao et al. demonstrated that targeting and imaging of tumors in live animals 
could be achieved simultaneously with new multifunctional QDs (Gao, Cui et al. 
2004). Its multifunction includes in vivo protection with an amphiphilic triblock 
copolymer, tumor antigen recognition with targeting ligands and improved 
biocompatibility and circulation with multiple PEG molecules. Particle aggregation 
and fluorescence loss previously encountered for QDs stored in physiological buffer 
or injected into live animals has been overcame by exploiting an amphiphilic triblock 
copolymer. In addition, this group examined the biodistribution, nonspecific uptake, 
cellular toxicity and pharmacokinetics of these multifunctional QDs in cells and 
animal models. 
There are two mechanisms that QD probes can be delivered to tumors. One is a 
passive targeting mechanism, and another is an active targeting mechanism. The 
passive targeting mode refers to QDs are stored at tumor sites through an enhanced 
 42 
permeability and retention effect (Lanza, Wallace et al. 1997; Jain 1999; Jain 2001). It 
was caused by two factors. First, angiogenic tumors produce vascular endothelial 
growth factor, which hyperpermeabilizes the tumor-associated neovasculature and 
result in the leakage of circulating macromolecules and small particles. Second, 
tumors lack an effective lymphatic drainage system, which cause subsequent 
macromolecule or nanoparticles accumulation. In active tumor targeting mode, Gao et 
al. pointed out that a prostate-specific membrane antigen (PSMA) can be targeted 
with antibody-conjugated QDs (Gao, Cui et al. 2004). Previous literature illustrated 
that PSMA acted as a cell-surface marker for both prostate epithelial cells and 
neovascular endothelial cells (Chang, Reuter et al. 2001). Additionally, PSMA is an 
effective target for both imaging and therapeutic intervention of prostate cancer 
(Schulke, Varlamova et al. 2003). Bander et al. reported that 
radioimmunoscintigraphic scanning and targeted therapy for human prostate cancer 
metastasis were based on the accumulation and retention of PSMA antibody at the site 
of tumor growth (Bander, Trabulsi et al. 2003). 
2.3.6 Cytotoxicity 
Evidently, biocompatibility of the nanoparticles is crucial for any clinical application. 
QDs also face this problem. Indeed, in vivo toxicity is likely to be a key factor in 
determining whether QD imaging probes would be approved for human clinical use. 
There are three pathways resulting in the potential toxicity for nanoparticles (Kirchner, 
Liedl et al. 2005): (1) Their inherent chemical composition of NPs such as heavy 
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metals. Derfus et al. claimed that the concentration of Cd2+ ions released from CdSe 
particles effect directly on the cytotoxicity (Derfus, Chan et al. 2004). This is not 
surprising because the energy of UV irradiation is close to that of a covalent chemical 
bond and dissolves the semiconductor particles in a process known as photolysis, 
releasing toxic cadmium ions into the culture medium. Derfus et al. also reported Cd2+ 
ions release due to oxidation can be inhibited through encapsulating CdSe with proper 
shells such as ZnS and organic shell. (2) Negative effect of their nanoscale properties. 
Hoshino et al. reported that the interaction of CdSe/ZnS particles surface with the 
cells is the main source of cytotoxicity for CdSe/ZnS particles, compared to the 
amount of Cd2+
Although some developments of solving the toxicity of QDs have been realized, 
further study such as cytotoxicity mechanism and the strategies about decreasing 
toxicity should be further done in order to utilize QDs for humans in tumor or 
vascular imaging.  
 ions (Hoshino, Fujioka et al. 2004). (3) The effect on the shape of 
NPs. 
2.3.7 Prospective 
Although QDs have already fulfilled some of their promise as a new class of 
molecular imaging agents, efforts to make a substantial progress in cellular labeling 
will required. Because of its toxicity, QDs can exclusively be used in animal models 
as tissue probes and contrast agents. One intriguing area of QDs is that capturing and 
visualizing low-copy-number biomolecules can be realized with the particles 
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combined magnetic and luminescent QDs. Recent reports illustrated the QDs are 
combined with Fe2O3
Although QDs address many advantages in contrast to organic dyes reagent, it is 
impossible to replace organic dyes reagent completely with QDs. Indeed, QDs are 
complement dye in particular applications such as in vivo imaging. The era of 
practical applications about QDs does not come, but QDs have represented some 
valuable applications in biological field. 
 and FePt nanoparticles (Gu, Zheng et al. 2004; Wang, He et al. 
2004).Thus, during an operation of surgeon, tiny tumors or other small lesions can be 
visually identify with this kind of multifunction nanoparticles, which contain the deep 
imaging capabilities of magnetic nanoparticles with optical feature of QDs. 
Consequently, the diseased cells and tissue can remove completely. This magnetic 
QDs probes allow for not only identifying disease non-invasively, but also providing 
a visual guide during surgery. Other interesting multifunctional nanoparticles can be 
created by combination QDs with a therapeutic agent. These multifunctional 
nanoparticles can realize tracking of pharmacokinetics and treat diseased tissue 
simultaneously in real time. 
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Chapter 3 Formulation, Characterization and In Vitro 
Evaluation of Quantum Dots Loaded in 
Poly(lactide)-vitamin E TPGS Nanoparticles for Cellular 
and Molecular Imaging 
 
3.1 Introduction  
Fluorescent semiconductor nanocrystals, also called quantum dots (QDs), have been 
widely used and investigated in the fields of analytical chemistry and bioengineering, 
especially in fluorescent labeling for both in vivo cellular and molecular imaging and 
in vitro assay detection. Applications of QDs include serving as specific markers for 
cellular and molecular structures, tracing cell line age, monitoring physiological 
events in live cells, measuring cell motility, and tracking cells in vivo. Compared with 
the organic dye molecules, QDs have several advantages. Organic dye molecules have 
narrow absorption bands which make it difficult to excite multiple colors with a single 
excitation source. The emission density of organic dye molecules relies on the 
environment. They could not offer long-term photostability. They suffer from fast 
photobleaching and broad, overlapping emission lines (Gerion, Pinaud et al. 2001). 
The biological applications of the traditional organic dye are thus limited. Instead, 
QDs give several interesting and powerful optical properties, such as tunable emission 
from visible to infrared wavelengths by changing their size and composition, broad 
excitation spectra with higher absorption coefficients, high quantum yield of 
fluorescence, stronger brightness and photostability, and high resistance to 
photobleaching. All those features have attracted tremendous interest in exploiting 
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biomedical applications of QDs (Ballou, Lagerholm et al. 2004; Alivisatos, Gu et al. 
2005). 
In spite of the great advantages, there have been strong concerns on QDs for their 
practical applications, which include (1) biocompatibility - the possible impact of 
QDs on health is not clear. The pharmacokinetic processes, i.e. absorption, 
distribution, metabolism and excretion (ADME) of QDs are yet to be understood; (2) 
Lack of targeting effects - imaging could thus be blurred by the background noise; (3) 
colloidal instability - QDs have problem in formulation. QDs may aggregate and thus 
deteriorate their optical/magnetic properties; (4) confinement by the physiological 
drug barriers such as gastrointestinal (GI) drug barrier for oral administration and the 
blood-brain barrier (BBB) for brain imaging; (5) fast excretion by the 
reticuloendothelial system (RES). QDs can be successfully applied in biology and 
medicine if
At present, the main challenge of QDs in biomedical application is to make stable 
water-soluble QDs. In most cases, QDs are synthesized in hydrophobic organic 
solvents. There is thus a layer of hydrophobic organic ligands on th
 these problems can be solved.  
eir surface, which 
make the QDs insoluble and thus confine their applications in the biological condition. 
There are two strategies to make QDs soluble in aqueous buffers (Michalet, Pinaud et 
al. 2005). One involves ligand exchange with thiol-containing molecules, which 
contains a hydrophilic end. Gao et al prepared highly luminescent and biocompatible 
CdSe QDs and synthesized QD-encoded micro- and nano-beads. They showed that 
chemically modified proteins can be used to coat the surface of water-soluble QDs to 
restore their fluorescence, and to provide functional groups for bioconjugation. In 
their work, mercaptoacetic acid (MAA) was linked to QDs, in which mercapto group 
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binds to Zn atom, and the carboxylic group allowed the QDs water-soluble and 
covalent coupling to biomolecules (Gao, Chan et al. 2002). Pinaud et al reported that 
synthetic phytochelatin-related peptides can be used as an organic coat on the surface 
of colloidal CdSe/ZnS QDs synthesized from the hydrophobic trioctyl phosphine 
oxide (TOPO) solvent. The peptides were designed to bind to the QDs via a 
C-terminal adhesive domain, which was composed of multiple repeats of cysteine 
pairs flanked by hydrophobic 3-cyclohexylalanines. This surface coating chemistry 
results in small, buffer soluble, monodisperse peptide-coated nanoparticles with high 
colloidal stability and ensemble photophysical properties similar to those of 
TOPO-coated nanocrystals (Pinaud, King et al. 2004). Kim and Bawendi reported that 
QDs were connected with oligomeric ligands to solve the problem of their tunable 
compatibility in diverse environments (Kim and Bawendi 2003). QDs were also 
encapsulated in Dendron box to make QDs biocompatible and stable under various 
environments (Guo, Li et al. 2003). The other is to coat the QDs by a layer of 
amphiphilic molecules, which contain hydrophilic and hydrophobic moieties. Gao et 
al developed a system of multifunctional nanoparticle probes based on semiconductor 
quantum dots (QDs) for cancer targeting and imaging in living animals, which 
involves encapsulating luminescent QDs with an ABC triblock copolymer and linking 
this amphiphilic polymer to tumor-targeting ligands and drug-delivery functionalities. 
They achieved sensitive and multicolor fluorescence imaging of cancer cells under in 
vivo conditions (Nasongkla, Shuai et al. 2004). Polymerized shells were also used to 
encapsulate QDs, which made them soluble in biological conditions (Gerion, Pinaud 
et al. 2001). QDs can also be coated by multiple layers of different molecules. The 
approach of formulating a double-layered solubilizing shell on the surface of QDs was 
reported by Sukhanova et al. This method made QDs biocompatible with high bright 
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(PL quantum yield >60%)  (Sukhanova, Devy et al. 2004). It was also reported that 
QDs could be encapsulated in an amphiphilic polymer shell by nonspecific 
hydrophobic interaction between the alkyl chains of poly (maleic anhydride 
alt-1-tetradecene) and the QDs surfactant molecules (Pellegrino, Manna et al. 2004). 
Meanwhile, QDs can be formulated in phospholipid micelles, which can be a mixture 
of n-poly(ethylene glycol) phosphatidylethanolamine (PEG-PE) and 
phosphatidylcholine (PEG-PC) (Dubertret, Skourides et al. 2002).  
In past two years, other materials were also used to encapsulate QDs in order to 
overcome its limitation of biologic applications. For example, it was reported that 
QDs or QDs/Gd-DTPA can be embedded in chitosan for biological applications (Tan, 
Huang et al. 2007; Tan and Zhang 2007). Other reports included QDs encapsulated in 
liposomes and solid lipid NPs (Chen, Yao et al. 2006; Liu, Liang et al. 2006). 
Biodegradable and biocompatible polymers have been used to formulate QDs in 
recent years. In 2006, Guo et al used the PLA polymer to formulate QDs (Guo, Liu et 
al. 2006; Guo, Liu et al. 2007). Other group also reported that QDs were incorporated 
into PLGA (Yang, Lin et al. 2006). PLA and PLGA are widely used in the literature 
for drug delivery and tissue engineering. However, they have disadvantages to be 
applied for drug formulation, which include too high hydrophobicity and too slow 
degradation. Consequently, it is necessary to synthesize novel biodegradable 
polymers/copolymers, which have desired hydrophobic-lipophilic balance (HLB) and 
desired degradation rate (Zhang and Feng 2006). We propose in this research to 
formulate QDs in the nanoparticles of biodegradable copolymers to improve their 
imaging effects and to reduce their side effects in biological and medical applications. 
The idea is inspired from our achievements in nanoparticles of biodegradable for 
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new-concept chemotherapy (Feng and S 2003; Feng 2004; Feng, Mu et al. 2004; Feng 
2006). The polymer used in this research is a novel copolymer, poly (lactide acid) - 
d-α-tocopheryl polyethylene glycol 1000 succinate (PLA-TPGS), which was 
innovatively synthesized in our Chemotherapeutic Engineering Laboratory. Vitamin E 
TPGS (or TPGS) is a water-soluble derivative of natur
For applications of QDs in vivo, it is essential to avoid being recognized and 
eliminated by the reticuloendothelial system (RES). The PEG component on the 
surface of the PLA-TPGS nanoparticles has been found to be a particularly effective 
steric stabilizer to protect nanoparticles from opsonization and phagocytocis. Also, the 
presence of PEG component can improve the water solubility of nanoparticles and 
inhibited coagulation and reduce nonspecific adsorption (Gref, Domb et al. 1995). 
Consequently, encapsulation of QDs in PLA-TPGS NPs could greatly improve 
biocompatibility, reduce nonspecific deposition, and realize prolong circulating 
al vitamin E, comprising 
lipophilic alkyl tail and hydrophilic polar head portion. It has been found that 
co-administration of TPGS could enhance cytotoxicity, inhibit P-glycoprotein 
mediated multi-drug resistance, and increase the oral bioavailability of anticancer 
drugs (Dintaman and Silverman 1999; Yu, Bridgers et al. 1999; Fischer JR 2002). In 
our earlier research, TPGS has been successfully applied as an efficient emulsifier, 67 
time more efficient than poly(vinyl alcohol) (PVA), in preparation of nanoparticles of 
biodegradable polymers for drug delivery, which can achieve 100% drug 
encapsulation efficiency (Mu and Feng 2002; Mu and Feng 2003; Mu, Teo et al. 
2005). PLA-TPGS was thus synthesized and PLA-TPGS nanoparticles were then 
prepared to formulate small molecule drugs and protein drugs as well as to realized 
targeted drug delivery (Zhang and Feng 2006; Lee SH 2007; Zhang.Z.P., SH et al. 
2007). 
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lifetime, which can thus have a wide range of biological applications of cellular and 
molecular imaging, including cellular and molecular labeling, deep-tissue imaging, 
assay labeling and being used as donors in efficient fluorescence resonance energy 
transfer (FRET). It was reported that PEG-shielded QDs can have the extended 
circulating lifetime of 48-72h in blood and that methoxy-PEG or carboxy-PEG QDs 
kept fluorescent about four months in vivo (Ballou, Lagerholm et al. 2004; Nasongkla, 
Shuai et al. 2004). We expect that our novel PLA-TPGS nanoparticle formulation of 
QDs would have even better performance than the PEG-QDs conjugation. 
In this research, the QDs-loaded PLA-TPGS NPs were prepared by a modified 
solvent extraction/evaporation method and their size and size distribution, surface 
morphology, surface chemistry, and QD encapsulation efficiency were conducted. 
Cellular imaging and toxicity of the QDs-loaded PLA-TPGS NPs was investigated in 
close comparison with those of the parent QDs.  
3.2 Materials and Methods 
3.2.1 Materials 
Organic Quantum Dots (Qdot®655 ITKTM) dispersed in 75/25 Methanol/Isopropanol 
mixture (catalog number 2172-1) were purchased from Invitrogen Corporation 
Singapore (http://probes.invitrogen.com/products/qdot/). Before used, quantum dots 
need to be pretreated according to the approach described by the Company. Lactide (3, 
6-dimethyl-1, 4-dioxane-2, 5-dione, C6H8O4) was purchased from Aldrich. It was 
recrystallized twice with ethyl acetate before put in reaction. D-a-tocopheryl 
polyethylene glycol 1000 succinate, (C33O5H54, Vitamin E TPGS or simply TPGS) 
was purchased from Eastman Chemical Company (USA). Stannous octoate 
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(Sn(OOCC7H15)2
3.2.2 Synthesis of PLA-TPGS copolymer 
) and polyvinyl alcohol (PVA,  Mw: 30,000-70,000), 
3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), MEM medium, 
penicillin-streptomycin solution, Trypsin-EDTA solution, were provided by Sigma. 
Fetal bovine serum (FBS) was purchased from Gibco (Life Technologies, AG, 
Switzerland). All chemicals used in this study were HPLC grade. Millipore water was 
produced by the Milli-Q Plus System (Millipore Corporation, Breford, USA). MCF-7 
breast cancer cells were provided by American Type Culture Collection 
PLA-TPGS of component ratio PLA: TPGS=88:12 w/w was synthesized by following 
a modified procedure as described in an earlier publication of our group (Zhang and 
Feng 2006). 0.1g 0.5wt% stannous octoate (in distilled toluene), 17g lactide, 3g TPGS 
were loaded into a 50 ml flask. The mixture was stirred for 12h at 145ºC under a 
nitrogen flow in silicone oil bath. After the polymerization, the product was dissolved 
in dichloromethane (DCM). Excess cold methanol was injected in order to precipitate 
the product and remove the excess lactide and TPGS. The final product was obtained 
by filtration and vacuum dried. 
3.2.3 Preparation of QDs-loaded PLA-TPGS NPs and MAA-coated QDs 
QDs-loaded PLA-TPGS NPs were prepared by a modified solvent 
exaction/evaporation technique (oil-in-water single emulsion) (Zhang and Feng 
2006; Zhang and Feng 2006). Typically, 300mg PVA was dissolved in 60ml water 
to form a water phase. 50mg PLA-TPGS copolymer and 0.15ml of 1µM organic 
QDs were dissolved in 4ml DCM to form an organic phase. The organic phase was 
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then poured slowly into the water phase. The emulsion was vortexed with a vortex 
mixer (Model: s0100-230v, Labnet Intenational Inc, USA) and then sonicated with 
a sonicator (Model: XL2000, Misonix incorporated, USA) for 3 min at 20 W 
output. The mixture was stirred for at least 12h at room temperature and then 
centrifuged at 10,500 rpm for 15min. The supernatant was discarded. The 
precipitation was freeze-dried to collect the NPs power, or directly dispersed in 
water and stored in refrigerator for in vitro and in vivo experiment. 
MAA-coated QDs were prepared for comparison of the imaging effects and side 
effects between alternative formulations, which were made by the method described 
in the literature (Chan and Nie 1998). Briefly, QDs were readily redissolved in 
chloroform based on the procedure from QDs company. And then, excess MAA was 
reacted with colloidal QDs in chloroform for 2 hours. Next, phosphate-buffered saline 
solution was added into this reaction mixture. Further, water-soluble QDs can be 
obtained after vigorous shaking and extracting. 
3.2.4 Characterization of QDs-loaded PLA-TPGS NPs 
3.2.4.1 Particle size analysis 
Particle size and size distribution of the QDs-loaded PLA-TPGS NPs were measured 
by the laser light scattering (LLS, 90 Plus Particle Size, Brookhaven Instruments Co. 
USA). 0.2ml QDs-loaded PLA-TPGS NPs suspension was put in 3 ml deionized 
water and sonicated for several minutes. The homogeneous suspension was used to 
determine the volume mean diameter, size distribution and polydispersity. 
3.2.4.2 Surface morphology 
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The shape and surface morphology of QDs-loaded PLA-TPGS NPs were investigated 
by field emission scanning electron microscopy (FESEM, JSM-6700F, JEOL, Japan), 
atomic force microscopy (AFM, Multimode scanning probing microscope, Digital 
Instruments, USA) and transmission electron microscope (TEM, JEM-2010F, JEOL, 
Japan). For FESEM, it is necessary to coat the QDs-loaded PLA-TPGS NPs by 
platinum, which was carried out by an Auto Fine Coater (JFC-1300, JEOL, USA). For 
AFM, the QDs-loaded PLA-TPGS NPs suspension was spread on a freshly cleaved 
mica sheet and dried at vacuum condition. AFM was operated in “tapping mode” in 
air. For TEM, the QDs-loaded PLA-TPGS NPs suspension was dropped on the 
surface of copper grid with carbon film and dried at room temperature. 
3.2.4.3 Surface chemistry of QDs-loaded PLA-TPGS NPs 
The surface chemistry of QDs-loaded PLA-TPGS NPs was analyzed by X-ray 
photoelectron spectroscopy (XPS, AXIS His-165 Ultra, Kratos Analytical, Shimadzu 
Corporation, Japan). A binding energy ranged from 0 to 1,100 eV was recorded in the 
survey spectrum with pass energy of 80 eV under the fixed transmission mode. The 
analysis of the data obtained by XPS was carried out by the software of XPS Peak 4.1. 
Fourier transform infra-red (FTIR, Shimadzu, Japan) was also employed to analyze 
the surface chemistry in order to have a further understanding of the chemical 
structure of the QDs-loaded PLA-TPGS NPs. The absorbance spectrum was obtained 
rapidly and directly from a controllable sampling depth. Before the measurement, a 
transparent tablet was formed by pressing the mixture of 99% KBr and 1% the 
QDs-loaded PLA-TPGS NPs, which was then scanned in the IR range from 400 to 
4000 cm-1 with a resolution of 16 cm-1 under the reference of carbon black. 
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3.2.5 Photophysical characterization 
3.2.5.1 Fluorescent images 
The true-color fluorescent images (excitation: 365nm) of the suspension of QDs in 
n-Decane ([QDs]=0.21nM) or the QDs-loaded PLA-TPGS NPs in water or PBS 
([QDs] =6.9nM) were recorded with a digital color camera (Coolpix4300, Nikon, 
Japan) under the radiation of UV lamp (Model UVGL-58, Mineralight lamp, UVP, 
USA). 
3.2.5.2 Emission spectra 
The suspension of QDs
3.2.5.3 The photostability 
 in n-Decane ([QDs] =0.21nM) or the QDs-loaded PLA-TPGS 
NPs in water ([QDs] =6.9 nM) was placed into 96-well black plates (Costar, IL, USA), 
PL spectrum was investigated with the microplate reader (Genios, Tecan, Männedorf, 
Switzerland) at excitation 530nm. 
To measure the photostability of the suspension of the QDs in n-Decane and the 
QDs-loaded PLA-TPGS NPs in PBS or water under continuous UV radiation at 
365nm (Model UVGL-58, Mineralight lamp, UVP, USA), a thin quartz cuvette was 
filled with 1 ml of the QDs suspension in n-Decane or 1 ml of the QDs-loaded 
PLA-TPGS NP suspension in PBS or water at the same 6.9nM QDs concentration. 
The microplate reader at excitation 530nm was used to determine the emission 
intensities, which were recorded and normalized by the control value. 
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3.2.6 QDs encapsulation efficiency 
The encapsulation
%100
process in the added QDs ofamount  Total
NPsin  QDs ofamount  edEncapsulat efficiency loading ×=
 efficiency of QDs in the PLA-TPGS NPs was evaluated by 
inductively coupled plasma optical emission spectrometry (ICP-OES, Model: Optima 
3000DV, Perkin-Elmer).  Three milligrams of the QDs-loaded PLGA-NPs were 
dissolved in 2ml reagent grade 30% hydrochloric acid. The solution was then heated 
in an oil bath until 60ºC, which was then filtered by 0.45μm poly(vinyl idene fluoride) 
(PVDF) syringe filter for further analysis by ICP-OES to determine the actual amount 
of the QDs encapsulated in the PLA-TPGS NPs. Moreover, the amount of QDs in the 
supernatant obtained from the centrifugation of the QDs-loaded PLA-TPGS NP 
emulsion can also be determined. The sum of the two results should be 100% of the 
QDs added in the process, which can be used as a double check to see if the 
measurement is correct. The QDs encapsulation efficiency was defined by the 
following calculation equation: 
 
3.2.7 Cell line experiment 
3.2.7.1 Cell culture 
MCF-7 breast cancer cells were used in this study. The Dulbecco's Modified Eagle's 
Medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin was utilized as cell culture medium. Cells were cultivated in 
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DMEM at 37℃ in humidified environment of 5%  CO2
3.2.7.2 In vitro cellular uptake of QDs-loaded PLA-TPGS NPs 
. Before experiment, the cells 
were pre-cultured until confluence has reached. 
MCF-7 cells were cultivated in the chambered cover glass system (LAB-TEK®, Nagle 
Nunc, IL) with 5% CO2 in the media at 37℃ as proposed by American Type Culture 
Collection. After 12h incubation, the adherent cells were washed twice with PBS. 0.9 
ml of QDs-loaded PLA-TPGS NPs diluted in the medium at concentration 0.25μg/μl 
were added into the chamber. After incubation for 24h to allow the cells to internalize 
the NPs, the cells were rinsed three times with PBS in order to remove the NPs 
remained in the chambers. Further, 75% ethanol was used to fix the cells. After 20 
minutes, the ethanol was removed. The nuclei of the cells were stained by 
4’
3.2.7.3 In vitro cytotoxicity of QDs-loaded PLA-TPGS NPs 
,6-Diamidino-2-phenylindole dihydrochloride, Fluka (DAPI) about 30 minutes. The 
cells were washed twice again with PBS. In order to visualize the cells, the chambers 
were mounted onto the confocal laser scanning microscope (CLSM, Zeiss LSM 410, 
Germany) with imaging software (Fluoview FV500). The images of the cells were 
determined with differential interference contrast (DIC) channel, and the images of 
QDs and the nuclei of the cells stained by DAPI were recorded with following 
channels: blue channel (DAPI) with excitation at 340nm and red channel (QDs) with 
excitation at 530nm. 
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MCF-7 cells were incubated in 96-well plates (Costar, IL, USA) as previously 
described. After for 24h seeding, the old medium was removed and the fresh medium 
containing QDs-loaded PLA-TPGS NPs or MAA-coated QDs with a designated QDs 
concentration were added into the wells. At given time intervals, the cultured cells 
were assayed for cell viability with methylthiazolyldiphenyl-tetrazolium bromide 
(MTT) assay. The wells were washed twice with PBS and 10μl of MTT supplemented 
with culture medium was added. After 4h incubation in the incubator, the culture 
medium was removed and the precipitate was dissolved in isopropanol. The 
absorbance intensity of the cells was measured by the microplate reader (Genios, 
Tecan, Männedorf, Switzerland) as the absorbance at 570nm minus background at 
660nm. The cell viability was evaluated as percentage of that for the control cells 
cultured without QDs. 
3.3 Result and Discussion 
3.3.1 Characterization of the PLA-TPGS copolymer 
PLA-TPGS copolymer with various PLA: TPGS ratios were synthesized in our 
Chemotherapeutic Engineering Laboratory (Zhang and Feng 2006a; Zhang and Feng 
2006b). The purpose is to obtain novel biodegradable copolymers of desired 
hydrophilic-lipophilic balance (HLB) to improve the drug encapsulation efficiency 
and the cellular uptake of the nanoparticles for drug delivery as well as to protect the 
bioactivity of proteins and peptides in the nanoparticles formulation (Zhang and Feng 
2006; Zhang and Feng 2006; Lee SH 2007). The structure of the synthesized 
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PLA-TPGS copolymers was detected by 1H NMR, which is shown in figure 3-1. The 
weight-averaged molecular weight (Mw) and the number-averaged molecular weight 
(Mn) of the PLA-TPGS copolymers can be determined by gel permeation 
chromatography (GPC) (Zhang and Feng 2006). The PLA: TPGS component ratio for 
the PLA-TPGS copolymer used in this research is 88:12 w/w, for which, it has been 
determined that Mw =23,072 and Mn= 14,790 with polydispersity 1.56. 
 
Figure 3-1 Molecular structure of PLA-TPGS copolymer 
3.3.2 Characterization of QDs-loaded PLA-TPGS NPs 
3.3.2.1 Size and size distribution 
The volume average hydrodynamic diameter for the QDs-loaded PLA-TPGS NPs, 
which was determined by laser light scattering, was found around 200nm with narrow 
size distribution of 0.15 polydispersity. Such a size may be ideal for QDs formulation 
since it has been found that NPs of 100-200 nm in diameter could have best effects in 
cellular uptake of the nanoparticles (Khin YW and Feng 2005). 
 59 
3.3.2.2 Surface morphology 
The FESEM image of QDs-loaded PLA-TPGS NPs is shown in figure 3-2, which 
reveals that the QDs-loaded PLA-TPGS NPs are spherical in shape and quite uniform 
in size distribution. The particle size measured directly from this FESEM image 
agrees with that determined by the laser light scattering. The AFM images obtained 
by using the tapping mode are shown in figure 3-3, which have higher resolution to 
observe the shape and surface morphology of the QDs-loaded PLA-TPGS NPs. The 
relative smooth surface of the NPs can be observed clearly from either the single 
nanoparticle or a handful of NPs. NPs of smooth surface can lead to a longer retention 
time by the cells than those of rough surface. These images also present the evidence 
that there are no free QDs on the surface of the NPs. 
 
Figure 3-2 Field emission scanning electron microscopy (FESEM) of quantum 




Figure 3-3 Atomic force microscopy (AFM) of quantum dots-loaded PLA-TPGS 
nanoparticles 
Figure 3-4A shows TEM image of the free QDs suspension, from which aggregation 
and cohesion of QDs with an average size of about 10 nm can be observed. Figure 
4-4B shows the TEM image of an individual QDs-loaded PLA-TPGS NP at high 
resolution, from which it can be seen that QDs (the black dots) are encapsulated in the 
matrix of the PLA-TPGS NP. Furthermore, it was found that there are no free QDs on 
the NP surface. 
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Figure 3-4 Transmission electron microscopy (TEM) of (A) the quantum dots 
suspension and (B) the quantum dots-loaded PLA-TPGS nanoparticles 
3.3.2.3 Surface chemistry of QDs-loaded PLA-TPGS NPs 
The C1s (atomic orbital 1s of carbon) XPS spectra of the pure PLA-TPGS copolymer 
and the QDs-loaded PLA-TPGS NPs are shown in figure 3-5. The peak at binding 
energy 286.2eV represents the carbon in C-O-C, which indicates the existence of PEG 
component of the TPGS on the surface of the NPs. This figure reveals that the C-O-C 
peak ratio increases from 22.32% for the pure PLA-TPGS copolymer to 25.69% for 
the QDs-loaded PLA-TPGS NPs, which were made by using PVA as emulsifier. The 
difference may be produced by the PVA residues on the nanoparticle surface since 
although the nanoparticles were repeatedly washed, some of the PVA residues may 
still have remained on the nanoparticle surface (Carrio A 1995; Birnbaum DT 2000; 
Sahoo SK 2002). 
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Figure 3-5 X-ray photoelectron spectroscopy (XPS) C 1s spectra of (A) the pure 
PLA-TPGS copolymer and (B) the quantum dots-loaded PLA-TPGS nanoparticles 
Figure 3-6 shows the full XPS spectrum of the QDs-loaded PLA-TPGS NPs, which 
shows that there is no sulfur element present on the surface of the QDs-loaded 
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PLA-TPGS NPs. It is thus evidenced that all encapsulated QDs are located in the 
PLA-TPGS matrix with none of them located on the nanoparticle surface. 
 
Figure 3-6 X-ray photoelectron spectroscopy (XPS) spectra of the quantum 
dots-loaded PLA-TPGS nanoparticles 
To investigate if there is any possible change in chemical structure of the 
PLA-TPGS copolymer before and after the nanoparticle formulation of the QDs, 
the FT-IR was performed and the spectra of the pure PLA-TPGS copolymer and 
the QDs-loaded PLA-TPGS NPs were shown in figure 3-7, from which it can be 
seen that there is no significant difference between the spectra of the pure 
PLA-TPGS copolymer and the QDs-loaded PLA-TPGS NPs. This further 
confirmed our finding that all encapsulated QDs are located in the PLA-TPGS 
matrix with none of them located on the nanoparticle surface. 
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Figure 3-7 Fourier transform infra-red spectroscopy (FTIR) spectra of (a) the pure 
PLA-TPGS copolymer and (b) the quantum dots-loaded PLA-TPGS nanoparticles 
3.3.3 Photophysical characterization 
3.3.3.1 Fluorescent colors and emission spectra  
Figure 3-8 shows the fluorescent colors of the QDs suspended in n-Decane and the 
QDs-loaded PLA-TPGS NPs dispersed in PBS or in water at the same QDs 
concentration with excitation wavelength 350nm. All are found emitting 
fluorescence with a pure color.  
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Figure 3-8 The fluorescent colors of the suspensions of (a) the QDs in n-Decane 
([QDs] =0.21nM), (b) the QDs-loaded PLA-TPGS nanoparticles in water ([QDs] 
=6.9nM), and (c) the QDs-loaded PLA-TPGS nanoparticles in PBS ([QDs] =6.9nM) 
Figure 3-9(a) shows the emission spectra of the QDs suspension and the QDs-loaded 
PLA-TPGS nanoparticles, which were measured by the microplate reader. It can be 
seen from this figure that the PLA-TPGS NP formulation of the QDs caused a shift of 
the emission peak to blue from 654 to 650 nm. The reason may be the decrease in 
QDs size after the NP formulation because of losing of surface atoms arising from 
oxidation. But the full width at half-maximum (FWHM, 32 nm) has hardly changed. 
It was reported that chalcogenide atoms (Se, S) on the surface of QDs can be oxidized 
by O2 to form oxides (SeO2, SO42-), which would be desorbed from the surface 
(Spanhel, Haase et al. 1987; Alivisatos 1996). Following this instruction we further 
investigated by using spectrofluorophotometer (RF-5301PC, SHIMADZU, Japan) and 
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we found that the shift was even smaller, which was only 0.8 nm. This result has been 
added in the revised version as figure 3-9(b). It should be noted that the shift in the 
emission spectrum between the parent QD and the PLA-TPGS NP formulation 
suspensions could be slightly different if measured by different instruments. To show 
how large such difference could be, we further applied the spectrofluorophotometer 
(RF-5301PC, SHIMADZU, Japan) to repeat the investigation and we found that the 
shift was the shift was 0.8 nm (figure 3-9(b)). Such small shift would not affect the 
photo properties. The visual difference shown in figure 3-8 was caused by the 






Figure 3-9 Emission spectra of the QDs suspension and the QDs-loaded PLA-TPGS 
nanoparticles measured by (a) microplate reader and (b) spectrofluorophotometer 
3.3.3.2 Photostability  
Figure 3-10 shows evolution of the relative emission intensities for the QDs-loaded 
PLA-TPGS nanoparticles suspended in PBS or water and that for the QDs suspension 
in n-Decane as function of the irradiation time. The relative emission intensity of free 
QDs decreased almost to zero at 12 h and reached zero at 72h, whereas the relative 
emission intensities were still present with little fluctuations for the QDs loaded NPs 
after 30 days irradiation process. This indicates that PLA-TPGS NP formulation of 
QDs has great advantages versus the QDs suspension in n-Decane in increasing their 
fluorescent intensity as well as their photostability, which thus improve the image 
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quality as well as extend their life-time for imaging. Such advantages are useful in 
cellular, tissue and whole-body imaging as well as in molecular imaging with 
biomarkers. Possibly, reduction in the emission intensity for the free QDs may be 
caused by decomposition of the QDs due to prolonged exposure to an oxidative 
environment. As the QDs-loaded PLA-TPGS NPs regard, QD surface oxidation is 
prevented by limited transportation of oxygen to the surface of the QDs encapsulated 
in the polymeric matrix. Here the TPGS-PLA matrix may act as a physical diffusion 
barrier for O2 molecules to the QD surface. In addition, figure 3-10 clearly shows that 
the QDs-loaded PLA-TPGS NPs suspended in water exhibited even higher 
photostability than those suspended in PBS. Although the detailed mechanism is 
unclear, the difference in the diffusivity of the QDs in PBS and water could provide 
an explanation, i.e. the dispensability and the specific distribution of the QDs in PBS 
and water may strongly affect their photostability under continuous UV irradiation. 
 
Figure 3-10 Evolution relative emission intensities for the QDs-loaded PLA-TPGS 
nanoparticles in PBS or in water and the QDs suspension in n-Decane as function of 
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the irradiation time. Data represent mean (n=5) +SD 
3.3.4 QDs encapsulation efficiency 
QDs encapsulation efficiency in the PLA-TPGS NPs in this research was measured by 
ICP-OES as described in the last section. It was found that about 46% of the QDs 
added in the process were encapsulated in the PLA-TPGS NPs in this preliminary 
investigation. It should be noticed that smaller NPs would resulted in lower 
encapsulation efficiency since the surface area per unit volume would be increased for 
smaller NPs, that will result in more loss of the QDs from the NPs, which may diffuse 
from the polymeric matrix to the solution at the NP preparation process (Gorner, Gref 
et al. 1999). The interaction between hydrophobic quantum dots and polymers is 
hydrophobic interaction, which is defined as the tendency of hydrocarbons or 
hydrocarbon-like groups in solutes to form intermolecular aggregates in an aqueous 
medium. This term arises from the attribution of the phenomenon to the apparent 
repulsion between water and hydrocarbons. 
3.3.5 In vitro evaluation 
3.3.5.1 Cellular uptake of nanoparticles 
Figure 3-11 shows that confocal laser scanning microscopy (CLSM) of the MCF-7 
cancer cells after 24h incubation with the QDs-loaded PLA-TPGS NP suspension in 
the Dulbecco’s modified Eagle’s medium (DMEM) at 0.25mg/ml NP concentration. 
The images were obtained from (A) the combined red channel and blue channel; (B) 
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the blue channel and (C) the red channel. Figure 3-11 clearly shows that the 
QDS-loaded PLA-TPGS NPs have been internalized into the cells. To further confirm 
the internalization of the NPs, the sectioning function of CLSM was applied. It was 
found that the internalized NPs were mostly accumulated in perinuclear vesicles 
around the nucleus stained by DAPI. 
 
Figure 3-11 Confocal laser scanning microscopy (CLSM) of the MCF-7 cancer cells 
after 24h incubation with the QDs-loaded PLA-TPGS NP suspension in DMEM at 
0.25μg/μl NPs concentration. The images were obtained from (A) the combined red 
channel and blue channel; (B) the blue channel and (C) the red channel 
3.3.5.2 In vitro cytotoxicity of QDs-loaded PLA-TPGS NPs 
Biocompatibility of QDs is a crucial issue for their potentials in clinical 
applications. There are three pathways which may result in certain toxicity of the 
nanoparticles (Service 2000): (1) their inherent chemical composition such as 
heavy metals. Derfus et al claimed that the concentration of Cd2+ ions released 
from CdSe QDs may have direct effect on their cytotoxicity. They reported that 
release of the Cd2+ ions from the QDs due to oxidation can be inhibited by coating 
the CdSe QDs with proper shells such as ZnS and organic shell (Derfus, Chan et 
al. 2004). (2) Negative effect of the nanoscale properties of the QDs. It was 
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reported that the interaction of the CdSe/ZnS QD surface with the biological cells 
is the main source of cytotoxicity for CdSe/ZnS QDs in comparison with the 
amount of Cd2+
Due to our success in synthesis of the PLA-TPGS copolymers and application of 
PLA-TPGS nanoparticle formulation for delivery of anticancer drugs (Zhang and 
Feng 2006; Zhang and Feng 2006; Lee SH 2007; Zhang.Z.P., SH et al. 2007), it is 
natural to use PLA-TPGS NPs for QDs formulation to improve their imaging 
effects and to decrease their side effects on health. Figure 3-12 shows that the 
cytotoxicity of the QDs-loaded PLA-TPGS NPs is dependent on the QD 
concentration and the incubation time. The MCF-7 cell viability decreases with 
increasing the QDs concentration. This is because the QDs are cytotoxic and the 
PLA-TPGS NP formulation can decrease but cannot completely eliminate their 
cytotoxicity. Figure 3-12 also demonstrated that the QDs-loaded PLA-TPGS NPs 
resulted in higher cell viability compared with the MAA-coated QDs when QDs 
concentrations are less than 1.0 nM. There may be two reasons to explain it. 
Firstly, polymer shell rather than MAA shell provides a better protection against of 
Cd
 ions (Kirchner, Liedl et al. 2005). (3) Possible effects of the QD 
shape. 
2+
However, the lower cytotoxicity of the QDs-loaded PLA-TPGS NPs compared 
with that of the MAA-coated QDs in same QDs concentration (1.5 nM) may be 
 ions from the surface of QDs. Secondly, PLA-TPGS NPs contain PEG group, 
which can decrease the non-specific cell uptake. 
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due to the too high concetration of NPs (0.435mg/ml). It has been reported that the 
concentration of NPs can influence the cell viability (Kirchner, Liedl et al. 2005). 
That article also pointed out that cells can be impaired when NPs precipitation on 
the cell surface. In high concentration of NPs, more NPs precipitate on the surface 
of cells, which result in more cells death. But these high concentration of NPs 
(0.435mg/ml) are unusual to be used in real practise. 
Furthermore, cell uptake at low NPs concentration (0.25mg/ml) was also accessed and 
the result is shown in figure 3-11, which confirmed that our QDs-loaded PLA-TPGS 
NPs are useful in cell imaging. In summary, encapsulation bare QDs into polymeric 
NPs can significantly decrease the cytotoxicity of QDs and improve the 
biocompatibility of QDs. 
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Figure 3-12 MCF-7 cell viability after incubation with the QDs-loaded PLA-TPGS 
NPs and the MMA-coated QDs after 1 day, 2 days and 3 days. Data represent mean 
(n=6) + SD 
3.4 Conclusion 
In this research, we formulated QDs by nanoparticles of a novel type of biodegradable 
copolymer to improve their imaging effects as well as to decrease their side effects. 
The QDs-loaded PLA-TPGS NPs were prepared by a modified solvent 
extraction/evaporation technique (single oil-in-water emulsion technique). The 
QDs-loaded PLA-TPGS NPs are found of ~200 nm in diameter. FESEM, AFM and 
TEM demonstrated that the QDs were encapsulated in the polymeric matrix of the 
PLA-TPGS NPs, which are of spherical shape and relatively uniform in size. The 
QDs encapsulation efficiency in the PLA-TPGS nanoparticles was measured by 
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ICP-OES, which was found to be 46%, which is quite high for nanoparticle of such 
small size. Surface chemistry of the QDs-loaded PLA-TPGS NPs were analyzed by 
XPS and FT-IR, which showed that there were no QDs on the nanoparticle surface 
and the QDs were encapsulated in the interior of the polymeric matrix. The in vitro 
cellular uptake of the QDs-loaded PLA-TPGS NPs was visualized by CLSM. In vitro 
MCF-7 cell cytotoxicity of the QDs-loaded PLA-TPGS NPs was at various QDs 
concentration in 1, 2 and 3 days, which showed that the cytotoxicity of the QDs 
increases with the QDs concentration and incubation time. Our research showed that 
the QDs-loaded PLA-TPGS NPs can have great advantages versus the bare QDs in 
improving the imaging quality and extending the half-life of the QDs. Compared with 
the MAA-coated QDs, our PLA-TPGS NP formulation can have less side effects at 
proper NPs concentration. With molecular probes conjugated onto the nanoparticle 
surface, the QDs-loaded PLA-TPGS NPs can be used for molecular imaging for 
detection of diseases at their earliest stage, which is a key to determine the prognosis 
of the treatment. 
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Chapter 4 Targeted Delivery of Paclitaxel Using 




There has been intensive research on nanoparticles (NPs) of biodegradable polymers 
for controlled drug delivery to improve the therapeutic effects and reduce the side 
effects of the formulated drug (Feng and Chien 2003; Feng 2004; Feng 2006; Feng, 
Zhao et al. 2007). However, lack of selectivity of the NPs between cancerous and 
healthy cells is a main disadvantage. Although passive targeting of the NPs to solid 
tumors can be realized through the enhanced permeability and retention (EPR) effect 
of the tumor vessels, the majority of the NPs would still be cleared by the 
reticuloendothelial system (RES) (Jain 1999; Jain 2001; Yamamoto, Nagasaki et al. 
2001; Duncan 2003). Active targeting can achieve specific effect and high uptake of 
the NPs in the tumor cells, and leave the healthy cells untouched, which further 
improves the therapeutic efficacy and reduces the side effects of chemotherapy. To 
achieve active targeting, the NPs should be equipped with functional molecules, 
which can recognize and adhere to the biomarkers on the surface of the corresponding 
cancer cells. The targeting molecules employed in the literature include small organic 
molecules such as folic acid (Yoo and Park 2004; Yoo and Park 2004; Park, Kim et al. 
2005; Park, Lee et al. 2005), peptide such as cRGD peptide (Nasongkla, Shuai et al. 
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2004), carbohydrates such as galactose and lactose (Yasugi, Nakamura et al. 1999; 
Nagasaki, Yasugi et al. 2001; Jule, Nagasaki et al. 2002; Jule, Nagasaki et al. 2003; 
Jeong, Seo et al. 2005), monoclonal antibodies such as Anti-GFA Ab (Kabanov, 
Chekhonin et al. 1989) and mAb 2C5 or mAb 2G4 (Torchilin, Lukyanov et al. 2003), 
and aptamers such as anti-PSMA aptamer (Farokhzad, Jon et al. 2004; Farokhzad, 
Cheng et al. 2006). Among them folic acid is used most often for breast cancer 
targeting.  
Folic acid (FOL), an oxidized form of folate, has high binding affinity for the folate 
receptors (Kd 10−10 M), stability during storage, and low cost, which is an essential 
vitamin for the biosynthesis of nucleotide bases and is consumed in elevated 
quantities by proliferating cells (Lu and Low 2003; Leamon and Reddy 2004; Lu, 
Sega et al. 2004). Folate receptor is overexpressed in the membrane of many human 
cancer cells such as brain, kidney, breast, ovarian and lung cancer cells (Sudimack 
and Lee 2000; Saul, Annapragada et al. 2003). It was reported that the expression 
level of the folate receptor in tumors was 100-300 times higher than that observed in 
normal tissue (Ross, Chaudhuri et al. 1994). Folate thus has become an attractive 
targeting ligand. In recent literature, liposomes, micelles and NPs of biodegradable 
polymer using folic acid as a targeting ligand have been reported. The polymers and 
copolymers used for this purpose include distearoylphosphatidyl ethanolamine - 
poly(ethylene glycol) (DSPE-PEG), methoxy poly(ethylene 
glycol)/poly(epsilon-caprolactone) (MPEG-PCL), poly (lactide-co-glycolide) - 
poly(ethylene glycol) (PLGA-PEG), and PLGA (Gref, Domb et al. 1995; Saul, 
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Annapragada et al. 2003; Yoo and Park 2004; Park, Kim et al. 2005; Lee 2006; 
Shmeeda, Mak et al. 2006; Wu, Liu et al. 2006). 
D-α-tocopheryl polyethylene glycol succinate (Vitamin E TPGS or simply TPGS) is a 
water-soluble derivative of natural vitamin E, comprising lipophilic alkyl tail and 
hydrophilic polar head portion. TPGS can act as an effective emulsifier due to its 
bulky structure and large surface area, which results in higher emulsification effect, 
higher drug encapsulation efficiency, better therapeutic effects for the nanoparticle 
formulation of anticancer drugs (Traber, Schiano et al. 1994; Feng, Mu et al. 2004; 
Win and Feng 2006). Furthermore, it has been reported that co-administration of 
TPGS could inhibit P-glycoprotein mediated multi-drug resistance (MDR) and thus 
increase the oral bioavailability of anticancer drugs (Dintaman and Silverman 1999; 
Rege, Kao et al. 2002; Bogman, Erne-Brand et al. 2003; Bogman, Zysset et al. 2005; 
Zhang, Huey Lee et al. 2007). We thus have a strong impetus to synthesize 
PLGA-TPGS NPs and PLA-TPGS NPs to achieve better effects for targeted delivery 
o anticancer drugs. We began with synthesizing PLGA-TPGS NPs for targeted 
delivery of hydrophilic drugs with doxorubicin used as model drug. The MCF-7 cell 
line experiment showed that the folate-decorated PLGA-TPGS NP formulation 
achieved 1.5 time higher cellular uptake of the NPs 6.2 times higher cytotoxicity 
compared with the bare PLGA-TPGS NPs at the same treatment condition (Zhang, 
Huey Lee et al. 2007).  
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In this study, we continued our work to synthesize folate-decorated PLA-TPGS (FD 
NPs) for targeted delivery of hydrophobic anticancer drugs with paclitaxel chosen as 
model drug. The PLA-TPGS copolymer was synthesized and characterized for its 
molecular structure and molecular weight. The carboxyl terminated TPGS 
(TPGS-COOH) and PLA-TPGS copolymer was blended at various weight ratios. The 
PLA-TPGS is used to increase the half-life of the NPs in the blood system, and the 
TPGS-COOH is used to facilitate the folate conjugation on the NP surface. The 
drug-loaded NPs of the copolymer blend were prepared by a modified solvent 
extraction/evaporation single emulsion method and then decorated by the folate, 
which were characterized by various state-of-the-art equipment including laser light 
scattering (LLS) for particles size and size distribution, zeta potential analyzer for 
surface charge and X-ray photoelectron spectroscopy (XPS) for surface chemistry. 
The drug encapsulation efficiency (EE) and in vitro drug release kinetics were 
measured by high performance liquid chromatography (HPLC). The targeting effect 
of the FD NPs was investigated in vitro by measuring the cellular uptake of the NPs. 
The therapeutic effect of paclitaxel formulated in the FD NPs was evaluated in vitro 
by measuring the viability of the MCF-7 breast cancer cells and the C6 glioma cells, 
which was made in close comparison with Taxol®. 
4.2 Materials and Methods 
4.2.1 Materials 
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Lactide (3, 6-dimethyl-1, 4-dioxane-2, 5-dione, C6H8O4) was purchased from Aldrich. 
It was recrystallized twice with ethyl acetate before used in reaction. D-α-tocopheryl 
polyethylene glycol 1000 succinate, (C33O5H54, Vitamin E TPGS or simply TPGS) 
was from Eastman Chemical Company (USA). Stannous octoate (Sn(OOCC7H15)2
MCF-7 breast cancer cells and C6 brain cancer were provided by American Type 
Culture Collection. 
), 
3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), MEM medium, 
penicillin-streptomycin solution, Trypsin-EDTA solution, 
N,N′-dicyclohexylcarbodiimide (DCC), 4-dimethylamino pyridine (DMAP), 
1-ethyl-3-(3-dimethylamino) propyl carbodiimide (EDC), N-hydroxysuccinimide 
(NHS), glutaric acid, FOL, pyridine, ethylene diamine and triethylamine (TEA) were 
obtained from Sigma-Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS) was 
purchased from Gibco (Life Technologies, AG, Switzerland). All chemicals used in 
this study were HPLC grade. Millipore water was produced by the Milli-Q Plus 
System (Millipore Corporation, Breford, USA).  
4.2.2 Synthesis and characterization of PLA-TPGS copolymer 
PLA-TPGS of component ratio PLA: TPGS=88:12 w/w was synthesized by a 
modified procedure described in an earlier publication of our group (Zhang and Feng 
2006). 0.1g 0.5wt% stannous octoate (in distilled toluene), pre-weighed portions of 
lactide and TPGS were loaded into a 50 ml flask. The mixture was stirred for 12h at 
145°C under a nitrogen flow in silicone oil bath. After polymerization, the product 
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was dissolved in DCM. Excess cold methanol was injected in order to precipitate the 
product and to remove the excess lactide and TPGS. The final product was obtained 
by filtration and vacuum dried. The synthesized PLA-TPGS copolymer was 
characterized by 1
4.2.3 Synthesis of TPGS-COOH and FOL-NH
H NMR and GPC.  
TPGS-COOH can be synthesized according to the method described before by our 
group in (Zhang, Huey Lee et al. 2007). In brief, TPGS-COOH was prepared by 
reacting TPGS, glutaric acid, DCC and DMAP in DMSO at TPGS/glutaric 
acid/DCC/DMAP=1/1/1/0.1 in stoichiometric molar ratio under nitrogen atmosphere 
at room temperature for 24 h. The carboxylic group of glutaric acid reacted with the 
hydroxyl-terminated TPGS via ester bond formation. Further. The product was 
filtered to remove N, N-dicyclohexylurea (DCU) and then dialyzed against DMSO for 
24 h to remove excess DCC and against water for 24 h to remove DMSO. After that, 
the resulting product was freeze-dried. 
2 
The amination of FOL was prepared as reported by Lee et al. (Lee, Na et al. 2003). 
FOL was reacted with DCC and NHS in DMSO at stoichiometric molar ratio of 
FOL/DCC/NHS=1/1.2/2 for 6 h at 50 °C. The activated folate was then reacted with 
excess ethylene diamine in the presence of pyridine as catalyst. The aminated folate 
(FOL-NH2) was precipitated out by adding excess acetonitrile, followed by vacuum 
filtration. 
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4.2.4 Formulation of paclitaxel-loaded NPs with folate-decoration  
The paclitaxel-loaded PLA-TPGS NPs were prepared by a modified solvent 
extraction/evaporation single emulsion method. First of all, we use 0%, 9.1%, 16.7%, 
33.3% TC NPs to denote the NPs of 0%, 9.1%, 16.7% and 33.3% TPGS-COOH 
component in the blend of two copolymers PLA-TPGS and TPGS-COOH, i.e. the 
NPs of  PLA-TPGS:TPGS-COOH weight ratio 1:0, 10:1, 5:1and 2:1 in the blend, 
respectively. In brief, 5 mg paclitaxel and 50 mg of the PLA-TPGS and TPGS-COOH 
blend at various weight ratios were dissolved in 4 ml DCM. The formed solution was 
poured into 60 ml of an aqueous phase containing 0.03% (w/v) TPGS as emulsifier 
under gentle stirring, which was sonicated for 120 s at 25 W output. The emulsion 
was evaporated overnight to allow the organic solvent to evaporate. The particles 
suspension was centrifuged at 10,500 rpm for 15 min. The samples were washed with 
deionized water. The pellet was then re-suspended in water and freeze-dried for 2 
days to get the NPs powder.  
Paclitaxel-loaded folate-decorated nanoparticles (FD NPs) were prepared as follows. 
10 mg of the nanoparticles were dispersed in 5 ml of water and placed in an ultrasonic 
bath for 30 min. The surface carboxyl group of the NPs was activated by 
N-hydroxysuccinimide (NHS) and EDC at TPGS-COOH/EDC/NHS=1/20/6.7 of the 
stoichiometric molar ratio for 2 hours at room temperature. FOL-NH2 was then added 
at TPGS-COOH/FOL-NH2=1/10 stoichiometric molar ratio). The pH of the reaction 
mixture was adjusted to pH8 using triethylamine. The reaction was allowed to take 
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place for 4 h at 37 ºC. After centrifugation, the mixture was washed with DMSO to 
eliminate un-reacted FOL-NH2, followed by washing with deionized water. The final 
yellowish product was then collected by freeze-drying. Here 16.7%, 9.1% and 33.3% 
FD NPs refer to NPs with folate prepared from 16.7%, 9.1% and 33.3% TC NPs, 
respectively. The detailed scheme for preparation of FD NPs is shown in figure 4-1. 
 
Figure 4-1 Schematic representation for preparation of the folate-decorated 
nanoparticles of the PLA-TPGS and TPGS-COOH copolymer blends (FD NPs) 
4.2.5 Characterization of paclitaxel-loaded NPs with folate decoration 
4.2.5.1 Particle size and size distribution 
Average particle size and size distribution of the paclitaxel-loaded FD NPs were 
measured by laser light scattering (LLS, 90 Plus Particle Size, Brookhaven 
Instruments Co. USA). NPs was diluted with deionized water and sonicated for 
several minutes before measurement.  
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4.2.5.2 Surface charge 
Zeta potential of paclitaxel-loaded FD NPs was determined with ZetaPlus zeta 
potential analyzer (Brookhaven Instruments Corporation) at room temperature. The 
samples were prepared by diluting the NPs suspension with deionized water. The data 
were obtained with the average of several measurements. 
4.2.5.3 Surface morphology 
The shape and surface morphology of paclitaxel-loaded FD NPs were investigated by 
field emission scanning electron microscopy (FESEM, JSM-6700F, JEOL, Japan) at 
an accelerating voltage of 10 kV. For FESEM, the particles were fixed on the stub 
with a double-sided sticky tape and then coated with platinum layer, which was 
carried out by an Auto Fine Coater (JEOL, Tokyo, Japan) for 50s. 
4.2.5.4 Drug encapsulation efficiency 
The paclitaxel formulated in the BD NPs was quantified by HPLC (Agilent LC1100) 
measurement (Mu and Feng 2003). A reverse phase Inertsil® ODS-3 column 
(150×4.6 mm, pore size 5 μm, GL Science Inc, Tokyo, Japan) was used. In brief, 3 
mg dried NPs were re-dissolved in 1 ml DCM and then extracted by 3 ml mobile 
phase (50/50 v/v acetonitrile/water solution). DCM was evaporated in a nitrogen 
atmosphere and the clear solution was then filtered with a 0.22 μm poly(vinyl idene 
fluoride) (PVDF) syringe filter for HPLC analysis. The column effluent was detected 
at 227 nm with a UV/vis detector. The calculation equation is: 
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4.2.6 Surface chemistry 
The decoration of folate on the surface of paclitaxel-loaded FD NPs was confirmed 
from the surface chemistry measured by X-ray photoelectron spectroscopy (XPS, 
AXIS His-165 Ultra, Kratos Analytical, Shimadzu Corporation, Japan). The 
binding energy spectrum was recorded from 0 to 1,100 eV with pass energy of 80 
eV under the fixed transmission mode.  
4.2.7 In vitro drug release kinetics 
The drug-loaded NPs was dispersed in PBS (0.1 m
4.2.8 Cell cultures 
, pH 7.4) containing 0.1% w/v 
Tween 80, which can improve the solubility of paclitaxel in PBS, in a centrifuge tube 
and then put in an orbital water bath shaking at 120 rpm at 37 °C. At the designated 
time intervals, the sample was taken out and centrifuged at a speed of 10,500 rpm for 
15 min. The pellet was re-dispersed in fresh PBS medium and put back to the orbital 
water bath for continued release study. The supernatant was extracted with DCM and 
transferred in mobile phase. After the evaporation of DCM by nitrogen stream, 
paclitaxel concentration was determined with HPLC.  
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MCF-7 breast cancer cells and C6 brain cancer cells (American Type Culture 
Collection, VA) were employed. RMPI 1640 medium without FOL, which was 
supplemented with 10% FBS and 1% antibiotics, was utilized as cell culture medium. 
Cells were cultivated in medium at 37 ºC in humidified environment of 5% CO2
4.2.9 In vitro cellular uptake of NPs 
. 
Before experiment, the cells were pre-cultured until confluence was reached (Yin Win 
and Feng 2005). The Error bars were obtained from triplicate samples. 
For quantitative study, MCF-7 and C6 cells were seeded into 96-well black plates 
(Costar, IL, USA) at 1.3×104 cells/well and after the cells reached 80% confluence, 
the medium was changed with the suspension of coumarin-6 loaded 16.7% TC NPs or 
16.7% FD NPs at a NP concentration 0.25 mg/ml for 0.5, 1.0, 2.0, 4.0 h, respectively. 
The coumarin-6 loaded NPs were prepared in the same way as for the 
paclitaxel-loaded NPs except 0.05% (w/v) coumarin-6 instead of paclitaxel was 
encapsulated in the NPs. After incubation, the NP suspension was removed and the 
wells were washed three times with 50 μl of PBS to remove the traces of NPs left in 
the wells. After that, 50 μl of 0.5% Triton X-100 in 0.2 n NaOH was added to the 
sample wells to lyse the cells. The fluorescence intensity present in each well was 
then measured by microplate reader (GENios Tecan) with excitation wavelength at 
430 nm and emission wavelength at 485 nm (Zhang and Feng 2006). The cellular 
uptake was expressed as the percentage of the fluorescence of the sample wells versus 
that of the positive control solution (Haioun, Mounier et al. 2005).  
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For qualitative study, MCF-7 cells and C6 were cultivated in the chambered cover 
glass system (LAB-TEK®, Nagle Nunc, IL) with 5% CO2
4.2.10 In vitro cytotoxicity 
 in the media at 37℃ as 
proposed by American Type Culture Collection. After 12h incubation, the adherent 
cells were washed twice with PBS. 0.9 ml of coumarin-6 loaded 16.7% TC NPs or 
16.7% FD NPs diluted in the medium at concentration 0.125μg/μl were added into the 
chamber. Cells were washed for four times after incubation for 2 h and then fixed by 
75% ethanol for 15 min. The cells were further washed twice with PBS and the nuclei 
were counterstained with propidium iodide (PI) for 30 min. The cell monolayer was 
washed twice with PBS and observed by confocal laser scanning microscope (CLSM) 
(Zeiss LSM 410). 
MCF-7 and C6 cells were incubated in 96-well plates (Costar, IL, USA) as previously 
described. After 24h seeding, the old medium was removed and the cells were 
incubated for 24h or 48h in the Taxol® or FD NPs containing media at the same 
10 μg/ml paclitaxel concentration. The NPs were sterilized with UV irradiation for 30 
min before use. At given time intervals, the cultured cells were assayed for cell 
viability with methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma). The wells 
were washed twice with PBS and 10μl of MTT supplemented with culture medium 
was added. After 4h incubation in the incubator, the culture medium was removed and 
the precipitate was dissolved in isopropanol. The absorbance intensity of the cells was 
measured by the microplate reader (Genios, Tecan, Männedorf, Switzerland) of the 
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absorbance wavelength at 570 nm minus background at 660nm. Cell viability was 
calculated by the following equation. 
%100
Int
Int (%)  viabilityCell
control
s ×=  
where Ints is the absorbance intensity of the cells incubated with the NP suspension 
and Intcontrol
4.3 Results and Discussion 
 is the absorbance intensity of the cells incubated with the culture medium 
only (positive control). 
4.3.1 Characterization of PLA–TPGS copolymers 
Molecular structure of PLA-TPGS copolymer is shown in figure 4-2. The structure of 
the synthesized PLA-TPGS copolymers was detected by 1H NMR. In the spectra 
shown in figure 4-3, formation of the PLA–TPGS copolymer was verified as the CH 
protons peak of the copolymer, which was located at 5.2 ppm as compared to 
5.07 ppm peak for the CH protons of the lactide monomer. The signals at 5.2 ppm (or 
1.69 ppm) and 3.65 ppm were assigned to PLA segment and TPGS segment, 
respectively (Zhang and Feng 2006).  
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Figure 4-2 Molecular structure of the PLA-TPGS copolymer 
 
Figure 4-3 1H NMR spectra of the PLA-TPGS copolymer in CDCl
Based on the spectra, the number-averaged molecular weight (M
3 
n) can be calculated 
with the method described by Zhang et al (Zhang and Feng 2006). The PLA:TPGS 
component ratio for the PLA-TPGS copolymer used in this research is 88:12 w/w, for 
which, it has been determined that Mw=18,500and and Mn=11,800 with 
polydispersity of 1.57. The weight-averaged molecular weight (Mw) and the 
number-averaged molecular weight (Mn) of the PLA-TPGS copolymers were also 
determined by gel permeation chromatography (GPC) (Zhang and Feng 2006). The 
results were found to be consistent with the 1H NMR data. 
 89 
4.3.2 Characterization of folate-decorated NPs 
4.3.2.1 Size and size distribution 
The size and size distribution of the TC NPs and FD NPs are shown in Table 4-1, 
from which it can be observed that there is no big difference between the two types of 
NPs, which demonstrates that the size and size distribution were not significantly 
affected during the process of decoration of the NPs with folate. 
Table 4-1 Characteristics of paclitaxel-loaded, folate-decorated nanoparticles of the 




polydispersity EE (%) 
zeta potential 
(mV) 
0% TC NPs 330.1±7.1 0.19±0.03 51.3±4.8 -47.92 
9.1% TC NPs 324.3±10.3 0.28±0.05 52.7±5.1 -41.55 
9.1% FD NPs 326.8±5.1 0.14±0.03 52.1±6.7 -36.83 
16.7% TC NPs 319.4±7.4 0.30±0.02 53.1±4.6 -41.27 
16.7% FD NPs 320.2±6.9 0.24±0.04 52.5±4.9 -26.87 
33.3% TC NPs 312.3±5.8 0.32±0.05 50.9±5.3 -41.03 
33.3% FD NPs 311.2±9.8 0.25±0.03 50.8±3.7 -25.50 
* 0%, 9.1%, 16.7%, 33.3% TC NPs to denote the NPs of 0%, 9.1%, 16.7% and 33.3% 
TPGS-COOH in the blends of the two polymers, i.e. the NPs of  PLA-TPGS:TPGS-COOH 
weight ratio 1:0, 10:1, and 5:1and 2:1 in these blends, respectively. Here 16.7%, 9.1% and 33.3% 
FD NPs refer to NPs with folate prepared from 16.7%, 9.1% and 33.3% TC NPs, respectively. 
4.3.2.2 Surface charge 
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Surface charge is an important factor for the stability of the NP suspension. Higher 
electric charge on the surface of the NPs can produce strong repellent forces among 
the particles to prevent their aggregation in the buffer solution (Mu and Feng 2002). 
Both of the TC NPs and FD NPs exhibited negatively charge as shown in Table 4-1.  
4.3.2.3 Surface morphology 
The FESEM images of 16.7% FD NPs are shown in figure 4-4, which reveals that the 
paclitaxel-loaded FD NPs are spherical in shape with narrow size distribution. The 
particle size observed from this FESEM image shows good agreement with that 
determined by the laser light scattering. 
 
Figure 4-4 FESEM image of paclitaxel-loaded, folate decorated nanoparticles of 
83.3% PLA-TPGS and 16.7% TPGS-COOH (denoted by 16.7% FD NPs) prepared 
with 0.03% TPGS as emulsifier 
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4.3.2.4 Drug encapsulation efficiency 
The dug encapsulation efficiency (EE) of the TC NPs and FD NPs are shown in Table 
4-1. In comparison to that of 0% TC NPs, the 9.1% and 16.7 % FD NPs have higher 
EE, which may be caused by the TPGS group of the copolymer blend. Feng’s group 
reported that TPGS has been shown to be an more effective emulsifier of less side 
effects compared with PVA in formulation of drug-loaded NPs (Mu and Feng 2002; 
Feng, Mu et al. 2004). However, when the copolymer blend of too much 
TPGS-COOH component was used, the NPs would have lower EE. It can be seen 
from Table 4-1 that the 16.7% FD NPs achieved slightly higher EE (52.5±4.9%) than 
the 33.3% FD NPs (EE is 50.8±3.7%). Two reasons may explain: one is that the blend 
of more TPGS-COOH component can result in higher hydrophilic property of the NPs; 
another is small molecular weight of TPGS-COOH. More drug molecules thus may 
diffuse from the NPs and washed away in the preparation process
4.3.3 Surface chemistry 
. 
Figure 4-5 shows the XPS N1s (atomic orbital 1s of nitrogen) region of the surface of 
the FD NPs with various copolymer blend ratio, which shows that there are 2.14%, 
3.85%, and 5.22% chemical composition weight percentages of nitrogen on the 
surface of the 9.1%, 16.7% and 33.3% FD NPs, respectively. It can be found that 
there are no nitrogen atoms in the chemical structure of PLA-TPGS or TPGS-COOH 
and that FOL-NH2 contains seven nitrogen atoms. Paclitaxel contains nitrogen 
element, but there is no N 1s signal detected from the surface of the 0% FD NPs, 
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which proved that the drug was completely encapsulated inside the polymeric matrix 
of the NPs. The successful folate decoration on the NP surface of the copolymer blend 
can be confirmed by the presence of the N 1s region in the XPS spectra. It can also be 
found from figure 4-5 that the percentage of the N 1s region increased with increase 
of the TPGS-COOH component ratio in the NPs of the PLA-TPGS and TPGS-COOH 
blend. This further confirmed that folate has been successfully conjugated on the NP 
surface. 
 
Figure 4-5 The XPS wide scan spectra of the paclitaxel-loaded 0%, 9.1%, 16.7% and 
33.3% FD NPs. The inset shows the relative nitrogen signals at high resolution 
4.3.4 In vitro drug release 
The in vitro drug release profiles of the 0% TC NPs, 9.1%, 16.7% and 33.3% FD NPs 
in the first 30 days were shown in figure 4-6, which exhibited a biphasic release with 
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an initial burst of 17.79±2.08%, 18.63±2.62%, 18.91±2.72% and 21.19±2.69% in the 
first day, respectively. After 30 days, 50.52±2.05%, 56.47±1.91%, 59.65±2.79% and 
62.47±2.63% accumulative release of paclitaxel were found for 0% TC NPs, 9.1%, 
16.7% and 33.3% FD NPs, respectively. From figure 4-6, it can be noticed that more 
PLA-TPGS component in the NPs leads to slower drug release. It may be caused by 
larger molecular weight and higher hydrophobicity of the PLA-TPGS in comparison 
with the TPGS-COOH component in the copolymer blend, which do not facilitate the 
water uptake and permeation into the NPs.  
 
Figure 4-6 In vitro paclitaxel release profiles from the FD NPs.  
Data represent mean ±SD, n=3 
4.3.5 In vitro cellular uptake of NPs 
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The MCF-7 breast adenocarcinoma cells have a high level of the folic acid receptor 
on their surface and the C6 glioma cells are also found rich of folate receptors 
(Sudimack and Lee 2000; Saul, Annapragada et al. 2003). The targeting effect of the 
FD NPs can thus be evaluated by employing these two types of cancer cells to 
investigate the cellular uptake of coumarin-6 loaded 16.7% TC NPs or 16.7% FD NPs. 
figure 4-7 shows (A) MCF-7 and (B) C6 cellular uptake efficiency of the coumarin-6 
loaded 16.7% TC NPs or 16.7% FD NPs at .25 mg/ml NP concentration for 0.5, 1.0, 
2.0, 4.0 h, respectively. It can be seen from figure 4-7 that 16.7% FD NPs 
demonstrated much higher cellular uptake efficiency for MCF-7 or C6 cells than the 
16.7% TC NPs. From figure 4-7, it can be found that the 16.7% FD NPs expressed 1.3, 
1.4-, 1.4-, and 1.5 fold higher cellular uptake than the 16.7% TC NPs after 0.5, 1.0, 2, 
4h culture with MCF-7 cells, respectively. Similarly, For C6 cells, the 16.7% FD NPs 
showed 1.5, 1.5-, 1.6-, and 1.6 fold cellular uptake in comparison with that of the 
16.7% TC NPs after 0.5, 1.0, 2, 4h cell culture, respectively. Moreover, it should be 
noticed in figure 4-7 that the longer the incubation time is, the higher cellular uptake 




Figure 4-7 (A) MCF-7 and (B) C6 cells uptake efficiency of coumarin 6-loaded 
16.7% TC NPs or 16.7% FD NPs at the NPs concentration of 0.25mg/ml for 0.5, 1.0, 
2.0, 4.0h, respectively(n=6) 
Targeting effect of NPs was also investigated by using confocal laser scanning 
microscopy (CLSM). Figure 4-8 shows a few confocal microscopic images of MCF-7 
cancer cells after 2h culture with the coumarin-6-loaded 16.7% TC NP or the 16.7% 
FD NP suspension at 0.125 mg/ml NP concentration at 37 °C. The sectioning function 
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of CLSM was employed in order to investigate the internalization of the fluorescent 
NPs. The images in the middle column were obtained from the PI channel and those 
in the right column were from FITC channel. The images in the left column were the 
overlaying images of those obtained from the FITC channel and the PI channel. For 
the 16.7% FD NPs, it can be noticed that intense green fluorescence from courmarin-6 
around the nucleus (red, stained by propidium iodide can be observed in comparison 
with weak fluorescence for the 16.7% TC NPs without targeting effect. These 
findings are in agreement with the previous results obtained for quantitative 
measurement. These quantitative and qualitative results of cellular uptake of the NPs 
provide strong evidence for the targeting effect of folate decoration for MCF-7 and 
C6 cells. 
 
Figure 4-8 Confocal microscopic images of MCF-7 cancer cells after 2h culture with 
(A-C) the coumarin-6-loaded 16.7% TC NP or (D-F) the 16.7% FD NP suspension at 
0.125 mg/ml NP concentration at 37 °C 
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4.3.6 In vitro cytotoxicity 
Figure 4-9 shows the in vitro viability of MCF-7 and C6 cells after 24h or 48h 
treatment of paclitaxel formulated in the 0% TC NPs, 16.7% FD NPs, 33.3% FD NPs 
or in its current clinical dosage form Taxol® at the same 25μg/ml drug concentration 
at 37 ºC (n=6). With a glance at figure 4-9, a few general conclusions can be 
immediately made, i.e. (1) The placebo NPs of PLA-TPGS and PTGS-COOH are 
biocompatible since they show little decease in cellular viability for MCF-7 and C6 
cells (mortality<3% in 24 hrs and <5% in 48 hrs); (2) the NP formulation 
demonstrated significant advantages vs the pristine drug, for example, MCF-7 cell 
viability decreased from 53.0% for Taxol® to 48.4% for the 0% TC NP formulation (a 
8.68% more effective in vitro therapeutic effect) after 24 h cell culture and from 
43.8% for Taxol® to 38.6% for the 0% TC NP formulation (a 11.9% more effective in 
vitro therapeutic effect) after 48 hr cell culture. C6 cell viability investigation showed 
similar trend; (3) the cellular viability deceased with the incubation period in all cases.   
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Figure 4-9 In vitro viability of (A) MCF-7 and (B) C6 cells after 24h (A1, B1) or 48h 
(A2, B2) treatment of paclitaxel formulated in the 0% TC NPs, 16.7% FD NPs, 
33.3% FD NPs or in its current clinical dosage form Taxol®
Moreover, figure 4-9 clearly demonstrates the targeting effect of the folate decoration 
on the nanoparticles of the PLA-TPGS and TPGS-COOH blend. It can be seen from 
figure 4-9(A1) and (A2) for MCF-7 cells that (1) the cellular viability decreased from 
48.4% for 0% TC NP formulation (no targeting effect) to 36.6% for the 16.7% FD NP 
formulation (a 24.4% more effective treatment) and to 33.4% for the 33.3% FD NP 
formulation (a 31.0% more effective treatment) for 24 hr incubation; and (2) the 
cellular viability decreased from 38.6% for 0% TC NP formulation to 29.2% for the 
16.7% FD NP formulation (a 23.3% more effective treatment) and to 27.9% for the 
 at the same 
25μg/ml drug concentration at 37 ºC (n=6). 
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33.3% FD NP formulation (a 27.7% more effective treatment) for 48 hr incubation at 
the same 25 µg/ml paclitaxel concentration, respectively. We can thus conclude that 
the targeting effect of the folate decoration for the nanoparticles of the PLA-TPGS 
and TPGS-COOH blend is significant and saturation may be reached with increase of 
the targeting molecules on the NP surface. The results for the C6 cell viability as 
shown in Fig 9(B1) and (B2) confirmed these conclusions.          
4.4 Conclusion 
In this study, two types of copolymers, PLA-TPGS copolymer and TPGS-COOH 
copolymer, were firstly synthesized and characterized. The PLA-TPGS copolymer is 
employed to achieve desired hydrophilic-lipophilic balance of the polymeric matrix 
material and the TPGS-COOH copolymer is used to facilitate folate decoration for 
targeting the cancer cells rich of the folate receptors on their surface. Nanoparticles of 
the two-copolymer blend at various component ratios were prepared by the solvent 
extraction/evaporation single emulsion method and then decorated by folate for 
controlled and targeted chemotherapy of paclitaxel employed as a model anticancer 
drug, which were then decorated with folate molecule. The targeting effect was 
qualitatively and quantitatively investigated by cancer cell uptake of the coumarin 
6-loaded NPs and further confirmed by the cytotoxicity of the cancer cells treated 
with the drug formulated in the folate-decorated nanoparticles of various copolymer 
blend ratio. We showed that the nanoparticle formulation has great advantages vs the 
pristine drug and the folate-decoration can significantly promote targeted delivery of 
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the drug to the corresponding cancer cells and thus enhance its therapeutic effects and 
reduced its side effects. 
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Chapter 5 Targeting and Imaging Cancer Cells by Folate 
Decorated, Quantum Dots Loaded Nanoparticles of 
Biodegradable Polymers 
5.1 Introduction 
Quantum dots (QDs) are widely studied as luminescence probes in biological and 
medical research in recent years. Compared with the conventional dyes used as 
imaging probes, QDs have several advantages in optical and chemical properties such 
as tunable emission from visible to infrared wavelengths by changing their size and 
composition, broader excitation spectra due to high absorption coefficients, high 
quantum yield of fluorescence, strong brightness, photostability, and high resistance 
to photobleaching. These unique properties of QDs have attracted tremendous interest 
in exploiting them in a variety of biological field (Alivisatos, Gu et al. 2005; Medintz, 
Uyeda et al. 2005; Michalet, Pinaud et al. 2005). However, the potential applications 
of quantum dots in biology and medicine were limited due to the toxic effects of 
semiconductor QDs, which have received enormous attention over the past few years. 
In order to reduce the cytotoxicity of QDs, two strategies were devised.  
One strategy is by surface modification and polymeric nanoparticle formulation such 
as coating with mercaptopropionic acid, silanizaion and PEG, or formulation by 
PLGA nanoparticles. Derfus et al demonstrated that the CdSe/ZnS QDs are highly 
toxic for the cells in culture due to the released Cd2+ ions, which was caused by 
surface oxidation of QDs (Derfus, Chan et al. 2004), and that the surface oxidation 
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was repressed by coating with appropriate shells, which decreased the cytotoxicity of 
QDs. The reported surface coating work includes encapsulating QDs with 
dendrimer-like compounds (Wang, Li et al. 2002), glass (Bruchez, Moronne et al. 
1998) and amphiphilic polymers (Wu, Liu et al. 2003). In 2005, Parak et al. extended 
the study of Derfus et al. and described that amphiphilic polymer-coated CdSe/ZnS 
nanocrystals in low concentrations could be a good formulation against release of 
Cd2+ ions from QDs surface, which reduced the cytotoxicity of QDs (Kirchner, Liedl 
et al. 2005). Our group reported recently
Another strategy is by targeted delivery of QDs, which can deliver QDs selectively to 
the cancer cells with greater efficiency. Passive targeting mode refers to QDs 
accumulation at the tumor sites through an enhanced permeability and retention (EPR) 
effect (Lanza, Wallace et al. 1997; Jain 1999; Jain 2001). This is caused by two 
factors. First, angiogenic tumors produce vascular endothelial growth factor, which 
hyperpermeabilizes the tumor-associated neovasculature and result in the leakage of 
circulating macromolecules and small particles. Second, tumors lack effective 
lymphatic drainage system, which causes subsequent macromolecule or nanoparticle 
 that the encapsulation hydrophobic QDs into 
PLA-TPGS NPs could greatly improve QDs biocompatibility and stability as well as 
realize a controlled and sustained release manner of QDs from the polymeric matrix, 
which offered a good chance for QDs biological applications in cellular and molecular 
imaging such as cellular and molecular labeling, deep-tissue imaging, assay labeling 
and being used as donors in efficient fluorescence resonance energy transfer (FRET) 
(Pan and Feng 2008). 
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accumulation. Active targeting can be realized by either coating QDs with polymers 
which are conjugated to molecular probes or by encapsulating QDs in nanoparticles of 
biodegradable polymers which are decorated with targeting antibody or other ligand 
and can selectively deliver QDs into the tumor cells of overexpression of 
corresponding antigen or receptor by the ligand-mediated approach (Gao, Yang et al. 
2005; Wang, Yang et al. 2008). Cytotoxicity of QDs could thus be minimized, 
Targeted delivery of QDs can also achieve high specificity and sensitivity of cancer 
detections, which can diagnose cancer at its earliest stage and thus greatly improve its 
prognosis. A typical work of QDs of active targeting function is Gao et al 2004, 
which demonstrated that tri-n-octylphosphine oxide (TOPO)-capped QDs coated with 
polymer and linked with tumor-targeting ligand
Folic acid, an oxidized form of folate, is an attractive target ligand due to its high 
binding affinity for the folate receptors (K
 achieved sensitive and multi-color 
fluorescence imaging of cancer cells under in vivo conditions (Gao, Cui et al. 2004). 
d 10−10 M). Folic acid is efficiently 
internalized into the cells through the receptor-mediated endocytosis even when 
conjugated with a wide variety of molecules (Leamon and Low 1991; Turek, Leamon 
et al. 1993). Folic acid and its conjugate were widely used for selective delivery of 
anticancer agents to cells with folate receptor, which are over-expressed in many 
kinds of human cancer cells such as ovarian, breast and prostate cancers while only 
minimally distributed in normal tissues (Sudimack and Lee 2000; Pan, Turner et al. 
2003; Leamon and Reddy 2004; Hilgenbrink and Low 2005; Dixit, Van den Bossche 
et al. 2006). In the literature, liposomes, micelles and NPs of biodegradable polymers 
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with folate decoration have been found to increase the cellular uptake of formulated 
anticancer drugs (Gref, Domb et al. 1995; Saul, Annapragada et al. 2003; Yoo and 
Park 2004; Park, Kim et al. 2005; Lee 2006; Shmeeda, Mak et al. 2006; Wu, Liu et al. 
2006; Pan and Feng 2008). Recently, QDs linked with folate for caner targeting and 
imaging were reported. For example, Schroeder et al described that hydrophobic 
TOPO-coated CdSe QDs entrapped in phospholipid micelles were decorated with 
folate-lipid conjugate for targeting to mouse and human tumor cells of overexpression 
of the folate receptor (Schroeder, Shwek et al. 2007). Dhruba et al developed the 
folate-conjugated QDs and proved their targeting effect with confocal microscopy in 
comparison of internalization of QDs by folate-receptor-overexpressing KB cells with 
that by A549 cells without folate receptor (Bharali, Lucey et al. 2005).  
The objective of this study is the development folate-decorated (FD) NPs 
encapsulating QDs to increase biocompatibility and stability of QDs, increase 
circulation time of QDs, and improve the selective uptake by and imaging specificity, 
sensitivity of cancer cells with minimal cytotoxicity to normal cells through selective 
delivery to appropriate tumor cell lines. This technology can be helpful in molecular 
imaging and medical diagnostics, especially the cancer detection in its early stage.  
In this work we developed a new strategy in developing folate-decorated 
nanoparticles for QDs formulation for targeted and sustained imaging for cancer 
diagnosis at its early stage, in which two copolymers of poly(lactide)-vitamin E TPGS 
(PLA-TPGS) and vitamin E TPGS-carboxyl (TPGS-COOH) were synthesized. The 
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carboxyl terminated TPGS (TPGS-COOH) and PLA-TPGS copolymer were blended 
at various weight ratios, which will ultimately decide the amount of folate ligand 
conjugated onto the NPs surface. Here the TPGS-COOH was utilized to conjugate 
with folate-NH2. The QDs-loaded PLA-TPGS/TPGS-COOH NPs were prepared by 
using solvent extraction method and then conjugated with the folate-NH2. Particle 
size and size distribution were determined with Laser Light Scattering (LLS). Zeta 
potential analyzer was used for surface charge measurement. Morphology of the NPs 
was investigated by using field emission scanning electron microscope (FESEM) and 
transmission electron microscope (TEM). Emission spectrum of the formulated QDs 
was investigated with the spectrofluorophotometer. The QDs encapsulation efficiency 
(EE) was determined by the inductively coupled plasma optical emission 
spectrometry (ICP-OES). Surface chemistry of the QDs-loaded NPs was investigated 
by using X-ray photoelectron spectroscopy (XPS). In vitro experiments on cellular 
uptake of the QDs-loaded, folate-decorated NPs were also carried out by using 
MCF-7 breast cancer and NIH 3T3 fibroblast cells. MCF-7 cells were used to test the 
targeting effect due to the over-expression of folate receptors on the cell surface. NIH 
3T3 cells with low folate receptor were used as a negative control. Confocal laser 
scanning microscopy (CLSM) was conducted to have a qualitative assessment cellular 
uptake of the folate decorated NPs in comparison with that of the NPs with no 
targeting effect. In vitro cytotoxicity of the QDs formulated in the folate-decorated 
PLA-TPGS/TPGS-COOH NPs were investigated also by employing MCF-7 cells and 
NIH 3T3 cells through the 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
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bromide
5.2 Materials and Methods 
 (MTT) assay, which was compared with that of the QDs formulated in the 
PLA-TPGS NPs with no targeting effects and that of the free QDs.   
5.2.1 Materials 
Organic Quantum Dots (Qdot®655 ITKTM; catalog number 2172-1) were provided 
from Invitrogen Corporation Singapore (http://probes.invitrogen.com/products/qdot/). 
Lactide (3, 6-dimethyl-1, 4-dioxane-2, 5-dione, C6H8O4) was purchased from Aldrich. 
Before used, it was recrystallized twice with ethyl acetate. D-a-tocopheryl 
polyethylene glycol 1000 succinate, (C33O5H54, Vitamin E TPGS or simply TPGS) 
was obtained from Eastman Chemical Company (Kingsport, TN, USA). Stannous octoate 
(Sn(OOCC7H15)2) and 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), penicillin-streptomycin solution, Trypsin-EDTA solution, 
N,N′-dicyclohexylcarbodiimide (DCC), 4-dimethylamino pyridine (DMAP), 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
N-hydroxysuccinimide (NHS), glutaric acid, folic acid, pyridine, ethylene diamine 
and triethylamine (TEA) were provided by Sigma-Aldrich (Sigma-Aldrich Pte Ltd, 
Singapore). Fetal bovine serum (FBS) was purchased from Gibco (Life Technologies 
AG, Switzerland). DMEM and RPMI-1640 medium without folic acid were from 
Invitrogen Corporation. All chemicals used in this study were HPLC grade. Millipore 
water was produced by the Milli-Q Plus System (Millipore Corporation, Bedford, 
USA). MCF-7 breast cancer cells and NIH 3T3 fibroblast cells were provided by 
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American Type Culture Collection. PLA-TPGS copolymer was synthesized in our 
previous work (Pan and Feng 2008). The PLA: TPGS component ratio for the 
PLA-TPGS copolymer used in this research is 88:12 w/w with weight-averaged 
molecular weight (Mw
5.2.2 Synthesis of TPGS-COOH and folate-NH
) =18,500. 
TPGS-COOH can be prepared based on previous method from our group (Zhang.Z.P., 
SH et al. 2007). TPGS-COOH was synthesized by reacting TPGS, glutaric acid, 
dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) at 
TPGS/glutaric acid/DCC/DMAP=1/1/1/0.1 in stoichiometric molar ratio in dimethyl 
sulfoxide (DMSO) under nitrogen gas protection at room temperature for 24 h. The 
product was first filtered to remove N, N-dicyclohexylurea (DCU), followed by 
dialyzing against DMSO for 24 h to remove excess DCC and finally against water for 
24 h to remove residual DMSO. The resultant product was obtained by freeze-drying. 
2 
The amination of folic acid was carried out using the method reported by Lee et al. 
(Lee, Na et al. 2003). Folic acid was reacted with DCC and N-hydroxysuccinimide 
(NHS) in DMSO at stoichiometric molar ratio of folic acid /DCC/NHS = 1/1.2/2 for 6 
h at 50 oC. This activates the folic acid was allowed to react with ethylene diamine 
with pyridine as catalyst. Excess acetonitrile was added to precipitate out folate-NH2
5.2.3 Formulation of QDs-loaded NPs with folate-decoration and free QDs 
 
and was collected by vacuum filtration. 
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The QDs-loaded NPs were prepared by a modified solvent extraction/evaporation 
method. 0%, 11.1% and 16.7% TC NPs are used to denote the NPs of 0%, 11.1%, and 
16.7% TPGS-COOH in the blends of the two polymers. The weight ratios between 
PLA-TPGS and TPGS-COOH in these blends are 1:0, 8:1 and 5:1 respectively. In 
short, 0.15 ml of 1µM QDs and 50 mg blends of the PLA-TPGS and TPGS-COOH at 
various weight ratios were dissolved in 4ml DCM. The resulting solution was poured 
gradually into 60ml aqueous phase containing 0.03 %( w/v) TPGS as emulsifier under 
gentle stirring. The mixture was then sonicated for 120s at 25W output. The resultant 
emulsion was stirred continuously overnight to allow the organic solvent (DCM) to 
evaporate. The particle suspension was centrifuged at 10,500 rpm for 15 min to obtain 
the NPs in the pellet. The NPs was washed twice with deionized (DI) water. The NPs 
powder was obtained after freeze-drying. 
Next, QDs-loaded FD NPs were prepared as follows. 10 mg of NPs was re-suspended 
in 5 ml of DI water and placed in an ultrasonic bath for 30 min to disperse the NPs. 
N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride (EDC) were reacted with TPGS-COOH in the NPs at 
TPGS-COOH/EDC/NHS = 1:20:6.7 in stoichiometric molar ratio for 2 h at room 
temperature. Folate-NH2 was then added at TPGS-COOH/ folate-NH2 = 1:15 
stoichiometric molar ratio. The pH of the reaction mixture was adjusted to 8 using 
triethylamine. The reaction was allowed to carry out for 4 h at 37 oC. After 
centrifugation of resulting NPs, the un-reacted folate-NH2 was removed with DMSO, 
followed by washing with DI water. The final yellowish product was then collected 
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with freeze-drying. Here, 11.1% and 16.7% FD NPs denote NPs with folate prepared 
from 11.1% and 16.7% TC NPs respectively. Figure 5-1 shows the detailed scheme 
for preparation of QDs-loaded FD NPs. 
 
Figure 5-1 Detailed scheme for preparation of QDs-loaded NPs with folate decoration 
MAA-coated QDs, called as free QDs in this study, were prepared with the method 
described by Nie SM et al. in 1998 (Chan and Nie 1998). The water soluble of 
hydrophobic QDs can be achieved by coating mercaptoacetic acid (MAA) on their 
surface. The minimal protection to organic QDs can be provided with MAA, which is 
one of the smallest solubilization ligands (Aldana, Wang et al. 2001). Thus 
MAA-coated QDs can be employed as a reference to QDs-loaded NPs in vitro study. 
5.2.4 Characterization of QDs-loaded NPs with folate decoration 
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5.2.4.1 Particle size and size distribution 
Average particle size and size distribution of the QDs-loaded FD NPs were measured 
using laser light scattering (LLS, 90 Plus Particle Size, Brookhaven Instruments Co. 
USA). The NPs were diluted with DI water and sonicated for 2 min before 
measurement. 
5.2.4.2 Surface charge 
Zeta potential of NPs was determined with ZetaPlus zeta potential analyzer 
(Brookhaven Instruments Corporation) at room temperature. The samples were 
prepared by diluting the NPs suspension with DI water. The reading was calculated 
from the average of 6 measurements. 
5.2.4.3 Surface morphology 
The shape and surface morphology of NPs were investigated by field emission 
scanning electron microscopy (FESEM, JSM-6700F, JEOL, Japan) and transmission 
electron microscope (TEM, JEM-2010F, JEOL, Japan). For FESEM, the particles 
were fixed on the stub with a double-sided sticky tape and then coated with platinum 
layer, which was carried out by an auto fine coater (JEOL, Tokyo, Japan) for 60s. For 
TEM, NPs suspension was dropped on the surface of copper grid with carbon film 
and dried at room temperature. 
5.2.4.4 Emission spectrum 
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The QDs-loaded FD NPs in water was placed into a quartz cuvette. Emission 
spectrum was recorded with spectrofluorophotometer (RF-5301PC, SHIMADZU, 
Japan) at excitation 480 nm. 
5.2.4.5 QDs encapsulation efficiency 
The encapsulation
%100
process in the used QDs ofamount  Total
NPsin  QDs ofamount  edEncapsulat Efficiencyion Encapsulat ×=
 efficiency of QDs in the NPs was evaluated by inductively coupled 
plasma optical emission spectrometry (ICP-OES, Model: Optima 3000DV, 
Perkin-Elmer).  Three milligrams of the QDs-loaded NPs were dissolved in 2ml 
reagent grade 30% hydrochloric acid at 60ºC, followed by filtering with 0.45μm poly 
(vinyl idene fluoride) (PVDF) syringe filter for ICP-OES analysis to determine the 
actual amount of the QDs encapsulated in the NPs. Moreover, the amount of QDs in 
the supernatant obtained from the centrifugation of the QDs-loaded NP emulsion can 
also be determined. The sum of the two results should be 100% of the QDs added in 
the process, which can be used as a double check to see if the measurement is correct. 
The QDs encapsulation efficiency was obtained with the following calculation 
equation: 
 
5.2.5 Surface chemistry 
The decoration of folate on the surface of NPs at various component ratios was 
confirmed using X-ray photoelectron spectroscopy (XPS, AXIS His-165 Ultra, 
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Kratos Analytical, Shimadzu Corporation, Japan). The binding energy spectrum 
was recorded from 0 to 1100eV with pass energy of 80 eV under the fixed 
transmission mode.   
5.2.6 Cell line experiment 
5.2.6.1 Cell cultures 
MCF-7 breast cancer cells that overexpress folate receptor (positive control) and NIH 
3T3 fibroblasts that have less folate receptor (negative control) were provided from 
American Type Culture Collection. RMPI 1640 medium without folic acid was used 
for MCF-7 cells and DMEM was used for NIH 3T3 cells, both mediums were 
supplemented with 10% FBS and 1% antibiotics. Cells were cultivated in medium at 
37 oC in humidified environment of 5% CO2
5.2.6.2 In vitro cellular uptake of NPs 
. Before the in vitro experiments, the 
cells were pre-cultured until confluence was reached (Khin YW and Feng 2005).  
For qualitative study, MCF-7 cells and NIH 3T3 cells were cultivated in the 
chambered cover glass system (LAB-TEK®, Nagle Nunc international, Rochester, NY) 
with 5% CO2 in their respective medium at 37 oC as proposed by American Type 
Culture Collection. After 24 h (for MCF-7) and 48 h (NIH-3T3) incubation time, the 
adherent cells were washed twice with PBS. And 0.6 ml of QDs-loaded 11.1% TC 
NPs or QDs-loaded 11.1% FD NPs diluted in the medium at 0.38 nM QDs 
concentration were added into the chambers. The cells were allowed to be incubated 
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with the NPs for 4 h and were washed 4 times with PBS after incubation. They were 
then fixed by 75% ethanol for 15 min. The cells were washed twice again with PBS 
and the nuclei were stained with 4’
5.2.6.3 In vitro cytotoxicity 
, 6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) for 30 min. The cells were washed twice with PBS and observed using the 
confocal laser scanning microscope (CLSM, Olympus Fluoview FV500, Japan). 
MCF-7 cancer cells and NIH 3T3 cells were incubated in 96-well plates (Nunc, 
Roskilde, Danmark), the cell density of the cells was in the range of 40,000 to 50,000 
cells/ml. After 24 h (for MCF-7) or 48 h (NIH-3T3) seeding, the old medium was 
discarded and the cells were incubated for 4 h or 24 h in free QDs, QDs-loaded 
11.1 % TC or QDs-loaded 11.1% FD NPs containing medium with the same 0.63 nM 
QDs concentration. At the 4 h and 24 h intervals, the cultured cells were assayed for 
cell viability with Methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma). The 
wells were first washed twice using PBS and 10μl of MTT supplemented with 90 μl 
culture medium, was added into each well. After 4 h incubation in the incubator, the 
culture medium was removed and the purple crystals were dissolved in isopropanol. 
The absorbance intensity of the cells was measured using the microplate reader 
(Genios, Tecan, Männedorf, Switzerland). The absorbance wavelength was set at 






 (%)  viabilityCell
control
s ×=  
Where Ints is the absorbance intensity of the cells incubated with the NPs suspension 
and Intcontrol
5.3 Results and Discussion 
 is the absorbance intensity of the cells incubated with the culture medium 
only. 
5.3.1 Characterization of QDs-loaded NPs with folate decoration 
5.3.1.1 Size and size distribution 
The size and size distribution of the NPs were measured using Laser Light Scattering 
(LLS) and were shown in Table 5-1. It can be observed that the FD NPs have 
diameter around 280 nm. 
Table 5-1 Characteristics of QDs-loaded NPs with or without folate decoration at 
various blend ratio (n=6)* 






0% TC NPs 300.1±9.5 0.24±0.05 43.8±3.6 2.98±0.06 - 42.1±3.7 
11.1% FD NPs 281.2±6.6 0.16±0.03 45.0±4.1 3.06±0.03 - 28.9±2.9 
16.7% FD NPs 280.4±8.1 0.20±0.08 45.2±3.9 3.07±0.07 - 23.9±3.6 
* 0% TC NPs denotes the NPs of 0% TPGS-COOH in the blends of the two polymers, i.e. the NPs 
of PLA-TPGS: TPGS-COOH weight ratio 1:0 in these blends. Here 11.1% and 16.7% FD NPs 
refer to NPs with folate prepared from 11.1% and16.7% TC NPs, respectively. 
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Actual QDs loading (nmol/g) = moles of actual QDs loaded in NPs/weight of NPs obtained 
5.3.1.2 Surface charge 
The QDs-loaded FD NPs were found to be negatively charged as shown in Table 5-1. 
Zeta potential is an important factor to maintain the stability of the NPs suspension. A 
higher electric charge on the surface of the NPs will prevent aggregation of the NPs in 
buffers solution because of the strong repellent forces among particles (Mu and Feng 
2002). Therefore, the NPs synthesized in this study were stable in solution. 
5.3.1.3 Surface morphology 
From the FESEM image of the QDs-loaded 11.1% FD NPs shown in figure 5-2A, it 
can be seen that the NPs are spherical in shape and have a narrow size distribution. 
The particle size observed was in good agreement with the value determined by LLS.  
 
Figure 5-2 (A) FESEM image, (B) TEM image and (C) Emission spectrum of 
QDs-loaded 11.1% FD NPs 
From the TEM image of QDs-loaded 11.1% FD NPs in figure 5-2B, well-formed NPs 
with encapsulated QDs can be clearly seen. The QDs (seen as dark spots) were 
encapsulated in each of the polymer NPs (seen as brighter circle).  
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5.3.1.4 Emission Spectrum 
Figure 5-2C shows the emission spectrum of the QDs-loaded 11.1% FD NPs from 
580 nm to 750 nm. The peak of the emission spectrum was at 651 nm with intensity 
1024. The shift of the peak from 655 nm (for Qdot®655 ITKTM
5.3.1.5 QDs encapsulation efficiency 
 dispersed in Decane) 
to 651 nm might be due to the decrease in QDs size after the NP formulation because 
of losing of surface atoms arising from oxidation. It can be seen from figure 5-2C that 
the intensity of the emission from the QDs is still very large even though they were 
encapsulated in polymer. 
QDs encapsulation efficiencies in the NPs are demonstrated in Table 5-1. It should be 
noticed that QDs-loaded 11.1% and 16.7% FD NPs have higher encapsulation 
efficiency compared to QDs-loaded 0% TC NPs, which maybe results from the TPGS 
effect. Compared to other many emulsifiers, TPGS is more effective emulsifier in 
preparation of NPs due to its high emulsification efficiency and entrapment efficiency 
(Mu and Feng 2002; Mu and Feng 2003; Ke, Lin et al. 2005; Mu, Teo et al. 2005; 
Somavarapul, Pandit et al. 2005). 
5.3.2 Surface chemistry  
Figure 5-3 shows the XPS wide scan spectra of the QDs-loaded FD NPs with various 
copolymer blend ratio. The inset shows the relative nitrogen signals at high resolution. 
The chemical composition weight percentages of nitrogen on the surface were 3.62% 
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and 4.33% respectively for the QDs-loaded 11.1% and 16.7 % FD NPs. From 
chemical structure it can be noticed that PLA-TPGS, TPGS-COOH and organic QDs 
do not contain any nitrogen atoms, while folate-NH2 contains 7 nitrogen atoms. This 
means that the presence of the N 1s region in the XPS spectra can be used to confirm 
the successful conjugation of folate on the NPs surface. It can be observed that there 
was an increase in the percentage of the N 1s region on the surface of the NPs as the 
weight ratio of TPGS-COOH increased.  
 
Figure 5-3 The XPS wide scan spectra of the QDs-loaded FD NPs with various 
copolymer blend ratio. The inset shows the relative nitrogen signals at high resolution 
5.3.3 In vitro cellular uptake of NPs 
Figure 5-4 shows confocal laser scanning microscopy (CLSM) of (A) MCF-7 cells 
treated with QDs-loaded 11.1% TC NPs , (B) MCF-7 cells treated with QDs-loaded 
11.1% FD NPs and (C) NIH-3T3 cells treated with QDs-loaded 11.1% TC NPs , (D) 
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NIH-3T3 cells treated with QDs-loaded 11.1% FD NPs at 0.38 nM QDs concentration 
at 37 oC after 4 h incubation. Here green channel shows the transmission images, 
while the intensity coded (red for QDs and blue for DAPI) channel shows the 
fluorescence. 
 
Figure 5-4 Confocal laser scanning microscopy (CLSM) of (A) MCF-7 cells treated 
with QDs-loaded 11.1% TC NPs, (B) MCF-7 cells treated with QDs-loaded 11.1% FD 
NPs and (C) NIH-3T3 cells treated with QDs-loaded 11.1% TC NPs, (D) NIH-3T3 
cells treated with QDs-loaded 11.1% FD NPs at 0.38 nM QDs concentration at 37 o
Confocal microscopy showed that small amounts of QDs-loaded NPs without FD 
were internalized by MCF-7 cells (figure 5-4A). In contrast for NPs without FD, the 
C 
after 4 h incubation. Here green channel shows the transmission images, while the 
intensity coded (red for QDs and blue for DAPI) channel shows the fluorescence 
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same cells incubated with QDs-loaded FD NPs were examined to find FD NPs 
containing QDs efficiently labeling the cells (targeted to folate receptors) (figure 
5-4B). These qualitative results of cell uptake present strong evidences about the 
targeting effects of QDs-loaded FD NPs for MCF-7 cells. 
To further confirm the targeting effect of FD NPs, the NIH 3T3 cells which lack 
folate receptors were treated with FD NPs and imaged under similar conditions. The 
reduced uptake of FD NPs by NIH 3T3 cells is clearly shown in figure 5-4D, when 
compared with MCF-7 cells under same conditions (figure 5-4B). This experiment 
found the red emission intensity of QDs from NIH 3T3 not as strong as that from 
MCF-7 cells, which confirmed that the successful targeting of QDs-loaded FD NPs to 
cells which have over-expression of folate receptors. At the same time, the intensity 
of red fluorescence from QDs in figure 5-4C and 5-4D were almost similar although 
the NPs used in figure 5-4C are without folate decoration. This is because the NIH 
3T3 cells do not have over-expression of folate receptors on the surface. Therefore, 
the NIH 3T3 cells take NPs with or without folate-decoration at the same rate. Hence, 
these results confirm that objective of increasing specificity and sensitivity of QDs 
image by labeling cancer cells with over-expression of folate receptors on the surface 
was achieved.  
5.3.4 In vitro cytotoxicity 
It was reported that QDs or iron oxide particles in applications such as biological 
imaging and detection have no significant effects on organisms over the duration of 
 120 
the experiments (Michalet, Pinaud et al. 2001; Niemeyer 2001; Miyawaki, Sawano et 
al. 2003; Alivisatos 2004). But in fact the cadmium present in QDs could be 
extremely toxic to cells (Celik, Comelekoglu et al. 2005). To some extent this 
phenomenon can be effectively prevented through the surface coating. For example, 
tumor cells labeled by QDs with surface coating survived the circulation and 
extravasated into tissues just as effectively as unlabeled cells, and no difference in 
their ability to form tumors in mice was observed after 40 days (Voura, Jaiswal et al. 
2004). It was also pointed out that nanocrystals that have PEG-functionalized 
exteriors exhibit generally much less toxicity and longer circulation time than 
water-soluble nanocrystals made with other agents (Derfus, Chan et al. 2004; Hoshino, 
Fujioka et al. 2004; Bentzen, Tomlinson et al. 2005; Kirchner, Liedl et al. 2005; 
Chang, Thekkek et al. 2006; Smith, Duan et al. 2006). Our in vitro cytotoxicity study 
on the QDs-loaded PLA-TPGS NPs (containing PEG group) with or without folate 
decoration confirmed that this kind of NPs can decrease efficiently toxicity of QDs to 
NIH-3T3 normal cells. 
Figure 5-5 shows a comparison of the in vitro MCF-7 cell viability of free QDs, 
QDs-loaded 11.1% TC NPs and QDs-loaded 11.1% FD NPs at the same 0.63 nM 
QDs concentration after 4 h and 24 h culture. For MCF-7 cancer cells, the cell 
viability after 4 h and 24 h for free QDs was the lowest compared to QDs-loaded 
11.1% TC NPs and QDs-loaded 11.1% FD NPs shown in the figure 5-5. The cell 
viability for QDs-loaded 11.1% FD NPs is 81.8 ± 5.9 % and 80.1 ± 8.0 % for 4 h and 
24 h incubation time respectively, which was higher than the cell viability for free 
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QDs which is 79.9 ± 5.1 % and 77.2 ± 11.5 % for 4 h and 24 h incubation time 
respectively. This shows that the encapsulation of the QDs with polymers decreased 
the cytotoxicity of the QDs. In addition, the cell viability for QDs-loaded 11.1% FD 
NPs is lower than the cell viability for QDs-loaded 11.1% TC NPs which was 94.2 ± 
4.6 % and 93.4 ± 8.8 % for 4 h and 24 h incubation time respectively. This may be 
attributed to the targeting effects of folate. It is possible that the increased uptake of 
FD NPs into the MCF-7 cells through the receptor-mediated endocytosis caused the 
decrease in cell viability. In summary, the in vitro cytotoxicity of QDs for MCF-7 
cancer cells was decreased by the encapsulation with polymer and there was increased 
uptake of FD NPs for MCF-7 cells, which resulted from the successful targeting 
effects of NPs with folate ligands specifically to cancer cells with over-expression of 
folate receptors. 
 
Figure 5-5 In vitro viability of MCF-7 cells treated with free QDs, QDs-loaded 11.1% 
TC NPs and QDs-loaded 11.1% FD NPs at the same 0.63 nM QDs concentration after 
4 h and 24 h culture (n=6) 
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Figure 6 shows a comparison of the in vitro NIH 3T3 cells viability of free QDs, 
QDs-loaded 11.1% TC NPs and QDs-loaded 11.1% FD NPs at the same 0.63 nM 
QDs concentration after 4 h and 24 h culture. The NIH 3T3 cells viability of free QDs 
was the lowest at 86.6 ± 7.7 % and 85.2 ± 5.1 %, for 4 h and 24 h incubation time 
respectively. On the other hand, the cell viabilities for QDs-loaded 11.1% FD NPs and 
QDs-loaded 11.1% TC NPs were about the same. The cell viability for QDs-loaded 
11.1% FD NPs was 89.7 ± 6.7% and 87.6 ± 7.8 %, for 4 h and 24 h incubation time 
respectively. While the cell viability for QDs-loaded 11.1% TC NPs is 90.3 ± 7.5 % 
and 88.5 ± 6.8 %, for 4 h and 24 h incubation time respectively. Therefore, the in vitro 
cell viability experiments shown that the NPs with or without folate decoration have 
less cytotoxicity compared to free QDs for NIH 3T3 fibroblasts normal cells. This is 
very important because the NPs are used for imaging purposes and should not damage 
the surrounding normal cells. The similar cell viability for FD and non-FD NPs is due 
to the lack of over-expression folate-receptors on the NIH 3T3 cells, therefore the rate 
of uptake of the two kinds of NPs were the same. Hence, only cancer cells with 
over-expression of folate receptors will uptake the FD NPs at a higher rate. The NIH 
3T3 cells viability experiments demonstrated that the encapsulation of QDs in 
polymer decreased the cytotoxicity of QDs for normal cells.  
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Figure 5-6 In vitro viability of NIH 3T3 cells treated with free QDs, QDs-loaded 
11.1% TC NPs and QDs-loaded 11.1% FD NPs at the same 0.63 nM QDs 
concentration after 4 h and 24 h culture (n=6) 
In summary, our in vitro cytotoxicity demonstrated that two strategies of surface 
coating and active targeting were utilized simultaneously to minimize effectively the 
cytotoxicity of QDs to normal cells. During cancer detection, QDs-loaded PLA-TPGS 
NPs with folate decoration will produce minimum damage to normal cells.  
5.4 Conclusion 
We developed a new strategy to prepare folate-decorated nanoparticles of 
biodegradable polymers for QDs formulation for targeted and sustained imaging for 
cancer diagnosis at its early stage Two copolymers of poly(lactide)-vitamin E TPGS 
(PLA-TPGS) and vitamin E TPGS-carboxyl (TPGS-COOH) were synthesized, which 
were blended at various weight ratio to make QDs-loaded nanoparticles which were 
decorated with folate for targeted and sustained imaging. Here the TPGS-COOH was 
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utilized to conjugate with folate-NH2. The merit is that the amount of folate ligand 
conjugated onto the NPs surface can be made as desired by adjusting the component 
ratio between PLA-TPGS and TPGS-COOH copolymers. The size of such NPs was 
found in the range of 280-300 nm. In vitro cellular uptakes of such NPs were 
investigated with CLSM, which demonstrated much higher internalization of the 
folate-decorated QDs-loaded PLA-TPGS/TPGS-COOH NPs by MCF-7 breast cancer 
cells which are of over-expression of folate receptors than the cellular uptake by NIH 
3T3 fibroblast cells which are of low expression of folate receptors. Compared with 
the free QDs, the QDs formulated in the PLA-TPGS/TPGS-COOH NPs showed lower 
in vitro cytotoxicity for both of MCF-7 cells and NIH 3T3 cells. Additionally, our 
findings indicated that under same conditions, cytotoxicity of QDs formulated in the 
PLA-TPGS/TPGS-COOH NPs is lower for normal cells such as NIH 3T3 cells than 
that for beast cancer such as MCF-7 breast cancer cells due to folate targeting 
effect. Our study showed that QDs formulated in folate-decorated nanoparticles of 
PLA-TPGS/TPGS=COOH copolymer blender is feasible for targeted imaging to 
improve imaging specificity and sensitivity as well as to reduce side effects of QDs to 
normal cells.  
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Chapter 6 Multifunctional QDs/ Docetaxel -loaded 
Poly(lactic-co-glycolic acid) Targeted Nanoparticles for 
Cancer Cell imaging and Therapy 
 
6.1 Introduction 
Nanoparticles (NPs) of biodegradable polymers have been intensively investigated in 
the literatures for sustained and controlled delivery of imaging and therapeutic agents 
for cancer diagnosis and treatment, which can result in high diagnostic and 
therapeutic efficiency and low side effects (Feng 2006; Pridgen, Langer et al. 2007; 
Chiellini, Piras et al. 2008; Feng 2008; Parveen and Sahoo 2008). Stealth, i.e. long 
circulating NPs, which can avoid being recognized and eliminated by the microphages, 
can be achieved by grafting, conjugating, or adsorbing sterically amphiphilic 
polymers such as polyethylene glycol (PEG) and d-α-tocopheryl polyethylene glycol 
succinate (Vitamin E TPGS or simply TPGS) to the nanoparticle surface (Gref, Lu ̈ck 
et al. 2000; Owens Iii and Peppas 2006; Feng SS 2007). Targeted delivery can be 
realized by conjugating specific targeting ligands on the NPs, which can thus 
recognize the corresponding receptors on the cancer cell membrane (Ferrari 2005; 
Akagi, Kaneko et al. 2006; Gu, Karnik et al. 2007; Zhang, Lee et al. 2007; Pan and 
Feng 2008; Sun BF 2008). Multifunctional NPs thus now become a focus in the area of 
nanomedicine or cancer nanotechnology since they can simultaneously achieve the 
functions of targeting, imaging, therapy-delivering and results reporting, which can be 
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realized by co-encapsulation of diagnostic, therapeutic and reporting agents in the 
NPs with molecular probes conjugated onto their surface. There have been a lot of 
publications showing nanoparticles of dual functions such as imaging and drug 
delivering, targeting and imaging, targeting and drug delivering, along with a little 
preliminary research on NPs of more than double functions (Bagalkot, Zhang et al. 
2007; Kim, Lee et al. 2008). In the present work, a multifunctional nanoparticle 
system is developed to simultaneously realize a sustained and controlled delivery of 
quantum dots (QDs) used as a model imaging agent and Docetaxel used as a model 
anticancer drug, which are conjugated with folic acid to target folate 
receptors-overexpressing cancer cells. The nanoparticles are made of a blend of two 
polymers. One is poly(lactic-co-glycolic acid) (PLGA). It is a US FDA approved 
biodegradable polymer
Semiconductor QDs used as a model imaging agent in this research are tiny 
light-emitting nanocrystals that have emerged on the forefront as fluorescent probes 
for imaging purposes in biology and medicine. QDs as imaging agents have 
 which has been used most often in the area of drug delivery. It 
is used in this research to maintain the mechanical strength and pursue long enough 
biodegradation of the NPs. Another is carboxyl Vitamin E TPGS (TPGS-COOH), a 
PEGylated vitamin E modified by carboxyl, which is used in this research to pursue 
high encapsulation efficiency, desired drug release profile and high cellular adhesion, 
and more importantly, a control of the targeting effects by varying the blend ratio 
between PLGA and TPGS-COOH, i.e. the carboxyl amount on the NPs surface for 
folic acid conjugation. 
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significant advantage compared with organic dyes. QDs have tunable emission from 
visible to infrared wavelengths by changing their size and composition, and broader 
adsorption spectra allowing simultaneous excitation of multiple fluorescence colors. 
Furthermore, QDs emit highly intense signals, and they are photostability, high 
resistance to photobleaching (Alivisatos, Gu et al. 2005; Medintz, Uyeda et al. 2005; 
Michalet, Pinaud et al. 2005; Smith, Duan et al. 2008).  
Docetaxel (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl) is a new generation of 
taxoids, which has higher patient reaction rate and less side effects than paclitaxel. 
Docetaxel is a semisynthetic analog of paclitaxel, prepared from a nontoxic precursor 
compound that is extracted from needles of European yew tree (Bissery, Nohynek et al. 
1995). It is an anticancer agent of the taxoid family and is clinically effective against 
cancer, such as head/neck, lung, ovarian carcinoma and breast cancer (Capri, Tarenzi et 
al. 1995). Docetaxel acts by binding to microtubules and inhibiting microtubule 
depolymerization to free tubulin. As a result, the equilibrium within the microtubule 
system is disrupted, leading to mitotic arrest in the G2
Folic acid (FOL) is an oxidized form of folate with high binding affinity for folate 
receptors (K
M phase of the cell cycle and 
ultimately to cell death (Gueritte-Voegelein, Guenard et al. 1991). In this research, 
Docetaxel is used as a model anticancer agent. 
d ~ 10-10 M). It is low in cost, stable under storage and is an essential 
vitamin for the biosynthesis of nucleotide bases consumed by proliferating cells in 
elevated quantities (Lu and Low 2002; Leamon and Reddy 2004; Lu, Sega et al. 
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2004). Compared with other high molecular weight targeting ligands such as 
antibodies, peptides, etc, folate has small size, which can lead to favorable 
pharmacokinetic properties of FOL conjugates, reduced probability of 
immunogenicity, convenient availability and lack of expression in normal tissue (Lu 
and Low 2002; Low and Antony 2004). The overexpression of folate receptors can be 
found in the membrane of many human cancer cells such as brain, kidney, lung, 
breast and ovarian cancer cells (Sudimack and Lee 2000). In addition, expression 
level of folate receptors in tumor has been reported to reach 100-300 times higher 
than that observed in normal tissue (Ross, Chaudhuri et al. 1994), henceforth 
becoming an attractive targeting ligand. Liposomes, micelles and NPs of 
biodegradable polymers with folate decoration were found to increase the cellular 
uptake of formulated anticancer drugs in some literatures (Saul, Annapragada et al. 
2003; Yoo and Park 2004; Park, Kim et al. 2005; Lee 2006; Shmeeda, Mak et al. 2006; 
Wu, Liu et al. 2006; Pan and Feng 2008). In recent literature, Esmaeili et al. and 
Murugesan et al. have reported the use of folate for the targeted delivery of docetaxel 
loaded nanoparticles (Esmaeili, Ghahremani et al. 2008; Murugesan, Mishra et al. 
2008). 
Folate-decorated PLGA/TPGS-COOH NPs loaded with QDs and docetaxel for 
targeted imaging and therapy of folate receptors-overexpressing cancer cells were 
prepared by the nanoprecipitation method, which were then characterized by laser 
light scattering (LLS) for particle size and size distribution, the zeta potential analyzer 
for nanoparticle surface charge, X-ray photoelectron spectroscopy (XPS) for 
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nanoparticles surface chemistry. field emission scanning electron microscope 
(FESEM) for nanoparticle surface morphology, transmission electron microscope 
(TEM) to visualize the QDs encapsulation in the NPs. Spectrofluorophotometer was 
used to measure the emission spectra of the QDs formulated in the NPs and to 
determine the QDs encapsulation efficiency. High performance liquid 
chromatography (HPLC) was utilized to determine the drug encapsulation efficiency 
of NPs. In vitro experiments were carried out on MCF-7 breast cancer cells, which are 
of over-expressed folate receptors, and NIH 3T3 cells, which are of low folate 
receptors on their surface, to evaluate the targeting effect of the folate conjugated 
PLGA/TPGS-COOH NPs. Quantitative assessment of the cellular uptake of the folate 
conjugated PLGA/TPGS-COOH NPs and bare (with no folate conjugation) 
PLGA/TPGS-COOH NPs was conducted to demonstrate the targeting effect of the 
folate nanoparticles. Confocal laser scanning microscopy (CLSM) was employed to 
visualize the NPs internalized in the PLGA/TPGS-COOH NPs. The in vitro 
cytotoxicity of Docetaxel formulated in the PLGA/TPGS-COOH NPs with or without 
folate conjugation was assessed by using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
6.2 Materials and Methods 
6.2.1. Materials 
Organic Quantum Dots (Qdot® 655 ITKTM) dispersed in Decane (catalog number 
2172-1) were purchased from InvitrogenTM Corporation Singapore 
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(http://probes.invitro-gen.com/products/qdot/). Before use, quantum dots were treated 
according to the directions described by the Company. Docetaxel of purity 99.56% 
was purchased from Jinhe Bio-Technology Co. Ltd (Shanghai, China). Taxotere® of 
80 mg in 2 ml Polysorbate 80 was purchased from Aventis Pharmaceuticals (USA). 
Poly(lactic-co-glycolic acid) (PLGA) (75:25) (Mw 90 000-126 000), 
N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylamino pyridine (DMAP), dimethyl 
sulfoxide (DMSO, anhydrous), folic acid, N-hydroxysuccinimide (NHS), ethyl 
Diamine, pyridine, 1-ethyl-3-(3-dimethylamino) propyl carbodiimide (EDC), 
triethylamine (TEA), dichloromethane (DCM), phosphate buffered saline (PBS), 
Dulbecco’s Modified Eagle’s Medium (DMEM) medium, antibiotics 
(penicillin-streptomycin solution), Trition X-100, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT), diethyl ether, 
glutaric acid, chloroform were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Tetrahydrofuran (THF), acetonitrile were purchased from Tedia Company Inc. (USA). 
D-α-Tocopheryl polyethylene glycol 1000 succinate (C33O5H54
6.2.2 Synthesis of TPGS-COOH 
, vitamin E TPGS or 
simply TPGS) was purchased from Eastman Chemical Company (USA). RPMI 1640 
medium without folic acid and fetal bovine serum (FBS) were purchased from Gibco 
(Life Technologies, AG, Switzerland). MCF-7 and NIH-3T3 cells were provided by 
American Type Culture Collection. Millipore water was produced by the Milli-Q Plus 
System. (Millipore Corporation, Bedford, USA). 
The preparation of TPGS-COOH involves reacting TPGS, glutaric acid, DCC and 
DMAP in DMSO with TPGS/glutaric acid/DCC/DMAP in the stoichiometric molar 
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ratio of 1:1:1:0.1 under nitrogen atmosphere at room temperature for 24 hours, which 
is described in an earlier work of our group (Zhang, Lee et al. 2007). This reaction 
allows for the ester bond formation between the carboxylic group of glutaric acid and 
the hydroxyl-terminated TPGS. The presence of N,N-dicyclohexylurea (DCU) in the 
product was removed through filtration. The resulting mixture was dialyzed against 
DMSO for 24 hours to remove excess DCC and against water for 24 hours to remove 
DMSO. The product was then freeze-dried. 
6.2.3 Synthesis of FOL-NH
The amination of folic acid (FOL) involves reacting DCC and NHS in DMSO with 
FOL/DCC/NHS in the stoichiometric molar ratio of 1:1.2:2 for 6 hours at 50 
2 
oC as 
reported by Lee et al (Lee, Na et al. 2002). Excess ethylene diamine was subsequently 
reacted with the activated folate in the presence of pyridine catalyst. The aminated 
folate (FOL-NH2
6.2.4 Preparation of QDs/docetaxel-loaded PLGA/TPGS-COOH NPs 
) was then precipitated out by adding excess acetonitrile and washed 
three times with diethyl ether before undergoing vacuum filtration.  
The QDs/docetaxel-loaded PLGA/TPGS-COOH NPs with no FOL conjugated, which 
are denoted by TC NPs from now on, were prepared using the nanoprecipitation 
method (Farokhzad, Cheng et al. 2006). We use 16.7% TC NPs to denote the 
QDs/docetaxel-loaded NPs of 16.7% TPGS-COOH and 83.3% PLGA in the 
polymeric blend, i.e. PLGA and TPGS-COOH are blended in the weight ratio of 5:1. 
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Accordingly, 16.7% FD NPs are used to denote the 16.7% TC NPs with FOL 
conjugated on their surface. To prepare 16.7% TC NPs, a 120 mg 
PLGA/TPGS-COOH 5:1 blend, 6 mg docetaxel and 0.8 ml of 0.5 μM of quantum 
dots (QDs) were dissolved in 12 ml tetrahydrofuran (THF). The mixture was then 
added dropwise into 120 ml deionised water with 0.03% (w/v) TPGS. The 
nanoparticle suspension was stirred at 500 rpm. The remaining organic solvent and 
surfactant was removed by washing and centrifuging at 10 000 g for 15 minutes for 4 
times. The formed nanoparticles were subsequently suspended in deionised water and 
filtered with a 0.45 μm poly(vinylidene fluoride) (PVDF) syringe filter in a sterile 
environment to remove large aggregates. 
6.2.5 Formulation of QDs/docetaxel-loaded PLGA/TPGS-COOH NPs with FOL 
conjugation 
The TC NPs formed in the last section were re-suspended in deionised water to give a 
nanoparticle concentration of 2 mg/ml and placed in an ultrasonic bath to disperse the 
nanoparticles. NHS and EDC were added in the stoichiometric molar ratio of 
TPGS-COOH/EDC/NHS= 1:20:6.7 to activate the surface carboxyl group of the NPs 
for a duration of 2 hours at room temperature. Folate-NH2 in DMSO was added to the 
nanoparticle suspension in the stoichiometric molar ratio of TPGS-COOH/FOL-NH2= 
1:15. Triethylamine (TEA) was then used to adjust the pH of the reaction mixture to 8. 
The reaction was allowed to take place for 4 hours at 37 oC. The mixture was then 
centrifuged at 10,000 g for 15 mins and un-reacted folate-NH2 was removed through 
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washing with deionised water for 2 times. The eventual yellow product obtained was 
collected by freeze-drying. Figure 6-1 schematically describes the preparation of the 
QDs/docetaxel-loaded PLGA/TPGS-COOH NPs with FOL conjugation, i.e. the FD 
NPs.  
 
Figure 6-1 Preparation scheme for folic acid-conjugated PLGA/TPGS-COOH 
nanoparticles loaded with quantum dots (QDs as a model imaging agent and docetaxel 
as a model drug (FD NPs) 
6.2.6 Characterization of TC and FD NPs 
6.2.6.1 Particle size and size distribution 
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Laser light scattering (LLS, 90 Plus Particle Size, Brookhaven Instruments Co. USA) 
was used to measure average particle size and size distribution of the TC and FD NPs
6.2.6.2 Drug encapsulation and loading efficiency 
. 
The nanoparticles were diluted with water and sonicated for several minutes before 
measurements were taken to ensure that the particles were well dispersed and the 
dispersion was homogeneous. 
The docetaxel formulated in the NPs was quantified by high performance liquid 





ODS-3 column (150x4.6mm, pore size 5 μm, GL Science Inc, Tokyo, Japan) was 
employed. 2 mg of dried nanoparticles were re-dissolved in 1ml DCM and left to 
evaporate overnight in the fume hood. 1ml of mobile phase (45/5/50 v/v/v 
acetonitrile/methanol/water solution) was subsequently added. The clear solution was 
filtered with a 0.22 μm poly(vinyl idene fluoride) (PVDF) syringe filter before HPLC 
analysis. The column effluent was detected at 230 nm with a UV/vis detector. The 
equation used for calculating drug encapsulation efficiency is: 
 
6.2.6.3 Surface charge 
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ZetaPlus zeta potential analyzer (Brookhaven Instruments Corporation) was used to 
measure the zeta potential of the NPs. Nanoparticle suspension was diluted with 
deionised water before measurements were taken. 
6.2.6.4 Surface morphology 
The surface morphology and shape of the NPs was determined by a field emission 
electron microscopy (FESEM, JEOL JSM-6700F, Japan) at an accelerating voltage of 
10kV and transmission electron microscope (TEM, JEM-2010F, JEOL, Japan). The 
TEM images can also visualize encapsulation and distribution of the QDs in the TC 
and FD NPs. The samples for FESEM were prepared from the nanoparticle 
suspension. A drop of the suspension was dripped onto a copper tape placed on the 
surface of a sample stub and dried overnight. The sample stub was then coated with a 
platinum layer by Auto Fine Platinum Coater (JEOL, Tokyo, Japan) for 40s. To 
prepare TEM samples, the nanoparticle suspension was dropped onto the surface of 
copper grid with carbon film and dried at room temperature. 
6.2.6.5 Surface chemistry 
Surface chemistry measured by X-ray photoelectron spectroscopy (XPS, AXIS 
His-165 Ultra, Kratos Analytical Shimadzu Corporation, Japan) was used for 
confirming the chemical compositions on the nanoparticle surface. The binding 
energy was recorded from a range of 0 to 1100eV with 80eV pass energy under the 
fixed transmission mode to check for carbon, oxygen, phosphorous and nitrogen 
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content. Samples to be measured were first attached to a glass piece which was then 
stuck onto a metal stub using double-sided sticky tape. 
6.2.7 In vitro drug release 
5 mg of the QDs/docetaxel loaded TC or FD NPs were put in a centrifuge tube and 
dispersed in 5 ml PBS (phosphate buffer solution, pH 7.4) containing 0.1% Tween-80. 
The tube was put in an orbital shaker water bath and vibrated at 120 rpm at 37.2°C. At 
designated time intervals, the tube was taken out and centrifuged at 10,000 g for 15 
min. The supernatant was extracted with DCM and transferred in mobile phase. After 
the evaporation of DCM by nitrogen stream, docetaxel concentration was determined 
with HPLC. The pellet was resuspended in 5 ml fresh PBS and put back in the shaker 
for continuous measurement. 
6.2.8 Photophysical characterization 
6.2.8.1 Fluorescent images 
2ml of the samples were placed in quartz cuvettes before recording with the camera. 
The true-color fluorescent images of the suspension of QDs in dichloromethane and 
those formulated in the TC or FD NPs suspended in water were recorded with a 
digital color camera (EOS 400D, Canon, Japan) under the radiation of UV lamp with 
excitation wavelength at 365 nm (Model UVGL-58, CA, USA).  
6.2.8.2 Emission spectra  
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The emission spectra of the QDs formulated in TC or FD NPs (excitation 
wavelength=458 nm) was investigated with spectrofluorophotometer (RF-5301PC, 
SHIMADZU, Japan). 
6.2.9 QDs encapsulation and loading efficiency 
The QDs encapsulation efficiency of the TC or FD NPs was quantified using 
spectrofluorophotometer (RF-5301PC, SHIMADZU, Japan). 1ml of nanoparticles 
suspension was freeze-dried and re-dissolved in 1ml of DCM before the emission 
analysis. The emission at 654 nm under excitation at 458 nm was measured to 











6.2.10 Cell line experiment 
6.2.10.1 Cell cultures 
 138 
In this study, two kinds of cells were used. One is MCF-7 breast cancer cells 
overexpressing folate receptor as positive control, and another is NIH-3T3 fibroblasts 
cells with less folate receptor as negative control. MCF-7 cells were cultured at 37 oC 
in humidified environment of 5% CO2
6.2.10.2 In vitro cellular uptake of NPs 
 in RPMI 1640 medium without folic acid, 
supplemented with 10% FBS and 1% antibiotics. NIH-3T3 cells were cultured in 
DMEM medium supplemented with 10% FBS and 1% antibiotics at the same 
conditions. 
For quantitative study, MCF-7 and NIH-3T3 cells were seeded into 96-well black 
plates (Costar, IL, USA) at 1x104 cells/well. After 80% confluence was reached by 
the cells, the medium was changed with the NPs suspension at a designated equivalent 
QDs concentration, say 0.75 nM. The wells with the NPs suspension were incubated 
for 0.5, 1, 2 and 4 hrs. Six wells for positive control and six wells for sampling were 
seeded for each sample. After incubation, the nanoparticle suspension was removed 
and the wells were washed with 50 μL of PBS for three times to remove traces of 
nanoparticles. 100 μL of fresh medium was then added to each sample well before 
adding in 50 μL of 0.5% Trition X-100 in 0.2N NaOH to lyse the cells for 40 mins 
(Zhang and Feng 2006). Microplate reader (Genios, Tecan, Männedorf, Switzerland) 
with excitation wavelength at 458 nm and emission wavelength at 652 nm was used to 
measure the fluorescence intensity of each sample well. The cellular uptake efficiency 
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was expressed as the percentage of sample well fluorescence versus that of the 
positive control solution (Mo and Lim 2005). 
For qualitative study, 0.6ml of MCF-7 and NIH-3T3 cells were cultivated with 5% 
CO2 in their respective medium at 37 oC (proposed by American Type Culture 
Collection) in the chambered cover glass system (LAB-TEK®
6.2.10.3 In vitro therapeutic effect and targeting effects 
, Nagle Nunc 
International, Rochester, NY). After 24hr and 48 hr of the incubation time for MCF-7 
and NIH-3T3 respectively, the medium was changed with that of the NPs suspension. 
0.6ml of the NPs diluted in the medium to reach 0.375 nM QDs concentration were 
added to the cells and allowed to be incubated for 1 h. The cells were washed for 3 
times after incubation to remove the NPs remaining in the chambers and then fixed 
with 0.6ml of 70% ethanol for 20 mins. Cells were washed thrice with PBS again 
before staining the nuclei with 20 μL of 4’, 6-Diamidino-2-pheylindole 
dihydrochloride (DAPI) and 0.8ml of PBS for 40 mins. The cells were subsequently 
washed thrice with PBS and observed through the confocal laser scanning microscope 
(CLSM, Olympus Fluoview FV500, Japan) after adding 0.6ml of PBS. The images of 
the QDs were recorded with blue channel (excitation at 340 nm) and red channel 
(excitation at 458 nm) respectively.  
To evaluate the in vitro therapeutic effect and the targeting effects of the 
QDs/Docetaxel loaded TC or FD NPs, MCF-7 cancer cells were employed, which 
were incubated in 96-well plates (Nunc, Roskilde, Danmark) whereby the cell density 
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ranged from 4000 to 5000 cells/well. After 24 hrs, the culture medium was removed 
and the cells were incubated for 24h, 48h and 72 hrs with 100 μL of the 
QDs/Docetaxel loaded TC or FD NPs





 suspension, which were of the equivalent 
docetaxel concentration ranging from 0.025 μg/ml to 2.5 μg/ml. At designated time 
intervals (24 hr, 48 hr and 72 hr), the cultured cells were assayed for cell viability 
with methylthiazolyldiphenyl-tetrazolium bromide (MTT, Sigma). The wells were 
first washed twice with PBS and 10 μL of MTT (5 mg/ml in PBS) supplemented with 
90 μL of culture medium were then added into each well. After 3 hrs of incubation, 
the culture medium was removed and the purple crystals were dissolved with 100 μL 
of isopropanol for 15 mins. The absorbance intensity was measured by the microplate 
reader (Genios, Tecan, Männedorf, Switzerland) at 570 nm with reference wavelength 
of 620 nm. Cell viability was expressed by the following equation: 
 
where Ints is the absorbance intensity of the cells incubated with the nanoparticle 
suspension and Intcontrol
6.3 Results and Discussion 
 is the absorbance intensity of the cells incubated with the 
incubation medium only (positive control).  
6.3.1 Characterization of QDs/docetaxel-loaded NPs  
6.3.1.1 Particle size and size distribution 
 141 
The size and the size distribution of the QDs/Docetaxel loaded PLGA/TPGS-COOH 
Nanoparticles with or without FOL conjugation, i.e. the FD NPs and the TC 
NPs measured using 
Table 6-1 Characteristics of QDs/docetaxel loaded NPs with or without folate 
decoration (n=3)* 
laser light scattering (LLS) are shown in Table 6-1, which are 
250-260 nm in diameter with small standard deviation. It can be seen that conjugation 
of folic acid onto the nanoparticles did not cause significant change in the 































































* 16.7% TC NPs denote the NPs of 16.7% TPGS-COOH in the blends of the two polymers, i.e. 
weight ratio of PLGA: TPGS-COOH = 5:1. 16.7% FD NPs refer to NPs conjugated with folate 
prepared from 16.7% TC NPs 
Theoretical drug loading (%) = [weight of drug used/ (weight of polymer +drug used)] ×100%. 
Actual drug loading (%) = [weight of actual drug loaded in NPs/ weight of NPs obtained] ×100%. 
NPs yield (%) = weight of recovered NPs/ (weight of polymer + drug used) ×100%. 
Drug EE (%) = [Theoretical drug loading/Actual drug loading] ×100%. 
 
6.3.1.2 Drug encapsulation and loading efficiency 
Drug encapsulation efficiency (EE) is an important factor for drug delivery systems. 
The drug EE of the TC and FD NPs determined by HPLC are also listed Table 6-1. 
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The drug EE for the 16.7% TC NPs is 34.5% and that for the 16.7% FD NPs and 
31.7%. The drug EE of the PLGA/TPGS-COOH NPs prepared by the 
nanoprecipitation method was not as high as that of other polymeric NPs such as the 
PLA-TPGS/TPGS-COOH NPs in our earlier work (Pan and Feng 2008).  
6.3.1.3. Surface charge 
The zeta potential observed for the QDs/docetaxel loaded TC or FD NPs can also be 
found from Table 6-1. Aggregation of the NPs in suspension can be avoided when 
higher electric charge on the nanoparticle
6.3.1.4. Surface morphology 
 surface, which provides repellent forces 
among the particles and thus stabilizes the nanoparticle suspension (Mu and Feng 
2002). 
The field emission scanning electron microscope (FESEM) image of the 16.7% FD 
NPs is shown in figure 6-2C. The image shows that the NPs are spherical in shape and 
their surface looks smooth in the given resolution level. It was said that NPs with 
smooth surface can be retained longer in cells than those with rougher surface (Pan, 
Wang et al. 2008). The particle size found from this image agrees with that measured 
by LLS in Section 3.1.1. It can also be seen from this image that the NPs are in a quite 
uniform size, i.e. have narrow size distributions. Figure 6-2D shows a transmission 
electron microscope (TEM) image of the 16.7% FD NPs, which visualizes the QDs 
(black dots) formulated in the NPs. The TEM image confirmed that the QDs have 
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been successfully encapsulated and quite well dispersed in the PLGA/TPGS-COOH 
nanoparticle matrix. 
 
Figure 6-2 (A) Fluorescent Images of free QDs and 16.7% FD NPs (B) Emission 
spectra of free QDs and 16.7% FD NPs (C) FESEM image and (D) TEM image of 
16.7% FD NPs (The inset shows TEM image of free QDs) 
6.3.1.5 Surface chemistry 
Figure 6-3 shows the XPS wide scan spectrum of the QDs/docetaxel-loaded 16.7% 
TC and 16.7% FD NPs. The insert shows the relative nitrogen signals at high 
resolution. It can be noticed from the chemical structure of the various elements that 
PLGA, TPGS-COOH and organic QDs contain no nitrogen atoms while 7 and 1 
nitrogen atoms are present in folate-NH2 and Docetaxel, respectively. Hence, the 
absence of the N 1s region in the XPS spectra of the TC NPs implies that there is no 
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Docetaxel on the NP surface and the drug is all encapsulated within the polymer 
matrix, and the presence of the N 1s region in the XPS spectra of the FD NPs can be 
used to indicate the successful conjugation of folic acid on the nanoparticles surface. 
In addition, measurement for the presence of phosphorous element was also 
performed by XPS. Since the free QDs were coated with TOPO, phosphorous atoms 
are thus present on the QDs surface. Moreover, the XPS spectra show the absence of 
the peak in the phosphorous region for both of the TC and FD NPs, which indicates 
that the there is no phosphorous on the surface of the NPs and all QDs are 
encapsulated within the polymer matrix. 
 
Figure 6-3 XPS wide scan of QDs/docetaxel loaded NPs. The inset shows the relative 
nitrogen signals at high resolution 
6.3.1.6 In vitro drug release 
The in vitro release profiles of docetaxel from the 0% TC NPs (i.e. the PLGA NPs) 
and the 16.6% FD NPs are shown in figure 6-4, which are in biphasic manner: a fast 
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release phase in the first 3 days followed by a first-order release (with constant release 
rate). In the first 3 days, the cumulative drug release was 21.4% for the 0% TC NPs 
and 33.8% for the 16.7% FD NPs, respectively. Such a fast release could be due to the 
short diffusion path for the drug molecules located near the nanoparticle surface. 
After 30 days, however, only 39.8% of the loaded drug for the 0% TC NPs and 58.6% 
of the loaded drug for the 16.7% FD NPs were released. Such slow releases were due 
to the long diffusion path for the drug molecules inside the particles out to the release 
medium. It is understandable why the drug release from the 16.7% FD NPs is faster 
than from 0% TC NPs, which contain no TPGS-COOH in the polymeric matrix. This 
could be due to larger molecular weight and higher hydrophobicity of the PLGA than 
the TPGS-COOH, which does not facilitate the water uptake and permeation into the 
polymeric matrix to speed the drug release. 
 
Figure 6-4 In vitro docetaxel release profiles from the 0% TC NPs and 16.7% FD NPs. 
Data represent mean ±SD, n=3 
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6.3.2 Photophysical characterization of QDs/docetaxel-loaded NPs 
6.3.2.1 Fluorescent images 
Figure 6-2A shows the fluorescent images of free QDs suspended in DCM and the 
QDs/docetaxel-loaded FD NPs dispersed in water under UV lamp with excitation 
wavelength of 365nm. Both were found to be emitting fluorescence with a pure color.  
6.3.2.2 Emission spectra 
The emission spectra of the free QDs in DCM and QDs/docetaxel-loaded NPs of FOL 
conjugation with excitation wavelength at 458 nm are shown in figure 6-2B. It can be 
seen that the NP formulation of QDs experienced a shift in the emission peak from 
654 (for free QDs in DCM) to 652 nm (for FD NPs in water). This could be due to the 
size decrement of the QDs resulted from the oxidation of its surface atoms during 
nanoparticle preparation (Pan, Wang et al. 2008). Chalcogenide atoms (Se, S) on the 
surface of QDs have been reported to undergo oxidation to form oxides (SeO2, SO42-
6.3.3 Quantum dots encapsulation and loading efficiency 
) 
which would subsequently desorb from the surface (Alivisatos 1996; Pan, Wang et al. 
2008). However, the full width at half-maximum has hardly changed. 
The quantum dots encapsulation efficiency of the TC and FD NPs determined using 
the spectrofluorophotometer are illustrated in Table 6-1. The values of the 
encapsulation efficiency were found to be lower that that reported in literature (Pan 
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and Feng 2009). Three possible reasons for such a phenomenon are (1) coexistence of 
the QDs and docetaxel within the polymer matrix, (2) the nanoprecipitation method, 
and (3) the filtration process. Also, smaller NPs have a higher surface area per unit 
volume and thus result in higher loss of quantum dots from the NPs during the 
fabrication process.  
6.3.4 In vitro evaluation 
6.3.4.1 In vitro cellular uptake of NPs 
The targeting effect of the FD NPs was evaluated by investigating the cellular uptake 
of the NPs by two types of cells: MCF-7 breast cancer cells, which have a high level 
of folate receptor on their surface, and NIH 3T3 normal cells, which lack folate 
receptors. Figure 6-5A and 6-5B show the cellular uptake efficiency of the 16.7% TC 
and 16.7% FD NPs by MCF-7 and NIH 3T3 cells, respectively. It is clear that the 
16.7% FD NPs (which are of FOL conjugation) demonstrated higher cellular uptake 
efficiency than the 16.7% TC NPs (which have no FOL conjugation) for MCF-7 cells, 
i.e. the 16.7% FD NPs achieved 1.03-, 1.12-, 1.12-, and 1.25-fold higher cellular 
uptake efficiency than the 16.7% TC NPs after 0.5, 1.0, 2.0 and 4.0 h incubation with 
MCF-7 cells respectively (figure 6-5A). Nevertheless, the 16.7% FD NPs showed no 
advantages over the 16.7% TC NPs in cellular uptake by NIH 3T3 cells (figure 6-5B). 
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Figure 6-5 (A) MCF-7 (B) NIH 3T3 cells uptake efficiency of 16.7% TC or 16.7% FD 
NPs at the QDs concentration of 0.75nM for 0.5,1.0, 2.0, 4.0 h, respectively (n=6) 
It can be further noticed from figure 6-5A that the cellular uptake efficiency for both 
of the 16.7% FD NPs and the 16.7% TC NPs by MCF-7 cells decreased after 2h 
incubation. One possible reason for this sudden decrease might be due to the action of 
the drug loaded in the NPs. The loaded drug might have diffused out from the NPs 
substantially, effectively killing the cells. As such, the dead cells would have detached 
from the cell walls and will be washed away with PBS during the washing process. 
Hence, some of the NPs being uptaked into the dead cells would have been washed 
away, leading to a decrease in fluorescence value measured by the microplate reader. 
Confocal laser scanning microscopy (CLSM) was also used to visualize the targeting 
effect of the 16.7% FD NPs vs 16.7% TC NPs. The intensity coded (red for QDs and 
blue for DAPI) channel shows the fluorescence. Figure 6-6 shows four CLSM images 
of the MCF-7 cells (upper row) and NIH 3T3 cells (lower row) after 1h incubation 
with the suspension of the 16.7% FD NPs and the 16.7% TC NPs at the equivalent 
QDs concentration of at 0.375 nM, respectively. It can be seen from the two images in 
the upper row that the 16.7% FD NPs demonstrated great advantages vs the 16.7% TC 
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NPs in cellular uptake by MCF-7 cells of folate over expression. Moreover, a 
comparison between the corresponding two figures in the same column can further 
confirm the targeting effect of the FD NPs for MCF-7 cells of folate overexpression 
vs the NIH 3T3 cell of no folate overexpression. 
 
Figure 6-6 (A, upper row) Confocal microscopic images of MCF-7 breast cancer cells 
treated with (A1) the 16.7% TC NPs and (A2) 16.7% FD NPs for 1h, respectively; (B, 
lower row) Confocal microscopic images of NIH 3T3 cells treated with (B1) the 
16.7% TC NPs and (B2) 16.7% FD NPs for 1h, respectively. The incubation was 
made at equivalent 0.375 nM QDs concentration at 37 oC. The intensity coded (red for 
QDs and blue for DAPI) channel shows the fluorescence 
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6.3.4.2 In vitro cytotoxicity 
The in vitro cell viability of MCF-7 cells after 24 h, 48 h and 72 h treatment with 
docetaxel formulated in the 16.7% TC NPs (with no folate conjugation), the 16.7% 
FD NPs (with folate conjugation) or its current clinical dosage form Taxotere® at 3 
different drug concentration (0.025, 0.25, and 2.5 μg/ml) at 37 oC is shown in figure 
6-7 as well as in figure 6-8 in further details, from which two conclusions can be 
made immediately. Firstly, it is evident that the NP formulation demonstrated 
significant advantages vs Taxotere®. For instance, The MCF-7 cell viability decreased 
from 96.2% for Taxotere® to 82.3% for the 16.7% TC NPs, which is a 14.4% 
increase in cellular cytotoxicity i.e. the in vitro therapeutic effect, and 80.7% for the 
16.7% FD NPs, which is a 16.1% increase in cellular cytotoxicity i.e. the in vitro 
therapeutic effect, at 0.025 μg/ml drug concentration after 24h treatment. Similar 
trends were also witnessed at other two drug concentrations and various incubation 
periods. Moreover, the cellular viability decreased with an increase of incubation 
period in all cases. Secondly, the targeting effect of the 16.7% FD NPs can be clearly 
observed.  For instance, MCF-7 cell viability decreased from 45.1% for the 16.7% 
TC NPs (with no folate conjugation) to 39.7% for the 16.7% FD NPs (of folate 
conjugation, which is a 12.0% increase in cytotoxicity i.e. the in vitro therapeutic 
effect, at 0.25 μg/ml drug concentration after 48h incubation. Similar trends were also 
witnessed at 0.025 μg/ml drug concentrations after 48h and 72h incubation period as 




Figure 6-7 In vitro cell viability of MCF-7 cells after 1, 2 and 3 days at drug 
concentrations of 0.025, 0.25 and 2.5μg/mL 
 
Figure 6-8 In vitro cell viability of MCF-7 cells at (A1) 0.025μg/mL drug 
concentration,(A2) 0.25μg/mL drug concentration, (A3) 2.5μg/mL drug concentration, 
(B1) 1 day incubation, (B2) 2 days incubation and (B3) 3 days incubation (n=6) 
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The IC50 for a given cell line in the designated time period is defined to be the drug 
concentration at which 50% cells have been killed, which can quantitatively describe 
the in vitro therapeutic effects of the drug. The IC50 values of the MCF-7 Cells after 
24, 48, 72 hours incubation with docetaxel formulated in Taxotere®, the TC NPs and 
the FD NPs at can be assessed from Figure 6-7 and Figure 6-8, which are listed in 
Table 6-2. It can be seen from this Table that (1) the nanoparticle formulation has 
significant advantages in achieving much higher in vitro therapeutic effects than the 
current clinical administration of Taxotere®, and (2) the 16.7% FD NPs (of folate 
conjugation) demonstrated even more significant increase in vitro therapeutic effects 
than the 16.7% TC NPs (of no targeting effects). For example, the IC50 values for 
MCF-7 cells decreased from 1.257 μg/ml for the Taxotere® 
Table 6-2 IC
to 0.166 μg/ml for the TC 
NPs formulation, and further to 0.112 μg/ml for the FD NPs after 48h treatment, 
which is a 7.57 fold and 11.22 fold decreases, respectively.  
50 of MCF-7 Cells after 24, 48, 72 hours incubation with docetaxel 
formulated in Taxotere®
Incubation time 








7.284 4.796 14.049 
48 0.166 0.112 1.257 
72 0.0868 0.0697 0.462 
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It should be pointed out that the cytotoxicity of the QDs has been neglected in the 
above analysis. Although there have been a few reports in the literature, which 
claimed no significant cytotoxicity of QDs was observed in various applications of 
biological imaging and detection over the time duration of the study (Michalet, 
Pinaud et al. 2001; Niemeyer 2001; Miyawaki, Sawano et al. 2003; Alivisatos 2004), 
this assumption may not be correct. The cadmium present in QDs can still be 
extremely toxic to cells (Celik, Comelekoglu et al. 2005). Derfus et al. demonstrated 
that the CdSe/ZnS QDs are highly toxic for the cells in culture due to the released 
Cd2+ ions, caused by surface oxidation of QDs, which was repressed by coating with 
appropriate shells to decrease the cytotoxicity of QDs (Derfus, Chan et al. 2004). 
Kirchner et al. in 2005 further described that the cytotoxicity of QDs can be reduced 
due to inhibit release of Cd2+
6.4 Conclusion 
 ions from QDs surface through amphiphilic polymer 
formulation in low NPs concentrations (Kirchner, Liedl et al. 2005). Our group has 
pointed out that cytotoxicity of QDs can be effectively prevented through surface 
modification and polymeric nanoparticle formulation (Pan, Wang et al. 2008; Pan and 
Feng 2009). Nevertheless, it is reasonable to assume that the toxicity of 
QDs/docetaxel loaded NPs with folate conjugation is mainly from the drug itself.  
A multifunctional nanoparticle system is developed in this research to realize a 
sustained, controlled and targeted delivery of quantum dots (QDs) used as a model 
imaging agent and Docetaxel used as a model anticancer drug. The nanoparticles are 
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made of a blend of two polymers. One is poly(lactic-co-glycolic acid) (PLGA), which 
is a US FDA approved biodegradable polymer and has been used most often in the 
literatures, another is carboxyl Vitamin E TPGS (TPGS-COOH), which is used to 
promote high encapsulation efficiency, high cellular adhesion, and more importantly, 
a control of the carboxyl amount on the NPs surface for folic acid conjugation to 
target the folate receptors-overexpressing cancer cells. The NPs were found spherical 
of 260 nm diameter. TEM and XPS investigation demonstrated successful 
encapsulation of QDs and docetaxel in the NPs as well as successful conjugation of 
the folic acid on the NPs surface. The targeting effects of the multifunctional NPs 
were investigated through the cellular uptake as well as the cytotoxicity of the 
QDs/docetaxel loaded NPs both quantitatively and qualitatively using MCF-7, which 
are of folate receptors overexpression, and NIH 3T3 cell, which have no folate 
receptors overexpression. It is found that the NPs of folate conjugation achieved 1.03-, 
1.12-, 1.12-, and 1.25-fold higher cellular uptake for MCF-7 cells than those of no 
folate conjugation after 0.5, 1.0, 2.0 and 4.0 h incubation respectively while no 
targeting effect could be observed for NIH 3T3 cells, which was also qualitatively 
confirmed by the confocal images. The investigation on the cytotoxicity of the drug 
evidenced that Docetaxel formulated in the NPs of folate conjugation showed great 
advantages over that formulated in the NPs of no folate conjugation and its current 
clinical formulation Taxotere®. For example, the IC50 values for MCF-7 cells after 48 
h treatment decreased from 1.257 μg/ml for the Taxotere® to 0.166 μg/ml for the TC 
NPs formulation, and further to 0.112 μg/ml for the FD NPs after 48h treatment, 
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which is 7.57 fold and 11.22 fold decrease, respectively. With imaging and 
therapeutic agents co-encapsulated in nanoparticles of polymers, the multifunctional 
PLGA/TPGS-COOH NPs have potential to be applied for cancer targeting, imaging 
and therapy delivering although in vivo confirmation is needed to confirm their 
advantages demonstrated in this research. 
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Chapter 7 Conclusions and Recommendations 
7.1 Conclusions 
In Chapter 3, a novel copolymer, PLA-TPGS, was successfully synthesized with 
various TPGS contents in the copolymers by ring-opening bulk polymerization of 
lactide monomer with vitamin E TPGS in presence of stannous octoate as catalyst. 
The QDs-loaded PLA-TPGS NPs were prepared by a modified solvent 
extraction/evaporation technique (single oil-in-water emulsion technique). Their size 
and size distribution, surface morphology, surface chemistry, and QD encapsulation 
efficiency were conducted. Cellular imaging and toxicity of the QDs-loaded 
PLA-TPGS NPs was investigated in close comparison with those of the parent QDs. 
Our research showed that the QDs-loaded PLA-TPGS NPs can have great advantages 
versus the bare QDs in improving the imaging quality and extending the half-life of 
the QDs. 
In Chapter 4, we synthesized nanoparticles (NPs) of the blend of two component 
copolymers for targeted chemotherapy with paclitaxel used as model drug. One 
component is poly(lactide) – d-α-tocopheryl polyethylene glycol succinate 
(PLA-TPGS), which is of desired hydrophobic-lipophilic balance, and another is 
TPGS-COOH, which facilitates the folate conjugation for targeting. The nanoparticles 
of the two-copolymer blend at various component ratio were prepared by the solvent 
extraction/evaporation single emulsion method and then decorated by folate, which 
were characterized by laser light scattering (LLS) for particles size and size 
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distribution, zeta potential analyzer for surface charge, and X-ray photoelectron 
spectroscopy (XPS) for surface chemistry. The drug encapsulation efficiency (EE) 
and in vitro drug release was measured by high performance liquid chromatography 
(HPLC). The targeting effect was investigated in vitro by cancer cell uptake of 
coumarin 6-loaded NPs and further confirmed by cytotoxicity of cancer cells treated 
with the drug formulated in the NPs. We showed that the NP formulation has great 
advantages vs the pristine drug in achieving better therapeutic effect, which increased 
8.68% for MCF-7 breast cancer cells, and that the folate-decoration can significantly 
promote targeted delivery of the drug into the corresponding cancer cells and thus 
enhance its therapeutic effect, which increased 24.4% for the NP formulation of 
16.7% TPGS-COOH component and 31.1% for the NP formulation of 33.3% 
TPGS-COOH component after 24 h treatment at the same 25 μg/ml paclitaxel 
concentration. The experiments on C6 glioma cells further confirmed 
these advantages
After that, in Chapter 5, we developed a new strategy in developing folate-decorated 
nanoparticles for QDs formulation for targeted and sustained imaging for cancer 
diagnosis at its early stage, in which two copolymers of poly(lactide)-vitamin E TPGS 
(PLA-TPGS) and vitamin E TPGS-carboxyl (TPGS-COOH) were synthesized. The 
carboxyl terminated TPGS (TPGS-COOH) and PLA-TPGS copolymer were blended 
at various weight ratios, which will ultimately decide the amount of folate ligand 
conjugated onto the NPs surface. Here the TPGS-COOH was utilized to conjugate 
with folate-NH
. 
2. The QDs-loaded PLA-TPGS/TPGS-COOH NPs were prepared by 
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using solvent extraction method and then conjugated with the folate-NH2. Particle 
size and size distribution were determined with Laser Light Scattering (LLS). Zeta 
potential analyzer was used for surface charge measurement. Morphology of the NPs 
was investigated by using field emission scanning electron microscope (FESEM) and 
transmission electron microscope (TEM). Emission spectrum of the formulated QDs 
was investigated with the spectrofluorophotometer. The QDs encapsulation efficiency 
(EE) was determined by the inductively coupled plasma optical emission 
spectrometry (ICP-OES). Surface chemistry of the QDs-loaded NPs was investigated 
by using X-ray photoelectron spectroscopy (XPS). In vitro experiments on cellular 
uptake of the QDs-loaded, folate-decorated NPs were also carried out by using 
MCF-7 breast cancer and NIH 3T3 fibroblast cells. MCF-7 cells were used to test the 
targeting effect due to the over-expression of folate receptors on the cell surface. NIH 
3T3 cells with low folate receptor were used as a negative control. Confocal laser 
scanning microscopy (CLSM) was conducted to have a qualitative assessment cellular 
uptake of the folate decorated NPs in comparison with that of the NPs with no 
targeting effect. In vitro cytotoxicity of the QDs formulated in the folate-decorated 
PLA-TPGS/TPGS-COOH NPs were investigated also by employing MCF-7 cells and 
NIH 3T3 cells through the 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide
In Chapter 6, folate-decorated nanoparticles loaded with quantum dots and docetaxel 
for targeted imaging and therapy of cancer were prepared. Poly(lactic-co-glycolic acid) 
 (MTT) assay, which was compared with that of the QDs formulated in the 
PLA-TPGS NPs with no targeting effects and that of the free QDs. 
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(PLGA) (75:25) was blended with vitamin E TPGS-carboxyl (TPGS-COOH) in the 
weight ratio of 5:1 to form the polymer matrix. TPGS-COOH was used to facilitate 
the conjugation of folate-NH2. The QDs/docetaxel-loaded nanoparticles were 
prepared using the nanoprecipitation method and subsequently conjugated with 
folate-NH2. Laser Light Scattering (LLS) was used to determine particle size and size 
distribution. Surface charge was measured using the zeta potential analyzer. Field 
emission scanning electron microscope (FESEM) and transmission electron 
microscope (TEM) were used to investigate the surface morphology of the 
nanoparticles. Spectrofluorophotometer was used to measure the emission spectra of 
NPs and to determine the QDs encapsulation efficiency. High performance liquid 
chromatography (HPLC) was utilized to determine the drug encapsulation efficiency 
of the nanoparticles. X-ray photoelectron spectroscopy (XPS) was used to investigate 
the surface chemistry of the nanocarriers. In vitro experiments were performed on 
MCF-7 breast cancer cells and NIH 3T3 fibroblast cells using the 
QDs/docetaxel-loaded nanoparticles decorated with folate. MCF-7 cells with 
over-expressed folate receptors on their surface were used to prove the targeting effect 
of the nanoparticles while NIH 3T3 cells with low folate receptor were used as a 
negative control. Quantitative assessment of the cellular uptake of the folate decorated 
nanoparticles and non-folate decorated nanoparticles was conducted to demonstrate 
the targeting effect of the folate nanoparticles. Confocal laser scanning microscopy 
(CLSM) was also carried out to confirm cellular uptake results qualitatively. Finally, 
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in vitro cytotoxicity of the nanoparticles on MCF-7 cells was investigated using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. 
This work of study will be helpful in cancer treatment, molecular imaging and 
medical diagnostics, especially the cancer detection in its early stage. 
7.2 Recommendations for Future Research 
To further develop polymeric nanoparticles for tumor targeting, tumor imaging and 
tumor therapy, the following work is recommended: 
 To further develop the multifunctional polymeric NPs and, thus, efficient 
simultaneous targeting delivery of drug and imaging agents 
 To research on time-dependence of IC50 and further fits of the kinetics based on 
IC50 
 To study on Biodistribution of drug/QDs loaded in multifunctional polymeric 
NPs 
analysis  
 To investigate on in vivo Pharmacokinetic studies of drug loaded in 
multifunctional polymeric NPs such as half-life, the circulation time of these NPs 
in vivo  
 To transplant different tumor models to animals and then to observe the inhibition 
effect of multifunctional polymeric NPs (xenograft);  
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 To apply copolymers nanoparticles for clinic phase I test and supervise side 
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